RNA sequencing library preparation method based on spatial transposition

By using the capture oligonucleotides of gene-specific capture sequence and spatial barcode information in the preparation of RNA sequence library, combining the synergy between reverse transcriptase and template conversion oligonucleotides, the capture efficiency of RNA sequence library in the prior art is solved. The low problem significantly improves the quality of the library and the accuracy of the sequencing results.

CN118974252APending Publication Date: 2024-11-15ILLUMINA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030055.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-11-30
Filing Date
2023-12-22
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing spatial transcriptomics methods are inefficient in capturing and transforming mRNA in tissue sections, with a capture rate of less than 1%, resulting in poor quality of RNA sequence library preparation, affecting the accuracy and quality of sequencing results.

Method used

Using a capture oligonucleotide containing gene-specific capture sequences and spatial barcode information, tissue samples are immobilized on the substrate, and mRNA is captured and transformed through synergistic effects of reverse transcriptase and template conversion oligonucleotides, followed by tagging. Processed to form a library containing a unique molecular identifier and a PCR adaptor.

Benefits of technology

It significantly improves the capture and transformation efficiency of RNA sequence libraries, improves the overall synthesis and alignment quality of RNA sequences, enhances the preparation effect of spatial transcriptomics libraries, and improves the accuracy and stability of sequencing results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118974252A_ABST
    Figure CN118974252A_ABST
Patent Text Reader

Abstract

Methods of RNA sequencing library preparation utilizing transposon with or with template conversion oligonucleotides to produce libraries with UMI and spatial barcode information, and methods of using template conversion and thermal amplification to improve the preparation of RNA libraries from tissue samples to improve the quality of the RNA libraries.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 477,103 filed on December 23, 2022, U.S. Provisional Patent Application No. 63 / 586,872 filed on September 29, 2023, and U.S. Provisional Patent Application No. 63 / 604,667 filed on November 30, 2023, each of which is incorporated by reference in its entirety.

[0003] Sequence Disclosure Incorporated by Reference

[0004] The sequence listing as part of this disclosure is submitted simultaneously with the specification as a computer-readable file. The file name containing the sequence listing is "IP-2528-PC_SeqListing.xml", which was created on December 15, 2023 and is 19,146 bytes in size. The subject matter of the sequence listing is incorporated herein by reference in its entirety. Technical Field

[0005] The present disclosure relates to a method based on spatial transposition for preparing an RNA sequence library, and in particular to a method for preparing an RNA sequencing library, including a method based on spatial transposition with and without template switching oligonucleotides. Background Art

[0006] Spatial transcriptomics enables highly multiplexed, spatially localized gene expression analysis from fresh frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples. To generate spatial sequencing libraries, surface library preparation methods must be used to spatially capture transcripts from tissue samples and barcode the transcripts. Sequencing libraries must also include unique molecular identifiers (UMIs) and sample indexes while maintaining the optimal length for sequencing. Current spatial workflows require fragmentation to produce libraries of optimal fragment sizes for sequencing and contain UMI information on the barcoded surface. Spatial workflows currently on the market capture and transform <1% of mRNA within tissue sections. Summary of the invention

[0007] Provided herein is a method for producing higher capture and spatial library conversion from preserved tissue samples (e.g., frozen or FFPE tissue samples). In situ polyadenylation can capture fragmented FFPE RNA on oligonucleotide-dT surfaces. Also provided herein is an improved method for synthesizing cDNA from isolated RNA transcripts to improve the overall synthesis of RNA sequences and the quality of comparison and the preparation of spatial transcriptomics libraries.

[0008] Provided herein is a method for preparing an RNA sequence library according to the present disclosure, the method may include mounting a tissue sample on a substrate comprising a plurality of capture oligonucleotides, wherein the capture oligonucleotides comprise one or more gene-specific capture sequences and library barcode information comprising a spatial barcode sequence (SBC); capturing mRNA transcripts on the substrate with the capture oligonucleotides; contacting the substrate with a first-strand synthesis mixture comprising a reverse transcriptase and a template switching oligonucleotide (TSO) under conditions that produce a first strand, the first strand comprising a first cDNA complementary to the mRNA transcript and a TSO complementary sequence hybridized to the 5' end of the first cDNA, wherein the reverse transcriptase incorporates an untemplated cytosine nucleotide at the 5' end of the first cDNA, and the TSO comprises a sequence hybridized to the untemplated cytosine nucleotide, and the reverse transcriptase extends to produce the TSO complementary sequence (which is the complement of the TSO) at the 5' end of the first cDNA; eluting the obtained RNA transcripts from the substrate; The mRNA transcript; contacting the first strand with a second strand synthesis mixture comprising a TSO primer, and extending the TSO primer using the first strand as a template to produce a second strand complementary to the first strand, the second strand comprising the TSO, a second cDNA complementary to the first cDNA, and a second strand barcode information comprising a spatial barcode sequence complementary sequence (SBC') complementary to the spatial barcode sequence (SBC); eluting the second strand; contacting the second strand with an extension mixture comprising an extension primer, and extending the extension primer using the second strand as a template to produce a double-stranded product while maintaining a single-stranded 3' region comprising the library barcode information, wherein the extension primer hybridizes to a region of the second strand that does not comprise the second strand barcode information; contacting the double-stranded product with a transposome under conditions that label the double-stranded product to form a labeling product comprising a unique molecular identifier (UMI) and a PCR adapter; and amplifying the labeling product using index PCR to produce the library. In some embodiments, the TSO comprises 2 to 5 guanosines that hybridize to untemplated cytosine nucleotides. In some embodiments, 2 to 5 guanosines are riboguanosines. In some embodiments, the TSO comprises rGrGrG. In some embodiments, the TSO comprises a locked nucleic acid (LNA).

[0009] A method for preparing an RNA sequence library according to the present disclosure, the method may include mounting a tissue sample on a substrate comprising a plurality of capture oligonucleotides, wherein the capture oligonucleotides comprise one or more gene-specific capture sequences and library barcode information comprising a spatial barcode sequence (SBC); capturing mRNA transcripts on the substrate with the capture oligonucleotides; contacting the substrate with a first-strand synthesis mixture comprising a reverse transcriptase and a template switching oligonucleotide (TSO) under conditions that produce a first strand, wherein the first strand comprises a first cDNA complementary to the mRNA transcript and a TSO complementary sequence hybridized to the 5' end of the first cDNA; eluting the mRNA transcript from the substrate; contacting the first strand with a blocker oligonucleotide and TSO to hybridize the blocker oligonucleotide and TSO to the first strand, wherein the blocker oligonucleotide is The TSO is hybridized so that there is a gap between the blocker oligonucleotide and the TSO; the hybridized first strand is contacted with a non-strand displacement polymerase to fill the gap and produce a second cDNA; the blocker oligonucleotide is removed to form a first strand without a blocker; the blocker-free first strand is contacted with a transposome under conditions that label the blocker-free first strand to form a labeling product comprising a unique molecular identifier (UMI) and a PCR adapter; the labeling product is contacted with an extension mixture to produce a second strand complementary to the first strand, the second strand comprising a second strand barcode information having a spatial barcode sequence complementary sequence (SBC') complementary to the spatial barcode sequence, the second cDNA, the unique molecular identifier and the PCR adapter; the second strand is eluted; and the second strand is amplified using index PCR to produce the library.

[0010] A method for preparing an RNA sequence library according to the present disclosure, the method may include mounting a tissue sample on a substrate comprising a plurality of capture oligonucleotides, wherein the capture oligonucleotides comprise one or more gene-specific capture sequences and library barcode information comprising a spatial barcode sequence (SBC); capturing mRNA transcripts on the substrate with the capture oligonucleotides; contacting the substrate with a first-strand synthesis mixture comprising a reverse transcriptase under conditions to produce a first strand, the first strand comprising a first cDNA complementary to the mRNA transcript; eluting the mRNA transcript from the substrate; contacting the first strand with a second-strand synthesis mixture comprising a random primer, and extending the random primer to produce a second strand comprising a second cDNA and a unique molecular identifier (UMI); eluting the second strand; amplifying the second strand to produce a double-stranded product; contacting the double-stranded product with a transposome under conditions to form a tagmentation product; and producing the library by amplifying the tagmentation product in a first index PCR to determine the SBC and amplifying the tagmentation product in a second index PCR to determine the UMI.

[0011] A method for preparing an RNA sequence library according to the present disclosure, the method may include mounting a tissue sample on a substrate comprising a plurality of capture oligonucleotides, wherein the capture oligonucleotides comprise a polyT sequence and library barcode information comprising a spatial barcode sequence (SBC); capturing polyadenylated mRNA transcripts on the substrate with the capture oligonucleotides; contacting the substrate with a first-strand synthesis mixture comprising a reverse transcriptase and a template switching oligonucleotide (TSO) under conditions that produce a first strand, the first strand comprising a first cDNA complementary to the polyadenylated mRNA transcript and a TSO complementary sequence hybridized to the 5' end of the first cDNA, wherein the reverse transcriptase incorporates an untemplated cytosine nucleotide at the 5' end of the first cDNA, and the TSO comprises a sequence hybridized to the untemplated cytosine nucleotide, and the reverse transcriptase extends to produce a complement of the TSO (the TSO complementary sequence) at the 5' end of the first cDNA; eluting the polyadenylated mRNA transcripts from the substrate; and eluting the first cDNA. The first strand is contacted with a second strand synthesis mixture comprising a TSO primer, and the TSO primer is extended using the first strand as a template to generate a second strand complementary to the first strand, the second strand comprising the TSO, a second cDNA complementary to the first cDNA, and a second strand barcode information comprising a spatial barcode sequence complementary sequence (SBC') complementary to the spatial barcode sequence (SBC); the second strand is eluted; the second strand is contacted with a Poly-TVN extension mixture comprising a Poly-TVN primer (e.g., a poly(T) primer having a VN anchor at the 3' end, wherein V is G, A or C, and N is any nucleotide), and the Poly-TVN primer is extended using the second strand as a template to generate a double-stranded product while maintaining a single-stranded 3' region containing the barcode information of the library; the double-stranded product is contacted with a transposome under conditions for tagging the double-stranded product to form a tagmentation product comprising a unique molecular identifier (UMI) and a PCR adapter; and the tagmentation product is amplified using index PCR to generate the library. In some embodiments, the extension of the second strand may include an incubation time with the Poly-TVN extension mixture of less than 2 hours, for example, 15 minutes to 60 minutes. In some embodiments, the TSO comprises 2 to 5 guanosines hybridized to the untemplated cytosine nucleotide. In some embodiments, the 2 to 5 guanosines are riboguanosines. In some embodiments, the TSO comprises rGrGrG, and in some embodiments, the TSO comprises a locked nucleic acid (LNA).

[0012] A method for preparing an RNA sequence library according to the present disclosure, the method may include mounting a tissue sample on a substrate comprising a plurality of capture oligonucleotides, wherein the capture oligonucleotides comprise a polyT sequence and library barcode information comprising a spatial barcode sequence (SBC); capturing polyadenylated mRNA transcripts on the substrate with the capture oligonucleotides; contacting the substrate with a first-strand synthesis mixture comprising a reverse transcriptase and a template switching oligonucleotide (TSO) under conditions that produce a first strand, wherein the first strand comprises a first cDNA complementary to the polyadenylated mRNA transcript and a TSO complementary sequence hybridized to the 5' end of the first cDNA; eluting the polyadenylated mRNA transcript from the substrate; contacting the first strand with a blocker oligonucleotide and TSO so that the blocker oligonucleotide and TSO hybridize with the first strand, wherein the blocker The oligonucleotide is hybridized to the TSO so that there is a gap between the blocker oligonucleotide and the TSO; the hybridized first strand is contacted with a non-strand displacement polymerase to fill the gap and produce a second cDNA; the blocker oligonucleotide is removed to form a first strand without a blocker; the first strand without a blocker is contacted with a transposome under conditions that label the first strand without a blocker to form a labeling product comprising a unique molecular identifier (UMI) and a PCR adapter; the labeling product is contacted with an extension mixture to produce a second strand complementary to the first strand, the second strand comprising a second strand barcode information having a spatial barcode sequence complementary sequence (SBC') complementary to the spatial barcode sequence, the second cDNA, the unique molecular identifier and the PCR adapter; the second strand is eluted; and the second strand is amplified using index PCR to produce the library. In an embodiment, the blocker oligonucleotide can be a 3'-blocked SBS12'-PolyA oligonucleotide.

[0013] A method for preparing an RNA sequence library according to the present disclosure, the method may include mounting a tissue sample on a substrate comprising a plurality of capture oligonucleotides, wherein the capture oligonucleotides comprise a polyT sequence and library barcode information comprising a spatial barcode sequence (SBC); capturing polyadenylated mRNA transcripts on the substrate with the capture oligonucleotides; contacting the substrate with a first-strand synthesis mixture comprising a reverse transcriptase under conditions to produce a first strand, the first strand comprising a first cDNA complementary to the polyadenylated mRNA transcript; eluting the polyadenylated mRNA transcript from the substrate; contacting the first strand with a second-strand synthesis mixture comprising a random primer to produce a second strand comprising a second cDNA and a unique molecular identifier (UMI); eluting the second strand; amplifying the second strand to produce a double-stranded product; contacting the double-stranded product with a transposome under conditions to form a tagmentation product; and generating the library by amplifying the tagmentation product in a first index PCR to determine the SBC and amplifying the tagmentation product in a second index PCR to determine the UMI.

[0014] In one aspect, the present disclosure provides a method for preparing a spatially barcoded RNA library from a tissue sample, the method comprising:

[0015] a) contacting the tissue sample with a plurality of capture oligonucleotides immobilized on a solid substrate and capable of hybridizing with RNA in the tissue sample, wherein the capture oligonucleotides comprise a capture nucleotide sequence, a spatial barcode sequence (SBC), and an adapter sequence, wherein RNA transcripts are captured by the capture nucleotide sequence of the plurality of capture oligonucleotides;

[0016] b) contacting the RNA transcript with a first strand synthesis mixture comprising a reverse transcriptase (RT) and a template switching oligonucleotide (TSO) encoding a first adaptor sequence under conditions that produce a first strand cDNA comprising

[0017] a first strand cDNA complementary to said RNA transcript and a TSO hybridized to a 3' end of said first strand cDNA, wherein said reverse transcriptase incorporates a non-templated cytosine nucleotide at said 3' end of said first strand cDNA, and said TSO comprising a first adaptor sequence is appended to said 3' end of said first strand cDNA, and said reverse transcriptase extends to produce a TSO complementary sequence; and wherein said contacting produces a mixture of template-switched molecules and non-template-switched molecules, wherein said non-template-switched molecules lack said complementary sequence to said first adaptor sequence;

[0018] c) contacting the mixture with a plurality of oligonucleotide ligation blockers, the plurality of oligonucleotide ligation blockers comprising the first adaptor sequence and capable of hybridizing to the 3' end of the template switching molecule, the 3' end of the template switching molecule comprising the complementary sequence of the first adaptor sequence;

[0019] d) performing a single-stranded ligation step comprising hybridizing a splint adaptor to the non-template switching molecule, wherein the splint adaptor comprises i) a single-stranded splint sequence comprising a random base sequence (NX) and ii) a double-stranded first adaptor sequence comprising a hybridized first adaptor and a complementary sequence to the first adaptor sequence, wherein the complementary sequence at the 5' end of the first adaptor sequence contains a phosphate group for ligating to the 3'OH end of the captured non-template switching molecule, and ligating the 5' end of the splint adaptor complementary sequence to the 3'OH end of the non-template switching molecule;

[0020] e) removing the ligation blocker and the splint sequence and the first adaptor from the ligated molecules.

[0021] In another aspect, the present disclosure provides a method for preparing a spatially barcoded RNA library from a tissue sample, the method comprising:

[0022] a) contacting the tissue sample with a plurality of capture oligonucleotides immobilized on a solid substrate and capable of hybridizing with RNA in the tissue sample, wherein the capture oligonucleotides comprise a capture nucleotide sequence, a spatial barcode sequence (SBC), and an adapter sequence, wherein RNA transcripts are captured by the capture nucleotide sequence of the plurality of capture oligonucleotides;

[0023] b) contacting the RNA transcript with a first strand synthesis mixture comprising a reverse transcriptase (RT) and a template switching oligonucleotide (TSO) encoding a first adaptor sequence under conditions that produce a first strand cDNA comprising

[0024] a first strand cDNA complementary to said RNA transcript and a TSO appended to the 3' end of said first strand cDNA, wherein said reverse transcriptase incorporates a non-templated cytosine nucleotide at said 3' end of said first strand cDNA and said TSO comprising a first adaptor sequence is appended to said 3' end of said first strand cDNA and said reverse transcriptase extends to produce a TSO complementary sequence; and wherein said contacting produces a mixture of template-switched molecules and non-template-switched molecules, wherein said non-template-switched molecules lack said complementary sequence to said first adaptor sequence;

[0025] c) contacting the mixture with a plurality of oligonucleotide ligation blockers and a plurality of complementary oligonucleotide blockers to generate a double-stranded 3' end of the capture oligonucleotide, wherein the plurality of oligonucleotide ligation blockers comprise the first adaptor sequence and are capable of hybridizing with the 3' end of the template switching molecule, wherein the 3' end of the template switching molecule comprises the complementary sequence of the first adaptor sequence, and the plurality of complementary oligonucleotide blockers comprise a nucleotide sequence complementary to all or part of the capture nucleotide sequence and a fixed sequence in the capture oligonucleotide;

[0026] d) performing a single-stranded ligation step comprising hybridizing a splint adaptor to the non-template switching molecule, wherein the splint adaptor comprises i) a single-stranded splint sequence comprising a random base sequence (NX) and ii) a double-stranded portion of a first adaptor sequence comprising a hybridized first adaptor and a complementary sequence to the first adaptor sequence, wherein the complementary sequence at the 5' end of the first adaptor sequence contains a phosphate group for ligating to the 3'OH end of the captured non-template switching molecule, and ligating the 5' end of the splint adaptor complementary sequence to the 3'OH end of the non-template switching molecule;

[0027] f) removing the ligation blocker and the splint strand of the adaptor.

[0028] It is contemplated that oligonucleotide ligation blockers block template switching molecules and / or capture nucleotides, e.g. Fig.12 As described in.

[0029] In various embodiments, the mixture of template-switching molecules and non-template-switching molecules is contacted with an exonuclease. In various embodiments, the exonuclease is DNA exonuclease I or RNase H.

[0030] In various embodiments, the NX sequence has a capping group at the 5' end of the NX sequence.In various embodiments, the hybridized first adaptor and the complement of the first adaptor sequence both comprise a capping group at the end of the first adaptor and the complement of the first adaptor sequence furthest from the splint sequence.

[0031] In various embodiments, the method further comprises, after the exonuclease, contacting the mixture with an alkaline solution.

[0032] In various embodiments, the method further includes, after the removal step, amplifying the template-switching molecules and non-template-switching molecules by contacting the mixture with a second-chain synthesis mixture comprising a single first adapter primer and extending the first adapter primer using the first-chain cDNA or its complementary sequence as a template to produce a second-chain cDNA complementary to the first chain or its complementary sequence, wherein the second-chain cDNA comprises a second cDNA complementary to the first-chain cDNA, and a second-chain barcode information containing a spatial barcode sequence complementary sequence (SBC') complementary to the spatial barcode sequence (SBC) in the capture oligonucleotide.

[0033] In various embodiments, the first adapter primer comprises a molecular identifier (SMI) sequence. In various embodiments, during synthesis of the second strand cDNA, the molecular identifier of the first adapter primer is incorporated. In various embodiments, the SMI is a UMI. In various embodiments, if the first strand cDNA comprises an SMI, then the SMI on the first adapter primer is expected to be different from the SMI in the first strand cDNA. See also Fig. 22 .

[0034] In various embodiments, the first adaptor primer is a full-length primer or a partial primer.

[0035] In various embodiments, the method further comprises eluting the amplified first strand and / or second strand cDNA molecules from the substrate, and generating a spatially barcoded RNA library from the eluted molecules using a library preparation kit.

[0036] In various embodiments, the ligated molecule of step (d) further comprises a cleavage sequence. In various embodiments, the capture oligonucleotide further comprises a cleavage site. In various embodiments, the cleavage site is located at the 5' end of the clustering sequence (eg, P7).

[0037] In various embodiments, the removal of the ligation blocker, the splint sequence, and the first adaptor from the ligated molecules is performed outside of the substrate. In various embodiments, the removal of the ligation blocker from the substrate, the amplification of the template-switched molecules and the non-template-switched molecules, the elution of the second strand cDNA, and the generation of the spatially barcoded library are performed in solution.

[0038] In various embodiments, the amplification step is carried out on a substrate. In various embodiments, the first strand and / or the second strand of the amplification also comprises a cleavage sequence. In various embodiments, the amplified molecule contains a cleavage sequence, and the amplified molecule is released from the substrate via the cleavage sequence.

[0039] In various embodiments, elution of the second strand cDNA and generation of the spatially barcoded library occurs in solution as the amplified molecules are cleaved from the substrate.

[0040] In various embodiments, the method optionally includes fixing the tissue sample on a substrate comprising a plurality of capture oligonucleotides prior to contacting the tissue with the plurality of capture oligonucleotides. In various embodiments, the capture nucleotide sequence is a poly-T sequence, a poly-A sequence, a gene-specific capture sequence, or a universal capture sequence. In various embodiments, the universal capture sequence is a random nucleotide sequence or a non-self-complementary semi-random sequence.

[0041] In various embodiments, the capture oligonucleotide comprises: a 5' clustering sequence, a random spatial barcode (SBC), a full-length second adaptor sequence (2FL), a molecular identifier (MI), a fixed sequence (FS), and a poly T capture sequence with a 3' VN terminus (polyTVN).

[0042] In various embodiments, the first adapter sequence is a read 1 (Rd1) sequence. In various embodiments, the first adapter sequence is a read 1 (Rd1) sequence, and the second adapter is a read2 (Rd2) sequence. In various embodiments, the first adapter is a partial adapter sequence.

[0043] In various embodiments, the molecular identifier is a unique molecular identifier, an endogenous molecular identifier, an exogenous molecular identifier, or a virtual molecular identifier.

[0044] In various embodiments, the ligating step comprises enzymatically ligating the splint adaptor to the non-template switched molecule. In various embodiments, the enzymatic ligation is performed by T4 ligase, other DNA ligases, or thermostable 5'App DNA / RNA ligase mediated ligation to synthetic pre-adenylated single stranded oligonucleotide adaptors.

[0045] In various embodiments, the ligation step includes chemically ligating the splint adapter to the non-template switching molecule. In various embodiments, the chemical ligation is performed using a click chemistry-mediated ligation in which the 3'azido terminus is joined to a synthetic 5'alkyne single-stranded oligonucleotide or a 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)-mediated ligation in which a cDNA having a 3'phosphate group is ligated to a splint adapter having a 5'hydroxyl terminus. In various embodiments, during first-strand cDNA synthesis, a 3'azido-ddNTP or 3'Phos-dATP is incorporated into the Rd1 adapter.

[0046] In various embodiments, the splint adapter random sequence comprises 6 to 10 nucleotides. In various embodiments, the splint adapter random sequence comprises 6, 7, 8, 9 or 10 nucleotides. In various embodiments, the splint adapter random sequence comprises 7 nucleotides.

[0047] In various embodiments, the splint adapter comprises a capping group at both 3' and 5' ends of the splint, and comprises a ligation capping group complementary to the splint strand at the 5' end of the adapter strand. In various embodiments, the ligation blocker group is a phosphate group, a 3' dideoxy C, a 3' reversed dT, a 3' carbon spacer, a 3' amino group, or a 3' biotin. In various embodiments, the ligation blocker group is a phosphate group.

[0048] In various embodiments, the ligation blocker and splint adaptor are removed by alkaline treatment. In various embodiments, the alkaline treatment comprises treatment with 0.08 M KOH or 0.1 N NaOH at room temperature for 5 minutes.

[0049] In various embodiments, the 5' clustering sequence comprises a P7 sequence.

[0050] In various embodiments, the capture oligonucleotides further comprise random oligonucleotides, semi-random sequences, or target-specific probes.

[0051] In various embodiments, the sequence that hybridizes to the untemplated cytosine nucleotide comprises 2 to 5 guanosines. In various embodiments, the guanosine is riboguanosine, a modified nucleic acid, or a locked nucleic acid (LNA). In various embodiments, the sequence is rGrGrG.

[0052] In various embodiments, the polyT sequence is 20 to 30 nucleotides.

[0053] In various embodiments, the SBC is a random oligonucleotide.In various embodiments, the SBC is 20 to 30 nucleotides.

[0054] In various embodiments, the capture oligonucleotide comprises at least 8 deoxythymidine residues. In various embodiments, the capture oligonucleotide is 8 to 80 nucleotides.

[0055] In various embodiments, the capture oligonucleotide comprises a plurality of different target-specific RNA capture probe sequences. In various embodiments, the target-specific probe comprises at least 8 nucleotides that are complementary to the nucleotide sequence of the target RNA. In various embodiments, the RNA capture oligonucleotide is 8 to 80 nucleotides, 10 to 70 nucleotides, 10 to 60 nucleotides, 10 to 50 nucleotides, 10 to 40 nucleotides, 10 to 30 nucleotides, 10 to 20 nucleotides, 20 to 80 nucleotides, 20 to 70 nucleotides, 20 to 60 nucleotides, 20 to 50 nucleotides, 20 to 40 nucleotides, or 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, or 80 nucleotides.

[0056] In various embodiments, the capture oligonucleotide comprises a P7 anchor sequence, a spatial barcode, and a sequence that hybridizes to the splint oligonucleotide.

[0057] In various embodiments, one or more of the first clustering sequence, index sequence, and / or Read 2 sequence are added during or prior to second strand synthesis.

[0058] In various embodiments, the method further comprises a step of performing end repair of RNA using a polynucleotide kinase prior to the step of capturing RNA from the tissue sample. In various embodiments, the method further comprises a step of performing in situ polyadenylation using a poly(A) polymerase prior to the step of capturing RNA from the tissue sample. In various embodiments, the method further comprises a step of performing end repair of RNA using a polynucleotide kinase followed by in situ polyadenylation using a poly(A) polymerase prior to the step of capturing RNA from the tissue sample.

[0059] In various embodiments, the RNA includes ribosomal RNA (rRNA), messenger RNA (mRNA), non-coding RNA (ncRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), and / or micro RNA (miRNA).

[0060] In various embodiments, the tissue sample is formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen (FF) tissue.

[0061] In various embodiments, removal of RNA is performed by melting the RNA or digestion with RNase.

[0062] In various embodiments, the tissue sample is permeabilized prior to contacting the tissue sample with the plurality of capture oligonucleotides. In various embodiments, the tissue sample is treated with one or more blocking agents prior to contacting the tissue sample with the plurality of capture oligonucleotides. In various embodiments, the tissue sample is permeabilized and treated with one or more blocking agents prior to contacting the tissue sample with the plurality of capture oligonucleotides.

[0063] In various embodiments, tissue is removed from the sample by enzymatic degradation. In various embodiments, tissue removal is performed prior to removing RNA from the tissue. In various embodiments, tissue is removed by degradation with proteinase K (e.g., at 37° C. for 40 minutes).

[0064] In various embodiments, the substrate is a bead, a bead array, a spotted array, a substrate comprising a plurality of wells, a flow cell, aggregated particles arranged on the surface of a chip, membrane or plate. In various embodiments, the substrate comprises a plurality of nanopores or micropores.

[0065] In various embodiments, the substrate or the surface of the substrate comprises a material selected from glass, silicon, poly-L-lysine coated material, nitrocellulose, polystyrene, cyclic olefin copolymer (COC), cyclic olefin polymer (COP), polyacrylamide, polypropylene, polyethylene or polycarbonate.

[0066] In various embodiments, the RNA library is an mRNA library.

[0067] In various embodiments, the method further comprises indexing and sequencing the second strand cDNA, comprising:

[0068] performing PCR on the second strand cDNA to generate a PCR template representing one or more RNA transcripts in the tissue sample;

[0069] eluting the PCR template; and

[0070] Index PCR is performed to generate a double-stranded PCR product comprising the first-strand PCR product and a second strand complementary to the first-strand PCR product.

[0071] In various embodiments, the method further comprises sequencing the PCR products and determining the location of the RNA transcripts in the tissue based on the spatial barcodes.

[0072] In various embodiments, the double-stranded PCR product comprises a second clustering sequence on a second strand that is complementary to the first-stranded PCR product, and optionally comprises an index sequence. In various embodiments, the double-stranded PCR product is further processed by tagmentation to generate a spatial transcriptomics library.

[0073] In various embodiments, tagging comprises tagging on a substrate.

[0074] In various embodiments, tagmentation comprises contacting the double-stranded product with a transposome and vector genomic DNA (gDNA).

[0075] In various embodiments, the method further comprises determining the spatial positions of the spatial barcodes of the plurality of capture oligonucleotide molecules prior to the step of contacting the tissue with the substrate.

[0076] In various embodiments, the method further comprises sequencing at least a portion of the spatially barcoded first strand cDNA or a copy thereof to determine the spatial barcode sequence of each molecule. In various embodiments, the spatially barcoded first strand cDNA is sequenced in situ.

[0077] In various embodiments, the method further comprises determining the spatial position of the spatially barcoded first-strand cDNA or one or more of its copies by associating the spatial barcode sequence of the spatially barcoded first-strand cDNA or its copies with the spatial position of a capture oligonucleotide molecule on a substrate containing the corresponding spatial barcode sequence. In various embodiments, the method further comprises recovering the spatially barcoded first-strand cDNA, and amplifying the first-strand cDNA to produce a cDNA library.

[0078] In various embodiments, the spatially barcoded first-strand cDNA on the substrate is contacted with a DNA polymerase and one or more primers to produce a spatially barcoded second-strand cDNA complementary to the spatially barcoded first-strand cDNA and remove the spatially barcoded second-strand cDNA from the substrate to recover the spatially barcoded first-strand cDNA. In various embodiments, the one or more primers each comprise a random priming sequence. In various embodiments, the random priming sequence comprises nine random nucleotides.

[0079] In various embodiments, the spatially barcoded second strand cDNAs each comprise a unique molecular identifier (UMI), wherein the UMI comprises an intrinsic sequence and an extrinsic sequence, wherein the extrinsic sequence is a sequence complementary to a random priming sequence used to generate the second strand cDNA, and wherein the intrinsic sequence is a sequence complementary to a first strand cDNA template sequence used to generate the second strand cDNA.

[0080] In various embodiments, the one or more primers each comprise a molecular identifier barcode. In various embodiments, the one or more primers each comprise a UMI barcode.

[0081] In various embodiments, the spatially barcoded second strand cDNA is removed from the substrate by chemical or physical dehybridization.

[0082] In various embodiments, the capture oligonucleotide comprises an anchor sequence comprising a cleavage site that anchors the capture oligonucleotide to the substrate, and the hybrid of the spatially barcoded first-strand cDNA and the second-strand cDNA is removed from the substrate by enzymatic cleavage at the cleavage site. In various embodiments, the cleavage site is a binding site for a restriction endonuclease.

[0083] In various embodiments, the method further comprises sequencing at least a portion of the cDNA library to determine the spatial barcode sequence of each molecule.

[0084] In various embodiments, the method further comprises determining the spatial position of the one or more cDNA molecules by correlating the spatial barcode sequences of the one or more cDNA molecules with the spatial positions of surface oligonucleotide molecules on the substrate containing the corresponding spatial barcode sequences.

[0085] In various embodiments, RNA expression is determined in a single cell within a tissue. In various embodiments, RNA expression is determined in a subcellular fraction within a single cell. In various embodiments, the subcellular fraction is nuclear, mitochondrial, ribosome, or cytoplasm.

[0086] The present disclosure also contemplates a kit comprising

[0087] a) a solid substrate comprising a capture oligonucleotide immobilized on the solid substrate, wherein the capture oligonucleotide comprises a capture nucleotide sequence, a spatial barcode sequence (SBC), and an adapter sequence;

[0088] b) a reverse transcriptase (RT) and a template switching oligonucleotide (TSO) encoding a first adaptor sequence; and

[0089] c) a splint adaptor, wherein the splint adaptor comprises

[0090] i) a single-stranded splint sequence comprising a random base sequence (NX) having a blocking group at the 5' end of the NX sequence; and

[0091] ii) a double-stranded first adapter sequence comprising the hybridized first adapter sequence and a sequence complementary to the first adapter sequence, optionally wherein

[0092] The hybridized first adaptor sequence and the sequence complementary to the first adaptor sequence comprise a capping group at the 5' end of the first adaptor and at the 3' end of the complementary sequence to the first adaptor sequence.

[0093] In various aspects, the present disclosure also provides methods for RNA-seq library preparation that utilize enzymatic extension and chain termination on a surface to normalize library size. In various embodiments, transcripts are captured on a barcoded surface and reverse transcriptase is primed with nucleotides such as dUTP or ddNTP to allow for reduction in fragment size. Such methods can be applied to various library preparation methods that require shorter library fragments.

[0094] Therefore, in some aspects, the present disclosure provides a method for preparing a fixed library of target nucleic acids of a biological sample, the method comprising: (a) providing a surface comprising a plurality of capture oligonucleotides fixed thereon, wherein one or more of the plurality of capture oligonucleotides comprises from 5' to 3': (i) a first clustering primer sequence; (ii) a spatial barcode (SBC) sequence; (iii) a first sequencing primer sequence; and (iv) a capture nucleotide sequence; (b) contacting the biological sample with the surface, wherein the contact causes the target nucleic acid of the biological sample to hybridize with the capture nucleotide sequences of the plurality of capture oligonucleotides to form hybridized capture oligonucleotides; (c) extending the capture nucleotide sequence of the hybridized capture oligonucleotide to form a first complementary chain of the target nucleic acid, wherein the extension is performed in the presence of an extension termination portion, and wherein the extension termination portion is allyl-T or deoxyuridine triphosphate (dUTP), thereby preparing a fixed library of the target nucleic acids. In some embodiments, the method further comprises (d) contacting the surface with an exonuclease; (e) hybridizing a plurality of oligonucleotide primers with the first complementary strand, wherein each of the plurality of oligonucleotide primers comprises from 5' to 3': (i) an adapter nucleotide sequence; and (ii) a random nucleotide sequence; (f) extending the plurality of oligonucleotide primers to generate one or more second complementary strands comprising the adapter nucleotide sequence at the end. In other embodiments, the method further comprises (g) removing the one or more second complementary strands from the surface and amplifying the one or more second complementary strands. In some embodiments, step (g) is performed in the presence of an exclusion amplification (ExAmp) mixture, wherein the ExAmp mixture comprises a primer containing the clustering primer sequence. In some embodiments, one or more of the plurality of capture oligonucleotides is fixed on the surface by a cleavage site. In other embodiments, the cleavage site is an enzyme cleavage site. In various embodiments, the enzyme cleavage site comprises a restriction enzyme cleavage site, uracil, 8-oxoguanine, or a combination thereof. In some embodiments, the cleavage site is a chemical cleavage site. In some embodiments, the cleavage site is cut after step (c). In other embodiments, one or more of the multiple capture oligonucleotides are fixed on the surface by the cleavage site. In some embodiments, the cleavage site is an enzyme cleavage site. In other embodiments, the enzyme cleavage site includes a restriction enzyme site, uracil, 8-oxoguanine or a combination thereof. In some embodiments, the cleavage site is a chemical cleavage site. In other embodiments, the cleavage site is cut after step (f). In various embodiments, the extension termination portion is deoxyuridine triphosphate (dUTP), and the method also includes contacting the surface with uracil-DNA glycosylase (UDG).In some embodiments, the extension termination moiety is allyl-T, and wherein the method further comprises contacting the surface with a universal cleavage mixture (UCM). In some embodiments, the extension termination moiety is deoxyuridine triphosphate (dUTP), and the method further comprises contacting the surface with uracil-DNA glycosylase (UDG). In some embodiments, the extension termination moiety is allyl-T, and wherein the method further comprises contacting the surface with a universal cleavage mixture (UCM) before step (e).

[0095] In some aspects, the present disclosure provides a method for preparing a fixed library of target nucleic acids of a biological sample, the method comprising: (a) providing a surface comprising a plurality of capture oligonucleotides fixed thereon, wherein one or more of the plurality of capture oligonucleotides comprises from 5' to 3': (i) a first clustering primer sequence; (ii) a spatial barcode (SBC) sequence; (iii) a first sequencing primer sequence; and (iv) a capture nucleotide sequence; (b) contacting the biological sample with the surface, wherein the contact causes the target nucleic acid of the biological sample to hybridize with the capture nucleotide sequences of the plurality of capture oligonucleotides to form hybridized capture oligonucleotides; (c) extending the capture nucleotide sequence of the hybridized capture oligonucleotide to form a first complementary chain of the target nucleic acid, wherein the extension is performed in the presence of an extension termination portion, and wherein the extension termination portion is a dideoxynucleoside triphosphate (ddNTP), thereby preparing a fixed library of the target nucleic acids. In some embodiments, the method further comprises (d) contacting the surface with an exonuclease; (e) hybridizing a plurality of oligonucleotide primers to the first complementary strand, wherein each of the plurality of oligonucleotide primers comprises from 5' to 3': (i) an adapter nucleotide sequence; and (ii) a random nucleotide sequence; (f) extending the plurality of oligonucleotide primers to generate one or more second complementary strands comprising the adapter nucleotide sequence at the end. In some embodiments, the method further comprises (g) removing the one or more second complementary strands from the surface and amplifying the one or more second complementary strands. In some embodiments, step (g) is performed in the presence of an exclusion amplification (ExAmp) mixture, wherein the ExAmp mixture comprises a primer containing the first clustering primer sequence. In some embodiments, one or more of the plurality of capture oligonucleotides is fixed on the surface by a cleavage site. In other embodiments, the cleavage site is an enzyme cleavage site. In some embodiments, the enzyme cleavage site comprises a restriction enzyme cleavage site, uracil, 8-oxoguanine, or a combination thereof. In other embodiments, the cleavage site is a chemical cleavage site. In some embodiments, the cleavage site is cut after step (c). In various embodiments, one or more of the multiple capture oligonucleotides are fixed on the surface by the cleavage site. In some embodiments, the cleavage site is an enzyme cleavage site. In other embodiments, the enzyme cleavage site includes a restriction enzyme site, uracil, 8-oxoguanine or a combination thereof. In other embodiments, the cleavage site is a chemical cleavage site. In some embodiments, the cleavage site is cut after step (f). In some embodiments, the ddNTP includes a first click chemistry handle.In some embodiments, the method further comprises, after step (c), contacting the surface with an adapter oligonucleotide comprising a second click chemistry handle capable of being cross-linked to the first click chemistry handle, thereby connecting the adapter oligonucleotide to the first complementary strand. In some embodiments, the adapter oligonucleotide further comprises a second sequencing primer sequence. In further embodiments, the first click chemistry handle is an azide, a tetrazine, a strained olefin, or an alkyne. In further embodiments, the second click chemistry handle is an azide, a tetrazine, a strained olefin, or an alkyne.

[0096] In other aspects, the present disclosure provides a method for preparing a fixed library of target nucleic acids of a biological sample, the method comprising: (a) providing a surface comprising a plurality of capture oligonucleotides fixed thereon, wherein one or more of the plurality of capture oligonucleotides comprises from 5' to 3': (i) a first clustering primer sequence; (ii) a spatial barcode (SBC) sequence; (iii) a first sequencing primer sequence; and (iv) a capture nucleotide sequence; (b) contacting the biological sample with the surface, wherein the contact causes the target nucleic acid of the biological sample to hybridize with the capture nucleotide sequences of the plurality of capture oligonucleotides to form hybridized capture oligonucleotides; (c) extending the capture nucleotide sequence of the hybridized capture oligonucleotide to form a first complementary chain of the target nucleic acid, wherein the extension is performed in the presence of an extension termination portion, and wherein the extension termination portion is a deoxynucleoside triphosphate (dNTP) comprising a 3' phosphate group, thereby preparing a fixed library of the target nucleic acids. In some embodiments, the method further comprises (d) contacting the surface with an exonuclease; and (e) contacting the surface with a ligase, thereby connecting the adapter oligonucleotide to the first complementary strand, wherein the adapter oligonucleotide comprises from 5' to 3': (i) an adapter nucleotide sequence; and (ii) a random nucleotide sequence, and wherein the adapter oligonucleotide also comprises a second oligonucleotide hybridized to the adapter nucleotide sequence. In some embodiments, the adapter nucleotide sequence comprises a second sequencing primer sequence. In other embodiments, the connection occurs by splinting of the adapter oligonucleotide with the first complementary strand. In other embodiments, the ligase is T4 DNA ligase. In some embodiments, the method further comprises (f) extending the adapter oligonucleotide, thereby generating one or more second complementary strands. In some embodiments, the method further comprises (d) contacting the surface with an exonuclease; and (e) contacting the surface with a ligase, thereby connecting the adapter oligonucleotide to the first complementary strand, wherein the adapter oligonucleotide comprises from 5' to 3': (i) a random nucleotide sequence; and (ii) an adapter nucleotide sequence. In some embodiments, the adapter nucleotide sequence comprises a second sequencing primer sequence. In some embodiments, the connection occurs by connecting the single-stranded DNA of the adapter oligonucleotide and the first complementary chain. In other embodiments, the ligase is a DNA / RNA ligase. In some embodiments, the method further comprises (f) extending the adapter oligonucleotide, thereby producing one or more second complementary chains. In other embodiments, the method further comprises (g) removing the one or more second complementary chains from the surface and amplifying the one or more second complementary chains. In some embodiments, step (g) is carried out in the presence of an exclusion amplification (ExAmp) mixture.In other embodiments, one or more of the multiple capture oligonucleotides are fixed on the surface by a cleavage site. In some embodiments, the cleavage site is an enzyme cleavage site. In other embodiments, the enzyme cleavage site includes a restriction enzyme site, uracil, 8-oxoguanine or a combination thereof. In some embodiments, the cleavage site is a chemical cleavage site. In other embodiments, the cleavage site is cut after step (c). In some embodiments, one or more of the multiple capture oligonucleotides are fixed on the surface by a cleavage site. In other embodiments, the cleavage site is an enzyme cleavage site. In various embodiments, the enzyme cleavage site includes a restriction enzyme site, uracil, 8-oxoguanine or a combination thereof. In some embodiments, the cleavage site is a chemical cleavage site. In other embodiments, the cleavage site is cut after step (e).

[0097] In other aspects, the present disclosure provides a method for preparing a fixed library of target nucleic acids of a biological sample, the method comprising: (a) providing a surface comprising a plurality of capture oligonucleotides fixed thereon, wherein one or more of the plurality of capture oligonucleotides comprises from 5' to 3': (i) a first clustering primer sequence; (ii) a spatial barcode (SBC) sequence; (iii) a first sequencing primer sequence; and (iv) a capture nucleotide sequence; (b) contacting the biological sample with the surface, wherein the contact causes the target nucleic acid of the biological sample to hybridize with the capture nucleotide sequences of the plurality of capture oligonucleotides to form hybridized capture oligonucleotides; (c) extending the capture nucleotide sequence of the hybridized capture oligonucleotide to form a first complementary chain of the target nucleic acid, wherein the extension is performed in the presence of an extension termination portion, and wherein the extension termination portion is a deoxynucleoside triphosphate (dNTP) comprising a 3' phosphate group or a dideoxynucleoside triphosphate (ddNTP) comprising a first click chemistry handle, thereby preparing a fixed library of the target nucleic acids. In some embodiments, the extension termination portion is a deoxynucleoside triphosphate (dNTP) comprising a 3' phosphate group. In some embodiments, the method further comprises (d) chemically connecting an adapter oligonucleotide to the first complementary chain by a cross-linking group, wherein the adapter oligonucleotide comprises from 5' to 3': (i) an adapter nucleotide sequence; and (ii) a random nucleotide sequence, and wherein the adapter oligonucleotide also comprises a second oligonucleotide hybridized with the adapter nucleotide sequence. In some embodiments, the adapter nucleotide sequence comprises a second sequencing primer sequence. In various embodiments, the cross-linking group is a carboxyl-amine reactive group, a BCN-azide reactive group, a DBCO-azide reactive group, a tetrazine-TCO reactive group, or a combination thereof. In some embodiments, the extension termination portion is a dideoxynucleoside triphosphate (ddNTP) comprising a first click chemistry handle. In some embodiments, the method further comprises (d) connecting an adapter oligonucleotide to the first complementary strand by click chemistry, wherein the adapter oligonucleotide comprises from 5' to 3': (i) an adapter nucleotide sequence; and (ii) a random nucleotide sequence, and wherein the adapter oligonucleotide further comprises a second oligonucleotide hybridized to the sequencing primer sequence, wherein the second oligonucleotide comprises a second click chemistry handle. In some embodiments, the adapter nucleotide sequence comprises a second sequencing primer sequence. In various embodiments, the first click chemistry handle is an azide, a tetrazine, a strained olefin, or an alkyne. In some embodiments, the second click chemistry handle is an azide, a tetrazine, a strained olefin, or an alkyne. In some embodiments, the method further comprises (e) extending the adapter oligonucleotide, thereby generating one or more second complementary strands.In some embodiments, the method further comprises (f) removing the one or more second complementary strands from the surface and amplifying the one or more second complementary strands. In some embodiments, step (f) is performed in the presence of an exclusion amplification (ExAmp) mixture. In some embodiments, one or more of a plurality of capture oligonucleotides is fixed on the surface by a cleavage site. In some embodiments, the cleavage site is an enzyme cleavage site. In various embodiments, the enzyme cleavage site includes a restriction enzyme cleavage site, uracil, 8-oxoguanine, or a combination thereof. In some embodiments, the cleavage site is a chemical cleavage site. In other embodiments, the cleavage site is cleaved after step (c). In some embodiments, one or more of a plurality of capture oligonucleotides is fixed on the surface by a cleavage site. In some embodiments, the cleavage site is an enzyme cleavage site. In various embodiments, the enzyme cleavage site includes a restriction enzyme cleavage site, uracil, 8-oxoguanine, or a combination thereof. In some embodiments, the cleavage site is a chemical cleavage site. In some embodiments, the cleavage site is cleaved after step (d).

[0098] In some embodiments, the method of the present disclosure further comprises removing the target nucleic acid from the surface after step (c). In some embodiments, the method of the present disclosure further comprises removing the biological sample from the surface after step (d). In various embodiments, each of the multiple capture oligonucleotides comprises the same capture nucleotide sequence. In some embodiments, the multiple capture oligonucleotides comprise a variety of different capture nucleotide sequences. In other embodiments, a variety of different capture nucleotide sequences comprise one or more gene-specific capture sequences, one or more universal capture sequences, or a combination thereof. In various embodiments, the capture nucleotide sequence is a poly-T sequence, a poly-A sequence, a gene-specific capture sequence, or a universal capture sequence. In some embodiments, the universal capture sequence is a random nucleotide sequence or a non-self-complementary semi-random sequence. In various embodiments, the target nucleic acid is mRNA, gDNA, rRNA, tRNA, or a combination thereof. In some embodiments, the target nucleic acid is RNA, mRNA, or a combination thereof. In some embodiments, the target nucleic acid is a cDNA generated from RNA by reverse transcription, wherein a homopolymer capture sequence (e.g., a poly-A sequence) is added to the 3' end of the cDNA (e.g., by ligation or by a terminal transferase such as terminal deoxynucleotidyl transferase (TdT)). In some embodiments, the extension of the capture nucleotide sequence in step (c) is carried out using a reverse transcriptase. In some embodiments, before the target nucleic acid is hybridized with the capture nucleotide sequence, the target nucleic acid is polyadenylated. In various embodiments, the target nucleic acid is polyadenylated using poly (A) polymerase. In other embodiments, the target nucleic acid is polyadenylated using chemical connection or enzymatic connection. In some embodiments, amplification includes adding a second clustering primer sequence to one or more second complementary chains. In some embodiments, amplification also includes adding an index sequence. In some embodiments, amplification includes index PCR, during which the first primer is hybridized with the first clustering primer sequence, and the second primer is hybridized with the adapter nucleotide sequence, wherein the second primer comprises the second clustering primer sequence. In some embodiments, the second primer also comprises an index sequence.

[0099] It should be understood that each feature or embodiment or combination described herein is a non-limiting, illustrative example of any aspect of the present invention, and is therefore meant to be combined with any other feature or embodiment or combination described herein. For example, where features are described using language such as "one embodiment," "various embodiments," "some embodiments," "certain embodiments," "additional embodiments," "particular exemplary embodiments," and / or "another embodiment," each of these types of embodiments is a non-limiting example of a feature that is intended to be combined with any other feature or combination of features described herein, without necessarily listing every possible combination.

[0100] These features or combinations of features are applicable to any aspect of the present invention. When examples of values ​​falling within a range are disclosed, any of these examples are considered possible endpoints of the range, any and all numerical values ​​between such endpoints are considered, and any and all combinations of upper and lower limits are considered possible. BRIEF DESCRIPTION OF THE DRAWINGS

[0101] Figure 1A is a schematic diagram of a method for preparing an RNA sequence library according to the present disclosure.

[0102] Figure 1B is a schematic diagram of adding TSO complementary sequences during first strand synthesis in the method according to the present disclosure. This figure is adapted from Integrated DNA Technologies, "Use of Template Switching Oligos (TSOligos, TSOs) for efficient cDNA library construction" Education webpage.

[0103] Figure 2 is a schematic diagram of the read sequence used in the method of FIG. 1 .

[0104] Figure 3 The present invention is a process flow chart of the method for preparing RNA sequence library.

[0105] Figure 4A is a graph showing Tapestation data for the disclosed method, comparing purification starting input 2.5×SPRI purification to 0.7×SPRI purification.

[0106] Figure 4B is a graph showing Tapestation data of fragment sizes for two indexed dilutions: high input P7 / TSO amplicon (2.5 ng) versus low input amplicon (100 pg).

[0107] Figure 5A is a schematic diagram of tagmentation testing of 500 pg, 100 pg and 10 pg of P7 / TSO amplicons on beads in a method according to the present disclosure.

[0108] Figure 5B It is shown Figure 5A Plot of the fragment sizes of the libraries tested in .

[0109] Figure 6 is a schematic diagram of the test conditions for evaluating the effect of the amount of transposase and purification relative to no purification.

[0110] Figure 7is a graph showing the distribution of alignments according to the method of the present disclosure compared to the commercially available Visium method.

[0111] Figure 8 is a graph showing transcript coverage according to the method of the present disclosure.

[0112] Fig.9A and Fig. 9B is a schematic diagram of methods according to the present disclosure (A) in solution and (B) on a surface.

[0113] Fig.10 is a schematic diagram comparing methods according to the present disclosure with and without template switching oligonucleotides.

[0114] Fig.11A A schematic diagram of the generation of a transposition-amplified TSO library is shown. Fig. 11B Shown is a basic composition diagram of Read 1 in a sample from the TSP library. Fig. 11C Library concentrations determined by Screenape analysis are shown. Fig.11D The number of UMIs per 5M input raw reads is shown.

[0115] Fig.12 is a workflow showing the steps in single-stranded RNA library preparation, which combines on-surface template switching and single-stranded enzymatic ligation (TSO-LIG) to convert tissue RNA into a spatially barcoded library.

[0116] Fig.13 is a workflow showing enzymatic and chemical methods for converting synthetic cDNA containing a second adaptor into a library by single-stranded ligation of the first adaptor sequence to the 3' end of the first strand cDNA.

[0117] Fig.14 The sensitivity of template switching (TSO), single-strand splint ligation (LIG), and the combination of the two methods (TSO+LIG) are shown. The results are shown as the sensitivity UMI fold change relative to TSO for 100 adapters per bin. Sensitivity was calculated as the median UMI detected per 100 μm × 100 μm and then normalized to the TSO condition. The error bars are the STDEV from 4 tissue sections.

[0118] FIG. 15A to FIG. 15B Shown are the relative Rd1 adaptor addition efficiencies of template switching (TSO), single-stranded splint ligation (LIG), and the combination of both methods (TSO+LIG). Fig.15A The assay workflow is shown. Results are shown as the fold change in Rd1 adaptor addition efficiency relative to TSO ( Fig. 15B ). The efficiency is calculated as 2 -(Cq内部-Cq外部), then normalized to TSO conditions. Error bars are STDEV from 4 tissue sections.

[0119] Fig.16 A schematic diagram showing the normalization of library fragment size using dUTP in the reverse transcription reaction.

[0120] Fig.17 The structure of the sequencing reads is shown.

[0121] Fig.18 Schematic diagram showing library fragment size normalization with in-tube second strand synthesis using dUTP / allyl-T.

[0122] Fig.19 Library size normalization using ddNTPs in the reverse transcription reaction is shown.

[0123] Fig. 20 It was demonstrated that ExAMP was used as a cDNA elution reagent and to establish redundant predicted sequences.

[0124] Fig.21 This indicates that cDNA fragments can be shortened using 3'phos dNTPs or azido-ddNTPs.

[0125] Fig. 22 An example of how to add a SMI (e.g., UMI) sequence during second strand cDNA synthesis in the TSO ligation method is shown. DETAILED DESCRIPTION

[0126] There are many problems in isolating RNA from preserved tissue samples and converting RNA to cDNA on a flat surface, including low-quality RNA transcripts isolated from tissue samples, shorter synthetic cDNA fragments (<450 bp) in library preparation products, and a high percentage of poly A present in cDNA regions in the final sequencing products. These problems lead to a low mapping rate of exonic mRNA transcript regions in subsequent RNA-seq alignments.

[0127] To address this issue, it is hypothesized that improved methods are needed to generate improved capture and spatial library conversion from FFPE tissue samples.

[0128] The methods of the present disclosure provide spatial RNA sequencing library preparation methods that can be used for fresh frozen tissues as well as formalin-fixed paraffin-embedded tissues. The methods of the present disclosure can utilize a transposition-based approach to ensure that the spatial barcodes remain intact during the library preparation method.

[0129] In one aspect, the template switching-tagmentation-based method (TSO-TAG) of the present disclosure utilizes a second strand priming and template switching oligonucleotide (TSO) process, tagging to fragment and add UMIs and adapters to library fragments. Using extension with an extension primer (such as a Poly-TVN primer), pre-transposition can allow the 3' region of the fragment to remain single-stranded to avoid transposition on the spatial barcode. The TSO-TAG method of the present disclosure can advantageously provide a simplified workflow for library preparation, wherein the second strand synthesis time is reduced to less than 2 hours, for example, 10 minutes to about 60 minutes or about 15 minutes to about 30 minutes. The resulting library fragments are full-length because TSO is added to the 5' end of the transcript. Transposition adds UMIs while fragmenting the library into the desired sequence, and the barcode region remains single-stranded during transposition.

[0130] In another aspect, a method based on spatial barcode tagging and UMI tagging utilizes random second strand priming and global PCR to build redundancy. Tagging is used for fragmentation, while random oligonucleotide second strand priming adds UMIs and adapters.

[0131] Refer to Figure 1 and Figure 3 According to one embodiment, a method for preparing an RNA sequence library may include fixing a tissue sample on a substrate comprising a plurality of capture oligonucleotides. The capture oligonucleotide may include one or more gene-specific capture sequences for capturing mRNA transcripts from the tissue. For example, the capture oligonucleotide may include a polyT sequence for capturing polyadenylated mRNA from the tissue. For example, fresh frozen tissue may be sliced ​​and fixed. The substrate may be, for example, part of a solid support. The solid support may be, for example, a flow cell. For example, an Illumina polyT barcoded capture flow cell may be used. The flow cell may be assembled into a pad that creates a separate sample well on the tissue section, wherein the substrate defines the bottom surface of the well. For methods using formalin-fixed paraffin-embedded tissue, the method may first include treating the tissue with polyadenylated formalin-fixed paraffin-embedded RNA transcripts to improve capture and library conversion, for example, when a polyT capture surface is used. Other pretreatments of the tissue may also be used to improve capture of one or more gene-specific sequences of the capture oligonucleotide.

[0132] The method of the present disclosure may include coating the substrate with an RNase inhibitor (such as 0.01×SSC / RNase inhibitor), and the solution may be removed. The tissue may then be permeabilized by contacting the tissue and substrate with a permeabilization mixture and incubating the tissue in the mixture. For example, the permeabilization mixture may include 0.1% pepsin, 0.1N HCl, and may be preheated. For example, the tissue may be incubated at 37° C. for about 7 minutes. The permeabilization mixture may then be removed, and the wells may be washed with a buffer and an RNase inhibitor.

[0133] The capture oligonucleotides may include one or more gene-specific capture sequences or polyT sequences and library barcode information including a spatial bar sequence (SBC).The mRNA transcripts from the tissue are captured or immobilized on a substrate by the capture oligonucleotides.

[0134] The reverse transcriptase is carried out with a template switching oligonucleotide, and a TSO complementary sequence is added to the 5' end of the transcript. Specifically, under the condition of producing a first cDNA complementary to the mRNA transcript and a first chain of a TSO complementary sequence hybridized to the 5' end of the first cDNA, the substrate is contacted with a first chain synthesis mixture comprising a reverse transcriptase and a template switching oligonucleotide (TSO). The reverse transcriptase incorporates untemplated cytosine nucleotides at the 5' end of the first cDNA. TSO includes a sequence hybridized to untemplated cytosine nucleotides. TSO hybridizes to untemplated cytosine nucleotides, and extends the reverse transcriptase to produce a complement of TSO attached to the '5 end of the cDNA (referred to herein as a TSO complementary sequence). For example, the untemplated cytosine nucleotide can be CCC. For example, the sequence hybridized to the untemplated cytosine nucleotide can be 2 to 5 guanosines. For example, 2 to 5 guanosines can be riboguanosines. For example, the sequence hybridized to the untemplated cytosine nucleotide can be rGrGrG.

[0135] The first strand synthesis mixture includes reverse transcriptase and TSO. The mixture may also include a reducing agent, a reverse transcriptase reagent, and water. The components of the first strand synthesis mixture may be premixed and added to the substrate, or one or more of the components may be added to the substrate stepwise.

[0136] The substrate can be incubated in the first strand synthesis mixture for any desired amount of time. For example, the incubation can be carried out at 53° C. for about 1 hour. The first strand synthesis mixture is then discarded from the substrate and the substrate can be washed with water.

[0137] After the first strand is generated, the mRNA transcript is eluted from the substrate. For example, formamide can be used for elution. For example, the substrate can be incubated in 100% formamide at 80°C for 10 minutes. If necessary, the mRNA eluate can be stored at -80°C, for example, for reverse transcription qPCR quality control checks.

[0138] After elution, the substrate can be washed. For example, the substrate can be washed three times with water. KOH can be added to the substrate. For example, the substrate can be incubated in KOH for 5 minutes at room temperature. The KOH solution is discarded and the substrate is washed with a buffer solution (e.g., Buffer EB (Qiagen)).

[0139] Then the second strand is synthesized with TSO primers. Specifically, the substrate with the first strand is contacted with the second strand synthesis mixture containing TSO primers, and the first strand is used as a template to extend the TSO primer to produce a second strand complementary to the first strand and having a second cDNA complementary to the first cDNA. The second strand also includes a second strand barcode information, which has a spatial barcode sequence complementary sequence (also referred to herein as a library barcode sequence) complementary to the barcode sequence present on the first strand. The second strand synthesis mixture may include TSO primers, second strand reagents, and second strand enzymes. The method disclosed herein advantageously provides a method in which the time required for the second strand synthesis can be significantly reduced compared to conventional methods. For example, the second strand synthesis may include incubating the first strand with the second strand synthesis mixture for less than 2 hours. For example, the incubation time may be about 10 minutes to about 15 minutes, about 15 minutes to about 60 minutes, about 30 minutes to about 90 minutes, about 15 minutes to about 30 minutes, or about 45 minutes to about 2 hours. Other suitable times can be about 15 minutes, 16 minutes, 17 minutes, 18 minutes, 19 minutes, 20 minutes, 22 minutes, 24 minutes, 26 minutes, 28 minutes, 30 minutes, 32 minutes, 35 minutes, 36 minutes, 38 minutes, 40 minutes, 42 minutes, 44 minutes, 46 minutes, 48 ​​minutes, 50 minutes, 52 minutes, 54 minutes, 56 minutes, 58 minutes, 60 minutes, 65 minutes, 70 minutes, 75 minutes, 80 minutes, 85 minutes, 90 minutes, 95 minutes, 100 minutes, 105 minutes, 110 minutes, 115 minutes or 120 minutes and any ranges defined by these values, and any values ​​therebetween. For example, the substrate can be incubated at 65° C. for 15 minutes in the second strand synthesis mixture. The solution is discarded and the substrate is washed with a buffer (e.g., buffer EB).

[0140] The second strand is then eluted from the substrate. For example, elution can be performed by incubating the substrate in KOH at room temperature. For example, the substrate can be incubated in 0.08M KOH for about 10 minutes to elute the second strand. The second strand eluted in KOH can be transferred to a different reaction vessel. For example, a strip tube can be used. The second strand eluted in KOH can be neutralized before further extension. For example, Tris buffer can be used to neutralize the eluted second strand.

[0141] The extension primer is then used to extend to produce a double-stranded library while maintaining the single-stranded 3' region containing the barcode information. For methods using polyT capture oligonucleotides, poly-TVN primers can be used as extension primers. For example, the second strand is contacted with a poly-TVN extension mixture containing a poly-TVN primer, and extended to produce a double-stranded product while maintaining the single-stranded 3' region containing the barcode information. For methods using gene-specific capture oligonucleotides, the extension primer can be a primer that hybridizes with the second strand in a region of the second strand that does not include the barcode information. Extension can be achieved by mixing the second strand with an extension primer mixture and thermal cycling. The extension primer mixture can be, for example, an Illumina AMS strand displacement extension mixture can be used. Thermal cycling can be performed, for example, the second time including a first temperature and a first time, a second temperature and a second time, and a holding temperature. The second temperature can be higher than the first temperature. The first temperature can be, for example, about 25°C to about 37°C. The first time can be about 10 minutes to about 30 minutes. The second temperature can be about 60°C to 65°C. The second time can be about 10 minutes. For example, thermal cycling conditions can be 37°C for 10 minutes, 60°C for 10 minutes, and hold at 4°C.

[0142] The double-stranded product can be purified using known purification methods. For example, SPRI purification can be used, and the double-stranded product can be eluted in water.

[0143] The double-stranded product is contacted with a transposome under conditions where the double-stranded product is labeled to form a labeled product with a unique molecule and a PCR adapter identified. For example, an Illumina Surcecell B15 Tn5 transposome can be used for transposition. For example, the transposome can be an A14 or B15 transposome. For example, the transposome can have a customized transposon. The transposome can be provided as a transposome-modified bead. The labeling process can include contacting the double-stranded product with a transposome and a carrier gDNA. The concentration of the carrier gDNA can be about 1 ng to about 10 nm. Diluted transposomes and labeling buffers can be used for labeling. For example, 5 to 20 times diluted transposomes can be used. Taking into account the amount of product captured from the tissue, a specific dilution can be easily determined. The double-stranded product can be incubated in the transposome, for example, at 55° C. for 5 minutes. Labeling can be terminated using a labeling termination buffer. The double-stranded product can be incubated at room temperature for example for 5 minutes with a labeling termination buffer.

[0144] Transposition can be performed as in-solution tagmentation, e.g., Tn5 tagmentation. Alternatively, transposition can be performed on beads. For example, A14 transposome beads can be produced and used to transpose double-stranded products.

[0145] The labeling products are amplified using index PCR to generate a library. Index PCR can be performed using a labeling PCR mixture, a P7 primer, and a transposome-index-P5 primer. For example, the labeling products can be amplified using P7 and primers containing B15-ME, a sample index, and P5. For transposition performed with an A14 transposome, a short P7 / PA14 can be used for amplification. The index PCR process can include 10 to 24 cycles. Each cycle can include, for example, maintaining a first time at a first temperature, maintaining a second time at a second temperature, and maintaining a third time at a third temperature, wherein the first temperature is higher than the second temperature and the third temperature, and the third temperature is higher than the second temperature. Each cycle can be about 15 minutes to 50 minutes. For example, a cycle can include maintaining at 95°C for 10 seconds, maintaining at 60°C for 45 seconds, and maintaining at 72°C for 60 seconds. It can be maintained at the first temperature before the cycle. After completing all cycles, a final extension can be performed by maintaining at the third temperature. For example, the final extension can be maintained for about 5 minutes to 10 minutes. For example, an initial hold pre-cycle may be at 95°C for 30 seconds and a final extension at 72°C for 5 minutes and hold at 4°C.

[0146] The resulting library can be purified and sequenced. For example, the library can be purified using 1× SPRI.

[0147] Figure 2 The sequencing read structure of TAG-TSO is shown. Read 1 reads into the cDNA region. Read 2 reads into the spatial barcode. Read 3 reads into the sample index. Refer 4 reads into the Poly-TVN and cDNA region. In embodiments of the method that do not use poly-TVN, the extension primer sequence will be at the position of the poly-TVN.

[0148] Fig.9A and Fig. 9B is a schematic diagram of the TSO-TAG method according to the present disclosure. Fig.9A In FIG, a method is shown in which the process is performed as a sequential one-pot process. The one-pot synthesis can be achieved by using a biotinylated TSO primer in the second strand synthesis step to produce a second strand with biotinylated TSO. After elution and neutralization of the second strand cDNA, the product can be hybridized to beads, and subsequent method steps can be performed on the beads, with washing steps performed on a magnet. For example, streptavidin beads can be used.

[0149] Fig. 9BAn on-the-surface process for performing the TAG-TSO method of the present disclosure is shown. After RNA removal, the blocker oligonucleotide and TSO are hybridized to the first strand such that a gap exists between the blocker oligonucleotide and the TSO. The blocking oligonucleotide can be, for example, a 3' blocked SBS12'-PolyA. The TSO complement oligonucleotide is then gap filled into the 5' region of the blocker oligonucleotide using a non-strand displacement polymerase.

[0150] The blocker is then melted to form a blocker-free first strand. Tagging is performed on the surface, for example, using an A14 transposome, to introduce UMIs and adapters. The tagging product with the UMIs and PCR adapters is then extended. An extension mixture is added to form a second strand. The second strand includes a second strand barcode information having a spatial barcode sequence complementary sequence (SBC') complementary to the spatial barcode sequence and a second cDNA complementary to the first cDNA, the UMI, and the PCR adapter. The second strand product is eluted from the surface and amplified using index PCR;

[0151] refer to Fig.10 , showing the SBC-TAG UMI-TAG method compared to the TSO-TAG method. The SBC-TAG, UMI-TAG method for preparing an RNA sequence library may include mounting a tissue sample on a substrate having a plurality of capture oligonucleotides. For example, the substrate may be a flow cell or a portion of a flow cell. The capture oligonucleotides include a polyT sequence or one or more gene-specific capture sequences and barcode information comprising a spatial barcode sequence (SBC). mRNA transcripts from the tissue are captured on the substrate by the capture oligonucleotides. In order to capture oligonucleotides having a polyT sequence, polyadenylated mRNA is captured.

[0152] Reverse transcription is performed using a first strand synthesis mix with a reverse transcriptase to generate a first strand of a first cDNA having complementarity to the mRNA transcript.

[0153] After the first strand is generated, the mRNA transcript is eluted from the substrate. For example, formamide can be used for elution. For example, the substrate can be incubated in 100% formamide at 80°C for 10 minutes. If necessary, the mRNA eluate can be stored at -80°C, for example, for reverse transcription qPCR quality control checks.

[0154] The second strand synthesis is performed using random primers to generate a second strand having a second cDNA, a UMI, and an adapter. For example, the first strand is contacted with a second strand synthesis mixture having random primers and incubated to generate a second strand.

[0155] Alternatively, the second strand synthesis can be performed without eluting the mRNA. For example, after the first strand is generated and the mRNA transcript is not eluted, a second strand synthesis mixture including DNA pol 1 and RNase H can be used to generate the second strand. For example, the Illumina second strand master mix can be used to generate the second strand. The first strand can be incubated with the second strand master mix, for example, at 16°C for 1 hour to generate the second strand.

[0156] The second strand is then eluted.

[0157] The second strand product is then amplified to generate a double strand product, and the double strand product is tagged to form a tagged product.

[0158] The tagmentation products were amplified with the first index PCR to determine the SBC and with the second index PCR to determine the UMI.

[0159] the term

[0160] As used in this specification and the paragraphs cited herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

[0161] "About" and "approximately" generally mean an acceptable degree of error for the amount measured given the nature or precision of the measurement. Exemplary degrees of error are within 20%-25% of the value or range of values, for example, within 20%, 10%, 5%, 4%, 3%, 2% or 1% of the value or range of values.

[0162] In the method, the capture oligonucleotide is fixed on a substrate by one or more polynucleotides (such as a polynucleotide). When referring to the fixation of a molecule (e.g., nucleic acid) to a solid support, the terms "fixed" and "attached" are used interchangeably herein, and unless otherwise explicitly or indicated by context, the two terms are intended to cover direct or indirect, covalent or non-covalent attachment. In some embodiments, covalent attachment can be used, but generally all that is required is that the molecule (e.g., nucleic acid) remains fixed or attached to the support under conditions intended to use the support (e.g., in applications requiring nucleic acid amplification and / or sequencing). The oligonucleotide to be used as a capture primer or an amplification primer can be fixed so that the 3'-end can be used for enzymatic extension, and at least a portion of the sequence can hybridize with a complementary sequence.

[0163] Immobilization may occur by hybridization to a surface-attached oligonucleotide, in which case the immobilized oligonucleotide or polynucleotide may be in a 3'-5' orientation. Alternatively, immobilization may occur by means other than base pairing hybridization, such as covalent attachment as described above.

[0164] As used herein, the term "fixed" refers to the state in which two things are joined, fastened, adhered, attached, connected or combined to each other. For example, an analyte (such as a nucleic acid) can be fixed on a material (such as a bead, a gel or a surface) by a covalent bond or a non-covalent bond. A covalent bond is characterized by sharing electron pairs between atoms. A non-covalent bond is a chemical bond that does not involve a shared electron pair, and can include, for example, hydrogen bonds, ionic bonds, van der Waals forces, hydrophilic interactions and hydrophobic interactions. In various embodiments, covalent attachment can be used, but all that is required is that the oligonucleotide remains fixed or attached to the surface under conditions intended to use the surface (for example, in applications requiring nucleic acid capture, amplification and / or sequencing).

[0165] Exemplary covalent linkages include, for example, those produced using click chemistry techniques. Exemplary non-covalent linkages include, but are not limited to, non-specific interactions (e.g., hydrogen bonding, ionic bonding, van der Waals interactions, etc.) or specific interactions (e.g., affinity interactions, receptor-ligand interactions, antibody epitope interactions, avidin-biotin interactions, streptavidin-biotin interactions, lectin carbohydrate interactions, etc.). Exemplary linkages are described in U.S. Patents 6,737,236, 7,259,258, 7,375,234, and 7,427,678; and U.S. Patent Publication 2011 / 0059865A1, each of which is incorporated herein by reference.

[0166] The terms "solid surface", "solid support" and other grammatical equivalents herein refer to any material that is suitable or can be modified to be suitable for attachment of capture oligonucleotides. As will be appreciated by those skilled in the art, the number of possible substrates is very large. Possible substrates include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylic, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethane, Teflon, polyvinyl alcohol, polyvinyl alcohol, polypropylene glycol ... TM The invention relates to a kind of solid support and solid surface. The solid support and solid surface of the present invention can be a kind of solid support or ...

[0167] As used herein, the term "substrate" is intended to represent a solid carrier or support structure. The term includes any material that can be used as a solid or semi-solid basis for the formation of features, such as holes for the deposition of biopolymers (including nucleic acids, polypeptides and / or other polymers), including the attachment of capture oligonucleotides. Non-limiting examples of substrates include bead arrays, spot arrays, aggregated particles arranged on the surface of a chip, membranes, porous plates, beads, and flow cells. For example, substrates as provided herein are modified or can be modified to adapt to the attachment of biopolymers by a variety of methods well known to those skilled in the art. Exemplary types of substrate materials include glass, modified glass, functionalized glass, inorganic glass, microspheres (including inert and / or magnetic particles), plastics, polysaccharides, nylon, nitrocellulose, ceramics, resins, silica, silica-based materials, carbon, metals, optical fibers or fiber bundles, various polymers other than those illustrated above, and porous microtiter plates. Exemplary plastics of specific types include acrylic resins, polystyrene, copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethane, and Teflon TM Specific types of exemplary silica-based materials include silicon and various forms of modified silicon.

[0168] As used herein, "surface" may refer to a portion of a substrate or support structure that can contact a reagent, bead, or analyte. The surface may be substantially flat or planar. Alternatively, the surface may be rounded or contoured. Exemplary contours that may be included on the surface are holes (e.g., micropores or nanopores), depressions, columns, ridges, channels, and the like. Exemplary materials that may be used as substrates or support structures include: glass, such as modified or functionalized glass; plastics, such as acrylic acid, polystyrene, or a copolymer of styrene and another material, polypropylene, polyethylene, polybutylene, polyurethane, or Teflon; polysaccharides or cross-linked polysaccharides, such as agarose or agarose gel; nylon; nitrocellulose; resins; silica or silica-based materials, including silicon and modified silicon, carbon fibers; metals; inorganic glass; fiber bundles, or a variety of other polymers. A single material or a mixture of several different materials may form a surface that can be used in certain examples. In some examples, the surface includes holes (e.g., micropores or nanopores). In some aspects, the surface comprises an array of holes (e.g., micropores or nanopores) on a solid support of glass, silicon, plastic, or other suitable gel with a patterned covalent attachment, such as poly (N-(5-azidoacetamidopentyl) acrylamide-co-acrylamide) (PAZAM, see, e.g., U.S. Patent Application Publication No. 2014 / 0079923A1, which is incorporated herein by reference). In some embodiments, each nanopore comprises a unique oligonucleotide (e.g., an oligonucleotide with a unique spatial barcode). In some examples, the support structure may comprise one or more layers. Non-limiting examples of surfaces include bead arrays, spotted arrays, aggregated particles arranged on a chip surface, membranes, porous plates, and flow cells. In various embodiments, the substrate or the surface of the substrate comprises a material selected from glass, silicon, a poly-L-lysine coated material, nitrocellulose, polystyrene, cyclic olefin copolymer (COC), cyclic olefin polymer (COP), polyacrylamide, polypropylene, polyethylene, or polycarbonate.

[0169] Exemplary flow cells include, but are not limited to, those used in nucleic acid sequencing devices, such as flow cells used in the following platforms: Genome or platform; or SOLiD commercialized by Life Technologies (Carlsbad, CA) TM or Ion Torrent TM Sequencing Platforms. Exemplary flow cells and methods of making and using the same are also described in, for example, WO 2014 / 142841 A1, US Patent Application Publication No. 2010 / 0111768 A1, and US Patent No. 8,951,781, each of which is incorporated herein by reference.

[0170] Those skilled in the art will know or understand that the composition and geometry of substrates as provided herein may vary according to the intended use and the preferred requirements of the user. Thus, although planar substrates such as slides, chips, wafers or beads may be used for microarrays, given the teachings and guidance provided herein, those skilled in the art will understand that various other substrates illustrated herein or well known in the art may also be used in the methods and / or compositions herein.

[0171] In some embodiments, the solid support comprises one or more surfaces capable of contacting a reagent, bead, or analyte. The surface may be substantially flat or planar. Alternatively, the surface may be rounded or contoured. Exemplary contours that may be included on the surface are holes (e.g., micropores or nanopores), depressions, columns, ridges, channels, etc. Exemplary materials that may be used as surfaces include: glass, such as modified or functionalized glass; plastics, such as acrylic acid, polystyrene, or copolymers of styrene and another material, polypropylene, polyethylene, polybutylene, polyurethane, or Teflon; polysaccharides or cross-linked polysaccharides, such as agarose or agarose gel; nylon; nitrocellulose; resin; silica or silica-based materials, including silicon and modified silicon, carbon fiber; metal; inorganic glass; fiber bundles, or a variety of other polymers. A single material or a mixture of several different materials may form a surface that can be used for certain examples. In some examples, the surface includes holes (e.g., micropores or nanopores). In some aspects, the surface comprises wells in an array of wells (e.g., microwells or nanowells) on a glass, silicon, plastic, or other suitable solid support having a patterned covalently attached gel such as poly(N-(5-azidoacetamidopentyl)acrylamide-co-acrylamide) (PAZAM, see, e.g., U.S. Patent Application Publication No. 2014 / 0079923A1, which is incorporated herein by reference). In some examples, the support structure may include one or more layers.

[0172] Certain embodiments can utilize solid supports consisting of inert substrates or matrices (e.g., slides, polymer beads, etc.), which have been functionalized, for example, by applying an intermediate material layer or coating comprising reactive groups, which allow covalent attachment to biomolecules such as polynucleotides. Examples of such supports include, but are not limited to, polyacrylamide hydrogels loaded on inert substrates (such as glass), especially polyacrylamide hydrogels as described in WO 2005 / 065814 and US2008 / 0280773, the contents of which are incorporated herein by reference in their entirety. In such embodiments, biomolecules (e.g., polynucleotides) can be covalently attached directly to intermediate materials (e.g., hydrogels), but the intermediate materials themselves can be non-covalently attached to substrates or matrices (e.g., glass substrates). The term "covalently attached to a solid support" should be interpreted accordingly as encompassing this type of arrangement.

[0173] In some embodiments, the solid support includes a patterned surface suitable for fixing the capture oligonucleotide in an ordered pattern. "Patterned surface" refers to the arrangement of different regions in or on the exposed layer of the solid support. For example, one or more regions in these regions can be a feature where one or more capture oligonucleotides are present. The feature can be separated by a gap region where there is no capture oligonucleotide. In some embodiments, the pattern can be an xy format of a feature in the form of rows and columns. In some embodiments, the pattern can be a repeated arrangement of a feature and / or gap region. In some embodiments, the pattern can be a random arrangement of a feature and / or gap region. In some embodiments, the capture oligonucleotide is randomly distributed on the solid support. In some embodiments, the capture oligonucleotide is distributed on the patterned surface. The exemplary patterned surface that can be used for the method and composition described herein is described in U.S. Application No. 13 / 661,524 and U.S. Patent Application Publication No. 2012 / 0316086A1, each of which is incorporated herein by reference.

[0174] In some embodiments, the solid carrier includes a hole (for example, micropore or nanopore) or a recessed array in the surface. This can be manufactured using a variety of techniques as generally known in the art, and these techniques include but are not limited to photolithography, imprinting technology, molding technology and micro-etching technology. In some respects, the solid carrier includes glass, silicon, plastic or other suitable gels with patterned covalent attachment such as poly-(N-(5-azidoacetamidopentyl) acrylamide-to-acrylamide) (PAZAM, see, for example, U.S. Patent Application Publication No. 2014 / 0079923A1, which is incorporated herein by reference) hole (for example, micropore or nanopore) array on the solid carrier. In some examples, the solid carrier may include one or more layers. Those skilled in the art will appreciate that the technology used will depend on the composition and shape of the array substrate.

[0175] The composition and geometry of the solid carrier can vary with its use. In some embodiments, the solid carrier is a planar structure, such as a slide, a chip, a microchip and / or an array. Therefore, the surface of the substrate can be in the form of a planar layer. In some embodiments, the solid carrier includes one or more surfaces of a flow cell.

[0176] In some embodiments, the solid support or a surface thereof is non-planar, such as the interior or exterior surface of a tube or container. In some embodiments, the solid support comprises microspheres or beads.

[0177] The attachment of nucleic acid to a carrier, whether rigid or semi-rigid, can be carried out by covalent or non-covalent connection. Exemplary connections are described in U.S. Patents 6,737,236, 7,259,258, 7,375,234, and 7,427,678; and U.S. Patent Publication 2011 / 0059865A1, each of which is incorporated herein by reference. In some embodiments, nucleic acid or other reaction components may be attached to a gel or other semi-solid carrier, which in turn is attached or adhered to a solid phase carrier. In such embodiments, nucleic acid or other reaction components are understood to be solid phase.

[0178] In some embodiments, the solid support comprises microparticles, beads, planar supports, patterned surfaces, or wells. In some embodiments, the planar support is the inner or outer surface of a tube.

[0179] The term "bead" refers to a small body made of a rigid or semi-rigid material. The body can have a shape characterized, for example, by spherical, ellipsoidal, microspherical, or other recognized particle shapes, whether of regular or irregular size. Exemplary materials that can be used for beads include, but are not limited to, glass; plastics such as acrylic, polystyrene or a copolymer of styrene and another material, polypropylene, polyethylene, polybutylene, polyurethane, or polytetrafluoroethylene (available from Chemours) ); polysaccharides or cross-linked polysaccharides, such as agarose or agarose gel; nylon; nitrocellulose; resins; silica or silica-based materials, including silicon and modified silicon; carbon fibers, metals; inorganic glass; fiber bundles, or a variety of other polymers. Exemplary beads include, but are not limited to, controlled pore glass beads, paramagnetic beads, thoria sols, agarose beads, nanocrystals, and other beads known in the art, such as those described in the Microsphere Detection Guide from Bangs Laboratories, Fishers Ind. The beads can also be coated with a polymer having a functional group that can be connected to an oligonucleotide. As used herein, the term "solid support" refers to a rigid substrate that is insoluble in aqueous liquids. The substrate can be nonporous or porous. The substrate may optionally be capable of absorbing liquids (e.g., due to porosity), but will generally be sufficiently rigid so that the substrate does not significantly expand when absorbing liquids and does not substantially shrink when the liquid is removed by drying. Nonporous solid supports are generally impermeable to liquids or gases. Exemplary solid supports include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylic, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethane, Teflon TM, cyclic olefins, polyimides, etc.), nylon, ceramics, resins, Zeonor, silica or silica-based materials (including silicon and modified silicon), carbon, metals, inorganic glasses, fiber bundles, and polymers. Particularly useful materials are glass. Other suitable substrate materials may include polymeric materials, plastics, silicon, quartz (fused quartz), borofloat glass, silica, silica-based materials, carbon, metals (including gold), optical fibers or fiber bundles, sapphire, or plastic materials (such as COC and epoxides). A specific material may be selected based on the properties desired for a particular use. For example, a material that is transparent to radiation of a desired wavelength may be used for analytical techniques that utilize radiation of a desired wavelength, such as one or more of the techniques described herein. Conversely, it may be desirable to select a material that does not pass radiation of a specific wavelength (e.g., opaque, absorptive, or reflective). This can be used to form a mask to be used during the manufacture of a structured substrate; or for chemical reactions or analytical detection using a structured substrate. Other properties of the material that can be used are inertness or reactivity to certain reagents used in downstream processes; or ease of handling or low cost during manufacturing processing. Additional examples of materials that can be used in the structured substrates or methods of the present disclosure are described in US Patent Application Publication Nos. 2012 / 0316086A1 and 2013 / 0116153, each of which is incorporated herein by reference in its entirety. In some embodiments, the solid support is a flow cell.

[0180] The beads need not be spherical; irregular particles may be used. Alternatively or in addition, the beads may be porous. Bead sizes range from nanometers (i.e., 100 nm) to millimeters (i.e., 1 mm), with beads ranging from 0.2 microns to 200 microns, or 0.5 microns to 5 microns, although smaller or larger beads may be used in some embodiments.

[0181] As used herein, the term "flow cell" is intended to mean a container having a chamber in which a reaction can be carried out, an inlet for delivering reagents to the chamber, and an outlet for removing reagents from the chamber. In some embodiments, a flow cell is a chamber comprising a solid surface, and one or more fluid reagents can flow through this solid surface. In some embodiments, a solid carrier comprises one or more surfaces of a flow cell. As used herein, the term "flow cell" comprises a chamber comprising a solid surface, and one or more fluid reagents can flow through this solid surface. A flow cell can be an ordered flow cell or a random flow cell.

[0182] Examples of flow cells and related fluid systems and detection platforms that can be readily used in the methods of the present disclosure are described, for example, in: Bentley et al., Nature 456:53-59 (2008); WO 04 / 018497, US 7,057,026, WO 91 / 06678, WO 07 / 123744, US 7,329,492, US 7,211,414, US 7,315,019, US 7,405,281, and US2008 / 0108082, each of which is incorporated herein by reference. In some embodiments, the chamber is configured to detect a reaction occurring in the chamber. For example, the chamber may include one or more transparent surfaces that allow optical detection of biological samples, optically labeled molecules, etc. in the chamber. Exemplary flow cells include, but are not limited to, those used in nucleic acid sequencing devices, such as flow cells for the following platforms: Genome or platform; or SOLiD commercialized by Life Technologies (Carlsbad, CA) TM or Ion Torrent TM Sequencing Platforms. Exemplary flow cells and methods of making and using the same are also described in, for example, WO 2014 / 142841A1, US Patent Application Publication No. 2010 / 0111768A1, and US Patent No. 8,951,781, each of which is incorporated herein by reference.

[0183] As used herein, when used with reference to nucleic acids, the term "different" means that the nucleic acids have nucleotide sequences that are not identical to each other. Two or more nucleic acids may have nucleotide sequences that differ along their entire length. Alternatively, two or more nucleic acids may have nucleotide sequences that differ along a substantial portion of their length. For example, two or more nucleic acids may have target nucleotide sequence portions that are different for two or more molecules, while also having common sequence portions that are identical on the two or more molecules. The term can be similarly applied to proteins that can be distinguished as different from each other based on amino acid sequence differences.

[0184] "Complementary sequence" means that the oligonucleotide comprises a nucleotide sequence that can form a double-stranded structure by matching a base pair with another oligonucleotide or its part. "Substantially complementary" means that the oligonucleotide and the complementary sequence have at least 85%, 90%, 95%, 98%, 99% or 100% overall sequence identity. In various embodiments, "complementary" oligonucleotides are 100% complementary to each other, and in other embodiments, the first oligonucleotide sequence is at least (meaning to be greater than or equal to) about 95% complementary to the second oligonucleotide sequence on the length of the first oligonucleotide, and at least about 90%, at least about 85%, at least about 80%, at least about 75%, at least about 70%, at least about 65%, at least about 60%, at least about 55% or at least about 50% complementary to the degree that the oligonucleotide can hybridize to each other under the conditions used on the length of the first oligonucleotide. Determine the complementarity percentage on the length of the oligonucleotide. For example, given a first oligonucleotide in which 18 of the first oligonucleotide's 20 nucleotides are complementary to a 20 nucleotide region in a second oligonucleotide having a total length of 100 nucleotides, the oligonucleotides will be 90% complementary. In this example, the remaining non-complementary nucleotides may be clustered or interspersed with the complementary nucleobases and need not be adjacent to each other or to the complementary nucleotides.

[0185] As used herein, "primer" is a nucleic acid molecule that can hybridize with a target sequence, such as an adapter attached to a library fragment. For example, an amplification primer can be used as a starting point for template amplification and cluster generation. For example, a synthetic nucleic acid (template) chain may include a site to which a primer (e.g., a sequencing primer) can hybridize, so as to initiate the synthesis of a new chain complementary to the synthetic nucleic acid chain. Any primer may include any combination of nucleotides or their analogs. In some examples, a primer is a single-stranded oligonucleotide or polynucleotide. Primer length can be any number of base lengths and can include a variety of non-natural nucleotides. In various embodiments, a sequencing primer is a short chain, ranging from 5 to 60 bases, 10 to 60 bases, 10 to 20 bases, 10 to 30 bases, 10 to 40 bases, 10 to 50 bases, or 20 to 40 bases.

[0186] As used herein, the terms "molecular identifier," "single molecule identifier," or "SMI" refer to a nucleotide sequence applied to or identified in a nucleic acid molecule that can be used to distinguish individuals or groups of nucleic acid molecules from each other. When incorporated into a nucleic acid, the SMI can be used to correct for subsequent amplification bias by directly counting single molecule identifiers (SMIs) sequenced after amplification. SMIs (e.g., UMIs) can be attached to similar nucleic acids (e.g., adapters) so that each nucleic acid is unique. SMIs (e.g., UMIs) can also be used to uniquely label a single molecule (e.g., a single mRNA molecule) in a sample (e.g., a single mRNA molecule in a tissue sample, a cell sample, or a sample library). In some embodiments, the UMI is a random nucleotide sequence (e.g., N9).

[0187] As used herein, the term "unique molecular identifier" or "UMI" refers to a nucleotide sequence applied to or identified in a nucleic acid molecule, which can be used to distinguish individuals of nucleic acid molecules from each other. UMIs can be sequenced together with the nucleic acid molecules to which they are associated to determine whether the read sequence is the sequence of a nucleic acid molecule of one source or another source. The term "UMI" can be used herein to refer to both the sequence information of a polynucleotide and the physical polynucleotide itself. When used for capture probes or other nucleic acids, a unique molecular index, unique molecular identifier, or UMI is intended to refer to a portion of a probe that can be used as a molecular barcode to uniquely mark each molecule in a sample library. The UMI can be represented as "NNNN..." in a nucleic acid string to designate that portion of the oligonucleotide as a UMI. The length of a UMI can be 6 to 20 nucleotides or longer. A UMI is similar to a barcode, which is typically used to distinguish the reads of one sample from the reads of other samples, but when many fragments from various samples are sequenced together, the UMI is used instead to distinguish the nucleic acid template fragment from another. UMIs can be defined in many ways, such as described in WO 2019 / 108972 and WO 2018 / 136248, which are incorporated herein by reference. In some aspects, the UMI comprises a spatial barcode.

[0188] As used herein, the term "universal sequence" refers to a series of nucleotides common to two or more nucleic acid molecules, even if these molecules also have sequence regions that are different from each other. Universal sequences present in different members of a molecular set can allow a population of universal capture nucleic acids complementary to the universal sequence to capture a variety of different nucleic acids. Similarly, universal sequences present in different members of a molecular set can allow a population of universal primers complementary to the universal sequence to replicate or amplify a variety of different nucleic acids. Therefore, universal capture nucleic acids or universal primers contain sequences that can specifically hybridize with universal sequences. Target nucleic acid molecules can be modified to attach universal adapters, for example, at one or both ends of different target sequences. Universal capture oligonucleotides are suitable for probing a variety of different oligonucleotides without having to distinguish different species, while target-specific capture sequences are suitable for distinguishing different species. A non-limiting example of a universal sequence is a polyT nucleotide sequence.

[0189] As used herein, a "semi-random" nucleotide sequence comprises or consists of a partially predetermined nucleotide sequence combined with a random nucleotide sequence.

[0190] As used herein, the terms “includes,” “including,” “includes,” “including,” “contains,” “containing,” and any variations thereof, are intended to cover a non-exclusive inclusion such that a process, method, product defined by a method, or composition of matter that includes, contains, or contains an element or list of elements includes not only those elements, but may include other elements not expressly listed or inherent to such process, method, product defined by a method, or composition of matter.

[0191] As used herein, the term "adapter" generally refers to any linear nucleic acid molecule that can be connected to an oligonucleotide of the present disclosure. In some embodiments, the adaptor includes two reverse complementary oligonucleotides that form a double-stranded structure. In some embodiments, the adaptor includes two oligonucleotides that are complementary in one part and mismatched in another part, forming a Y-shaped or forked adaptor that is double-stranded in the complementary part and has two soft overhangs in the mismatched part. In some embodiments, the adaptor is copied to the library molecule using templated polymerase synthesis (for example, second-strand cDNA synthesis as described herein). In some embodiments, the adaptor is connected to the first complementary strand of the present disclosure. In some embodiments, the adaptor comprises two oligonucleotides, which are double-stranded in one part and single-stranded in another part, forming an adaptor with an overhang. In some embodiments, the oligonucleotide primer comprises an adaptor nucleotide sequence (for example, a B15 nucleotide sequence). In some embodiments, the adaptor comprises a sequence complementary to a primer. In other embodiments, the adaptor comprises a sequence complementary to a P5 primer or a P5' primer. In some embodiments, the adapter comprises a sequence complementary to a P7 primer or a P7' primer. In some embodiments, the adapter comprises a sequence complementary to a B15 primer or a B15' primer. When referring to examples of oligonucleotide sequences of primers (e.g., cluster primers) and / or oligonucleotide sequences complementary to primers, the terms "P5", "P7", "B15", "P5'" (P5 prime), "P7'" (P7 prime), "B15'" (B15 prime), "P15", "P17" and "A14" may be used. The terms "P5'" (P5 prime), "P7'" (P7 prime), "B15'" (B15 prime), and "A14" (A14 prime) refer to the complementary sequences of P5, P7, B15 and A14, respectively. It should be understood that any suitable primer can be used in the methods presented herein, and the use of P5, P5', P7, P7', P15, P17, B15, B15', A14 and A14' is only an exemplary embodiment. The use of primers such as P5, P5', P7, P7', P15, P17, B15, B15', A14 and A14' or their complementary sequences on a flow cell is known in the art, as exemplified by the disclosures of WO 2019 / 222264, WO 2007 / 010251, WO 2006 / 064199, WO 2005 / 065814, WO 2015 / 106941, WO 1998 / 044151 and WO 2000 / 018957, each of which is incorporated herein by reference in its entirety.

[0192] For example, any suitable forward amplification primer, whether fixed or in solution, can be used in the methods presented herein for hybridization with complementary sequences and amplification of sequences. Similarly, any suitable reverse amplification primer, whether fixed or in solution, can be used in the methods presented herein for hybridization with complementary sequences and amplification of sequences. Those skilled in the art will understand how to design and use primer sequences suitable for capturing and / or amplifying nucleic acids presented herein. In some embodiments, the "first clustering primer" as described herein is a P5 primer. In some embodiments, the "first clustering primer" as described herein is a P7 primer. In some embodiments, the "first clustering primer" as described herein is a P5' primer. In some embodiments, the "first clustering primer" as described herein is a P7' primer. In some embodiments, the "second clustering primer" as described herein is a P5 primer. In some embodiments, the "second clustering primer" as described herein is a P7 primer. In some embodiments, the "second clustering primer" as described herein is a P5' primer. In some embodiments, the "second clustering primer" as described herein is a P7' primer. In some embodiments, P5 comprises a polynucleotide sequence 5'AAT GAT ACG GCG ACC ACC GA 3' (SEQ ID NO: 1) or a variant thereof or consists thereof. In some embodiments, P5 comprises a polynucleotide sequence 5'AAT GAT ACG GCG ACC ACC GAG ATC TAC AC3' (SEQ ID NO: 2) or a variant thereof or consists thereof. In some embodiments, P7 comprises a polynucleotide sequence 5'CAAGCA GAA GAC GGC ATA CG 3' (SEQ ID NO.3) or a variant thereof or consists thereof. In some embodiments, P7 comprises a polynucleotide sequence 5'CAA GCA GAA GAC GGC ATA CGA GAT 3' (SEQ ID NO.4) or a variant thereof or consists thereof. In some embodiments, P5' comprises a polynucleotide sequence 5'TCG GTG GTC GCC GTA TCA TT 3' (SEQ ID NO: 5) or a variant thereof or consists thereof. In some embodiments, P5' comprises or consists of the polynucleotide sequence 5'GTG TAGATC TCG GTG GTC GCC GTA TCA TT 3' (SEQ ID NO: 6) or a variant thereof. In some embodiments, P7' comprises the polynucleotide sequence 5'CGT ATG CCG TCT TCT GCT TG 3' (SEQ ID NO. 7) or a variant thereof.In some embodiments, P7' comprises the polynucleotide sequence 5'ATC TCG TAT GCC GTC TTC TGC TTG 3' (SEQID NO.8) or a variant thereof or consists thereof. In some embodiments, B15 comprises the polynucleotide sequence 5'GTCTCGTGGGCTCGG 3' (SEQ ID NO:9) or a variant thereof or consists thereof. In some embodiments, B15' comprises the polynucleotide sequence 5'CCGAGCCCACGAGAC 3' (SEQ ID NO:10) or a variant thereof or consists thereof. In some embodiments, P15 comprises the polynucleotide sequence 5'TTTTTTAATG ATACGGCGAC CACCGAGANC TACAC 3' (SEQ ID NO:11) or a variant thereof or consists thereof. In some embodiments, P17 comprises the polynucleotide sequence 5'TTTTTTNNNCAAGCAGAAGA CGGCATACGA GAT 3' (SEQ ID NO:12) or a variant thereof or consists thereof. When referring to any sequence described herein, the term "variant" as used herein refers to a variant nucleic acid that is substantially identical to, for example, a non-variant sequence (i.e., only has some nucleotide sequence variations). In some embodiments, the variant has at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or at least 99% overall nucleotide sequence identity with the non-variant nucleic acid sequence. It should be understood that P5 and P7 mentioned herein can refer to different primer sequences. The disclosure encompasses any suitable primer sequence combination.

[0193] As used herein, "anchor" refers to a moiety that attaches a nanoscaffold to a substrate. Anchors include chemical moieties, peptides, or oligonucleotides. Polynucleotide anchors can be 4 to 20 nucleotides.

[0194] As used herein, a "splint oligonucleotide" refers to an oligonucleotide comprising a sequence complementary to a region on a surface probe and another sequence complementary to a capture oligonucleotide (e.g., attached to a substrate). The length of a splint oligonucleotide is typically 10 nucleotides or longer. A splint oligonucleotide may be 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 60, 75, or 80 nucleotides.

[0195] As used herein, "surface oligonucleotide" refers to an oligonucleotide comprising an anchor sequence for attaching the oligonucleotide to the substrate surface, a spatial barcode sequence, and a sequence for hybridizing with a splint oligonucleotide. The length of the surface oligonucleotide is typically 20 nucleotides or longer. The surface oligonucleotide may be 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 60, 75 or 80 nucleotides or more.

[0196] As used herein, the terms "address," "tag," "barcode," or "index," when used in reference to a nucleotide sequence, are intended to mean a unique nucleotide sequence that is distinguishable from other indexes and from other nucleotide sequences within a polynucleotide contained within a sample. A nucleotide "address," "tag," "barcode," or "index" may be a random or specifically designed nucleotide sequence. An "address," "tag," "barcode," or "index" may have any desired sequence length, as long as it has a length sufficient to make it a unique nucleotide sequence within multiple indexes in a population and / or within a plurality of polynucleotides being analyzed or probed. The nucleotide "address," "tag," "barcode," or "index" of the present disclosure may be used, for example, to attach to a target polynucleotide to tag or label a particular species to identify all members of the tagged species within a population. Thus, an index may be used as a barcode, wherein different members of the same molecular species may contain the same index, and wherein different species within a population of different polynucleotides may have different indexes.

[0197] As used herein, the term "barcode" is also intended to mean a series of nucleotides in an oligonucleotide that can be used to provide barcode information, including one or more of the identification of the oligonucleotide, the spatial address on the surface, the characteristics of the oligonucleotide, or the operation that has been performed on the oligonucleotide. The barcode can be a naturally occurring nucleotide sequence or a nucleotide sequence that does not naturally occur in the organism from which the barcoded nucleic acid is obtained. For example, each nucleic acid capture probe in a population on a substrate for spatial capture of nucleic acids in a biological sample (e.g., permeabilized tissue sample, cell suspension) may include a different barcode sequence from all other nucleic acid capture probes in the population. Alternatively, each nucleic acid probe in a population may include a different barcode sequence from some or most other nucleic acid capture probes in the population. For example, each capture probe in a population may have a barcode that exists for several different capture probes in the population, even if the capture probes with a common barcode differ from each other at other sequence regions along their length. In various embodiments, one or more barcode sequences for biological tissues are not present in the genome, transcriptome, or other nucleic acids of a biological specimen. For example, a barcode sequence may have less than 80%, 70%, 60%, 50%, or 40% sequence identity to a nucleic acid sequence in a particular biological tissue.

[0198] The label / index / barcode sequence may be unique to a single nucleic acid species in a population, or may be shared by several different nucleic acid species in a population. For example, each nucleic acid probe in a population may include a label / index / barcode sequence that is different from all other nucleic acid probes in the population. Alternatively, each nucleic acid probe in a population may include a label / index / barcode sequence that is different from some or most other nucleic acid probes in the population. For example, each probe in a population may have a label / index / barcode that exists for several different probes in the population, even if the probes with a common label / index / barcode differ from each other at other sequence regions along their length. In a specific embodiment, one or more label / index / barcode sequences for a biological sample are not present in the genome, transcriptome, or other nucleic acid of the biological sample. For example, the label / index / barcode sequence may have a sequence identity of less than 80%, 70%, 60%, 50%, or 40% with a nucleic acid sequence in a specific biological sample.

[0199] As used herein, "spatial address," "spatial tag," "spatial barcode," "spatial barcode sequence," or "spatial index," when used in reference to a nucleotide sequence, means an address, tag, barcode, or index that encodes spatial information associated with the region or location of origin of an addressed, tagged, barcoded, or indexed nucleic acid in a tissue sample. The sequence may be a naturally occurring sequence or a sequence that does not naturally occur in the organism from which the barcoded nucleic acid was obtained.

[0200] As used herein, "template switching oligonucleotide" or "TSO" refers to an oligonucleotide that can be used in a DNA sequencing method, wherein the oligonucleotide hybridizes to an untemplated cytosine (C) nucleotide that is added to the end of a target RNA or DNA template by a reverse transcriptase during reverse transcription. For example, the TSO comprises a poly G sequence that binds to a poly C sequence added to a target template. In some embodiments, the TSO comprises 2 to 5 guanosines that hybridize to an untemplated cytosine nucleotide. In some embodiments, the 2 to 5 guanosines are riboguanosines, or modified nucleic acids or locked nucleic acids. In some embodiments, the TSO comprises rGrGrG.

[0201] As used herein, the term "amplicon" when used to refer to nucleic acid, means a product of replicating the nucleic acid, wherein the product has a nucleotide sequence identical or complementary to at least a portion of the nucleotide sequence of the nucleic acid. Amplicon can be produced by any of a variety of amplification methods using nucleic acid or its amplicon as a template, including, for example, polymerase extension, polymerase chain reaction (PCR), rolling circle amplification (RCA), connection extension or ligase chain reaction. Amplicon can be a nucleic acid molecule with a single copy (e.g., PCR product) of a specific nucleotide sequence or multiple copies (e.g., tandem products of RCA) of the nucleotide sequence. The first amplicon of a target nucleic acid can be a complementary copy. Subsequent amplicon is a copy formed by the target nucleic acid or by the first amplicon after generating the first amplicon. Subsequent amplicon can have a sequence that is substantially complementary to the target nucleic acid or substantially identical to the target nucleic acid.

[0202] The number of template copies or amplicons that can be generated can be adjusted by appropriately modifying the amplification reaction, including, for example, changing the number of amplification cycles run, using polymerases with different processivities in the amplification reaction, and / or changing the length of time the amplification reaction is run, as well as modifying other conditions known in the art that affect amplification yield. The number of copies of the nucleic acid template can be at least 1, 10, 100, 200, 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, and 10,000 copies, and can vary depending on the specific application.

[0203] As used herein, when used to refer to a polynucleotide, the term "complementary" is intended to mean a polynucleotide comprising a nucleotide sequence that can selectively anneal to an identification region of a target polynucleotide under certain conditions, for example, a first oligonucleotide sequence can form a double-stranded structure by matching base pairs with a second oligonucleotide sequence or a portion thereof. In various embodiments, "complementary" oligonucleotides are 100% complementary to each other, while in other embodiments, a first oligonucleotide sequence is at least (meaning greater than or equal to) about 95% complementary to a second oligonucleotide sequence over the length of the first oligonucleotide, at least about 90%, at least about 85%, at least about 80%, at least about 75%, at least about 70%, at least about 65%, at least about 60%, at least about 55% or at least about 50% complementary to a second oligonucleotide sequence over the length of the first oligonucleotide to the extent that the oligonucleotides can hybridize to each other under the conditions used. The complementarity percentage is determined over the length of the oligonucleotide. For example, given a first oligonucleotide in which 18 of the 20 nucleotides of the first oligonucleotide are complementary to a 20 nucleotide region in a second oligonucleotide having a total length of 100 nucleotides, the oligonucleotide will be 90% complementary. In this example, the remaining non-complementary nucleotides can be gathered or interspersed with complementary core bases, and do not need to be adjacent to each other or adjacent to complementary nucleotides. As used herein, the term "substantially complementary" and grammatical equivalents are intended to represent a polynucleotide comprising a nucleotide sequence that includes an identification region that can be specifically annealed to a target polynucleotide under certain conditions. Annealing refers to the nucleotide base pairing interaction of a nucleic acid with another nucleic acid, which results in the formation of a duplex, triplex or other higher ordered structures. The main interactions are usually nucleotide base specificity, such as A:T, A:U and G:C, through Watson-Crick and Hoogsteen type hydrogen bonds. In certain embodiments, base stacking and hydrophobic interactions also may contribute to duplex stability. Conditions for annealing polynucleotides to complementary or substantially complementary regions of target nucleic acids are well known in the art, for example, as described in Nucleic Acid Hybridization, A Practical Approach, edited by Hames and Higgins, IRL Press, Washington, DC (1985), and Wetmur and Davidson, Mol. Biol. 31:349 (1968). Annealing conditions will depend on the specific application and can be routinely determined by those skilled in the art without undue experimentation.

[0204] As used herein, the term "array" refers to a group of sites that can be distinguished from each other according to relative positions. Different molecules located at different sites of an array can be distinguished from each other according to the position of the site in the array. A single site of an array may contain one or more specific types of molecules. For example, a site may contain a single nucleic acid molecule with a specific sequence, or a site may contain several nucleic acid molecules with the same sequence (and / or its complementary sequence). The sites of an array may be different features located on the same substrate. Exemplary features include, but are not limited to, beads (or other particles) in or on a substrate, droplets in a substrate, holes, projections of a substrate, ridges on a substrate, or channels in a substrate. The sites of an array may be separate substrates each with different molecules. Different molecules attached to a separate substrate may be identified according to the position of the substrate on a surface associated with the substrate, or according to the position of the substrate in a liquid or gel. Exemplary arrays in which separate substrates are located on the surface include, but are not limited to, those arrays with beads in holes.

[0205] As used herein, the term "dNTP" refers to deoxynucleoside triphosphates. NTP refers to ribonucleotide triphosphates. Purine bases (Pu) include adenine (A), guanine (G) and their derivatives and analogs. Pyrimidine bases (Py) include cytosine (C), thymine (T), uracil (U) and their derivatives and analogs. By way of illustration and not limitation, examples of such derivatives or analogs are those modified with reporter groups, biotinylation, amine modification, radiolabeling, alkylation, etc., and also include thiophosphates, phosphites, ring atom-modified derivatives, etc. The reporter group can be a fluorescent group (such as fluorescein), a chemiluminescent group (such as luminol), a terbium chelator (such as N-(hydroxyethyl)ethylenediaminetriacetic acid that can be detected by delayed fluorescence), etc.

[0206] As used herein, the terms "link", "linked" and their grammatical equivalents are intended to mean the formation of a covalent bond or connection between the ends of two or more nucleic acids (e.g., oligonucleotides and / or polynucleotides), typically in a template-driven reaction. The nature of the bond or connection can vary widely, and the connection can be performed enzymatically or chemically. As used herein, the connection is typically performed enzymatically to form a phosphodiester bond between the 5' carbon-terminal nucleotide of one oligonucleotide and the 3' carbon of another nucleotide. Template-driven ligation reactions are described in the following references: U.S. Patents 4,883,750; 5,476,930; 5,593,826 and 5,871,921, which are incorporated herein by reference in their entirety. The term "link" also encompasses the non-enzymatic formation of phosphodiester bonds, as well as the formation of non-phosphodiester covalent bonds (such as phosphorothioate bonds, disulfide bonds, etc.) between the ends of oligonucleotides.

[0207] As used herein, the term "each," when used in reference to a collection of items, is intended to identify a single item in the collection, but does not necessarily refer to every item in the collection unless the context clearly indicates otherwise.

[0208] As used herein, when used to refer to nucleic acid, the term "extension" is intended to mean adding at least one nucleotide or oligonucleotide to a nucleic acid. In a specific embodiment, one or more nucleotides can be added to the 3' end of a nucleic acid, for example, by polymerase catalysis (e.g., DNA polymerase, RNA polymerase or reverse transcriptase). Chemical or enzymatic methods can be used to add one or more nucleotides to the 3' or 5' end of a nucleic acid. One or more oligonucleotides can be added to the 3' or 5' end of a nucleic acid, for example, by chemical or enzymatic (e.g., ligase catalysis) methods. An extension reaction is carried out in the presence of a polymerase such as a DNA or RNA polymerase, wherein nucleotides are added to the 3' end of an oligonucleotide (e.g., a primer). In some embodiments, the polymerase is a non-thermostable isothermal chain displacement polymerase. Suitable non-thermostable chain displacement polymerases according to the present disclosure can be found, for example, by New England BioLabs, Inc., and include phi29, Bsu, Klenow, DNA polymerase I (Escherichia coli (E.coli)) and a thermistor. In some embodiments, an extension reaction is carried out by recombinase polymerase amplification (RPA). RPA comprises three core enzymes - recombinase, single-stranded DNA binding protein (SSB) and strand displacement polymerase. As described by Daher et al. (Rana K Daher, Gale Stewart, Maurice Boissinot, Michel G Bergeron, "Recombinase Polymerase Amplification for Diagnostic Applications", Clinical Chemistry, Vol. 62, No. 7, July 1, 2016). One or more oligonucleotides can be added to the 3' or 5' end of the nucleic acid, for example, by chemical or enzymatic (e.g., ligase catalysis) methods. The nucleic acid can be extended in a template-guided manner, whereby the extension product is complementary to the template nucleic acid, which hybridizes to the extended nucleic acid.

[0209] Provided herein are arrays and methods for spatial detection and analysis of nucleic acids in tissue samples (e.g., mutation analysis or single nucleotide variation (SNV) detection and insertion and deletion detection). The arrays described herein may include a substrate on which a plurality of capture probes are fixed so that each capture probe occupies a different position on the array. Some or all of the capture probes in the plurality of capture probes may contain a unique position label (i.e., a spatial address or index sequence). The spatial address may describe the position of the capture probe on the array. The position of the capture probe on the array may be associated with the position in the tissue sample.

[0210] As used herein, when used to refer to a nucleic acid sequence (e.g., a capture nucleotide sequence), the term "poly T" or "poly A" is intended to mean a series of two or more thiamine (T) or adenine (A) bases, respectively. Poly T or poly A may include at least about 2, 5, 8, 10, 12, 15, 18, 20, 22, 25, 28, 30, 32, 35, 38, 40 or more T or A bases, respectively. Alternatively or in addition, poly T or poly A may include up to about 40, 38, 35, 32, 30, 28, 25, 22, 20, 18, 15, 12, 10, 8, 5 or 2 T or A bases, respectively. In some embodiments, the present disclosure contemplates the use of a "polyTVN" sequence, where "T" is a capture nucleotide sequence, "V" is adenine (A), cytosine (C), or guanine (G), and "N" is adenine (A), cytosine (C), guanine (G), or thymine (T). In some embodiments, the polyTVN sequence is used to bias reverse transcription toward bases of the poly A tail on an mRNA molecule, for example, in template switching.

[0211] As used herein, the terms "tag", "label", or "labeled" refer to the conversion of nucleic acids (e.g., DNA) into adaptor-modified templates in solution ready for cluster formation and sequencing by using transposase-mediated fragmentation and labeling. The method generally involves the modification of nucleic acids by a transposome complex comprising a transposase complexed with an adaptor comprising a transposon end sequence. Tagging results in simultaneous fragmentation of the nucleic acid and ligation of the adaptor to the 5' ends of both strands of the duplex fragments. Following a purification step to remove the transposase, additional sequences are added to the ends of the adapted fragments by PCR.

[0212] "Transposase" refers to an enzyme that can form a functional complex with a composition (e.g., a transposon, a transposon end, a transposon end composition) comprising a transposon end, and, for example, in an in vitro transposition reaction, catalyzes the insertion or transposition of a composition containing a transposon end into a double-stranded target nucleic acid incubated therewith. Transposases as shown herein may also include integrases from retrotransposons and retroviruses. Transposases, transpososomes, and transposome complexes are generally known to those skilled in the art, as shown in the disclosure of U.S. Patent Publication No. 2010 / 0120098, the contents of which are incorporated herein by reference in their entirety. Although many of the embodiments described herein relate to Tn5 transposases and / or highly active Tn5 transposases, it should be understood that any transposition system capable of inserting a transposon end into a 5'-tag and fragmenting a target nucleic acid for its intended purpose with sufficient efficiency can be used in the present invention. In a specific embodiment, a preferred transposition system is capable of inserting a transposon end into a 5'-tag and fragmenting a target nucleic acid in a random or nearly random manner.

[0213] As used herein, the term "transposition reaction" refers to a reaction in which one or more transposons are inserted into a target nucleic acid, for example, at random sites or nearly random sites. The essential components in a transposition reaction are a transposase and a DNA oligonucleotide that exhibits the nucleotide sequence of the transposon, including the transposon sequence transferred and its complementary sequence (non-transferred transposon end sequence) and other components required to form a functional transposition or transposome complex. The DNA oligonucleotide may also contain additional sequences (e.g., adapter or primer sequences) as needed or desired. In some embodiments, the methods provided herein are exemplified by the following: using a transposition complex formed by a hyperactive Tn5 transposase and a Tn5-type transposon end (Goryshin and Reznikoff, 1998, J. Biol. Chem., 273: 7367) or by a MuA transposase and a Mu transposon end comprising R1 and R2 terminal sequences (Mizuuchi, 1983, Cell, 35: 785; Savilahti et al., 1995, EMBO J., 14: 4893). However, any transposition system capable of inserting transposon ends into 5'-tags in a random or nearly random manner with sufficient efficiency and fragmenting target DNA for its intended purpose can be used in the present invention.Examples of transposition systems known in the art that can be used in the methods of the present invention include, but are not limited to, Staphylococcus aureus Tn552 (Colegio et al., 2001, J Bacterid., 183:2384-2388; Kirby et al., 2002, Mol Microbiol, 43:173-186), TyI (Devine and Boeke, 1994, Nucleic Acids Res., 22:3765-3772 and International Patent Application No. WO 95 / 23875), transposon Tn7 (Craig, 1996, Science. 271:1512; Craig, 1996, Review in: Curr Top Microbiol Immunol, 204:27-48), Tn10 and IS10 (Kleckner et al., 1996, Curr Top Microbiol Immunol, 205:27-48), Microbiol Immunol, 204: 49-82), Mariner transposase (Lampe et al., 1996, EMBO J., 15: 5470-5479), Tci (Plasterk, 1996, Curr Top Microbiol Immunol, 204: 125-43), P factor (Gloor, 2004, Methods Mol Biol, 260: 97-114), TnJ (Ichikawa and Ohtsubo, 1990, J Biol Chem. 265: 18829-18832), bacterial insertion sequence (Ohtsubo and Sekine, 1996, Curr. Top. Microbiol. Immunol. 204: 1-26), retrovirus (Brown et al., 1989, Proc Natl Acad Sci USA, 86: 2525-2529), and yeast retrotransposons (Boeke and Corces, 1989, Annu Rev Microbiol. 43: 403-34). The method for inserting the transposon end into the target sequence can be performed in vitro using any suitable transposon system, for which a suitable in vitro transposition system is available or can be developed based on knowledge in the art. Generally speaking, the in vitro transposition system suitable for the methods provided herein requires at least a transposase and a transposon end of sufficient purity, sufficient concentration and sufficient in vitro transposition activity, and the transposase forms a functional complex with the transposon end, and the functional complex has a corresponding transposase that can catalyze the transposition reaction. Suitable transposase transposon end sequences that can be used in the present invention include, but are not limited to, wild-type, derivative or mutant transposon end sequences that form a complex with a transposase selected from a wild-type, derivative or mutant transposase.As used herein, the term "transposome complex" refers to a transposase that is non-covalently bound to a double-stranded nucleic acid. For example, the complex can be a transposase that is pre-incubated with a double-stranded transposon DNA under conditions that support the formation of a non-covalent complex. The double-stranded transposon DNA can include, but is not limited to, Tn5 DNA, a portion of Tn5 DNA, a transposon end composition, a mixture of transposon end compositions, or other double-stranded DNAs that can interact with a transposase (such as a highly active Tn5 transposase).

[0214] As used herein, the term "random" can be used to refer to the spatial arrangement or composition of positions on a surface. For example, there are at least two types of order for the arrays described herein, the first involving the spacing and relative positions of features (also referred to as "sites"), and the second involving the identity or predetermined knowledge of molecules of a specific species present in a specific feature. Therefore, the features of the array can be randomly spaced so that the nearest adjacent features have a variable spacing between each other. Alternatively, the spacing between features can be ordered, for example, forming a regular pattern, such as a rectilinear grid or a hexagonal grid. In another aspect, the features of the array can be random in terms of the identity or predetermined knowledge of the target gene (e.g., a nucleic acid of a specific sequence) occupying each feature, regardless of whether the spacing produces a random pattern or an ordered pattern. The arrays described herein can be ordered in one aspect and random in another aspect. For example, in some embodiments described herein, a surface is contacted with a nucleic acid population under such conditions: wherein the nucleic acids are attached at sites that are "randomly positioned" with respect to their relative positions but with respect to the knowledge of the sequence of the nucleic acid species present in any specific site. By "randomly distributing" nucleic acids at locations on a surface it is intended that it is not known or predetermined as to which nucleic acid will be captured at which location (whether or not the locations are arranged in an ordered pattern).

[0215] As used herein, a "biological sample" may include one or more biological or chemical substances, such as nucleic acids, oligonucleotides, proteins, cells, tissues, organisms, and / or biologically active chemical compounds, such as analogs or mimetics of the foregoing.

[0216] As used herein, the term "tissue" is intended to represent an aggregate of cells and optional intercellular substances. Typically, cells in tissues are not free-floating in a solution, but attached to each other to form a multicellular structure. Exemplary tissue types include muscle, nerve, epidermis, and connective tissue. In some cases, biological samples may include whole blood, lymph, serum, plasma, sweat, tears, saliva, sputum, cerebrospinal fluid, amniotic fluid, semen, vaginal secretions, serous fluid, synovial fluid, pericardial fluid, peritoneal fluid, pleural effusion, transudate, exudate, gallbladder fluid, bile, urine, gastric juice, intestinal fluid, stool samples, liquid containing single or multiple cells, liquid containing organelles, fluidized tissue, fluidized organisms, viruses (including viral pathogens), liquid containing multicellular organisms, biological swabs, and biological washes. In other examples, the sample can be derived from an organ, including, for example, an organ of the musculoskeletal system, such as a muscle, bone, tendon, or ligament; an organ of the digestive system, such as a salivary gland, pharynx, esophagus, stomach, small intestine, large intestine, liver, gall bladder, or pancreas; an organ of the respiratory system, such as the larynx, trachea, bronchi, lungs, or diaphragm; an organ of the urinary system, such as the kidney, ureter, bladder, or urethra; a reproductive organ, such as an ovary, fallopian tube, uterus, vagina, placenta, testis, epididymis, vas deferens, seminal vesicle, prostate, penis, or scrotum; an organ of the endocrine system, such as the pituitary gland, pineal gland, thyroid gland, parathyroid gland, or adrenal gland; an organ of the circulatory system, such as the heart, arteries, veins, or capillaries; an organ of the lymphatic system, such as a lymphatic vessel, lymph node, bone marrow, thymus, or spleen; an organ of the central nervous system, such as the brain, brainstem, cerebellum, spinal cord, cranial nerves, or spinal nerves; a sensory organ, such as an eye, ear, nose, or tongue; or an integumentary organ, such as the skin, subcutaneous tissue, or breast. In various embodiments, tissue can be derived from multicellular organisms. In some embodiments, tissue sections can be contacted with a surface, for example, by placing the tissue on the surface. Tissue can be freshly excised from an organism, or it can be stored in advance, for example, by freezing (for example, fresh frozen tissue), embedding in a material such as paraffin (for example, formalin-fixed paraffin-embedded (FFPE) samples), formalin fixation, infiltration, dehydration, etc. Optionally, tissue sections can be attached to a surface, for example, using the technology and composition described in, for example, U.S. Patent No. 11,390,912, which is incorporated herein by reference in its entirety. In some embodiments, when tissue is in contact with a surface, the tissue can be permeabilized and the cells of the tissue can be lysed. Any of a variety of treatments can be used, such as those described above for lysed cells. Target proteins and / or nucleic acids released from permeabilized tissues can be captured by capture oligonucleotides on the surface. Therefore, in various embodiments, biological samples are tissue samples. The thickness of tissue samples or other biological samples contacted with a surface in the methods described herein can be any suitable thickness required.In representative embodiments, the thickness will be at least 0.1 μm, 0.25 μm, 0.5 μm, 0.75 μm, 1 μm, 5 μm, 10 μm, 50 μm, 100 μm or thicker. Alternatively or in addition, the thickness of the biological sample in contact with the surface does not exceed 100 μm, 50 μm, 10 μm, 5 μm, 1 μm, 0.5 μm, 0.25 μm, 0.1 μm or thinner.

[0217] As used herein, the term "tissue sample" refers to a piece of tissue that has been obtained from a subject, optionally fixed, sliced ​​and mounted on a planar surface (e.g., a microscope slide). The tissue sample can be a formalin-fixed paraffin-embedded (FFPE) tissue sample or a fresh tissue sample or a frozen tissue sample, etc. The method disclosed herein can be performed before or after staining the tissue sample. For example, after hematoxylin and eosin staining, the tissue sample can be spatially analyzed according to the method provided herein. The method may include (e.g., using hematoxylin and eosin staining) analyzing the histological features of the sample, and then spatially analyzing the tissue. In various embodiments, tissue is removed from the sample by enzymatic degradation. In various embodiments, tissue removal is performed before RNA is removed from the tissue. In various embodiments, tissue is removed by degradation with proteinase K (e.g., 40 minutes at 37°C).

[0218] As used herein, the term "formalin-fixed paraffin-embedded (FFPE) tissue section" refers to a piece of tissue, e.g., a biopsy tissue, that has been obtained from a subject, fixed in formaldehyde (e.g., 3% to 5% formaldehyde in phosphate-buffered saline) or Bouin's solution, embedded in wax, cut into thin sections, and then mounted on a planar surface (e.g., a microscope slide).

[0219] As used herein, the term "subject" encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the class of mammals: humans, non-human primates such as chimpanzees and other apes and monkey species, cows, horses, sheep, goats, pigs, rabbits, dogs, cats, rodents, rats, mice, guinea pigs, etc. Examples of non-mammals include, but are not limited to, birds, fish, etc. The term does not denote a particular age or sex.

[0220] When referring to the example of adapters, the terms "P5" and "P7" may be used. The terms "P5'" (apostrophe on P5) and "P7'" (apostrophe on P7) refer to the complementary sequences of P5 and P7, respectively. It should be understood that any suitable adapter can be used in the methods presented herein, and the use of P5 and P7 is merely an exemplary embodiment. The use of adapters such as P5 and P7 or their complementary sequences on a circulation cell is known in the art, as exemplified by the disclosures of WO 2007 / 010251, WO 2006 / 064199, WO 2005 / 065814, WO 2015 / 106941, WO 1998 / 044151 and WO 2000 / 018957, each of which is incorporated herein by reference in its entirety. For example, any suitable forward amplification primer, whether fixed or in solution, can be used in the methods presented herein for hybridizing with a complementary sequence and amplifying the sequence. Similarly, any suitable reverse amplification primer, whether fixed or in solution, can be used in the methods presented herein for hybridizing with complementary sequences and amplifying sequences. Those skilled in the art will understand how to design and use primer sequences suitable for capturing and / or amplifying nucleic acids presented herein.

[0221] As used herein, "hybridize" is intended to mean that a first oligonucleotide and a second oligonucleotide non-covalently associate along the length of those polymers to form a double-stranded "duplex". As used herein, the term "hybridize" refers to a process in which two single-stranded polynucleotides are non-covalently bound to form a stable double-stranded polynucleotide. The resulting double-stranded polynucleotide is a "hybrid" or "duplex". For example, two DNA oligonucleotide chains can associate by complementary base pairing. The strength of association between the first oligonucleotide and the second oligonucleotide increases with the complementarity between the nucleotide sequences within those oligonucleotides. The hybridization strength between oligonucleotides can be characterized by a melting temperature (Tm), at which 50% of the duplexes have oligonucleotide chains that dissociate from each other. Oligonucleotides that "partially" hybridize to each other refer to that they have sequences that are complementary to each other, but such sequences only hybridize to each other along a portion of their length to form a partial duplex. Oligonucleotides that "cannot" hybridize include those oligonucleotides that are physically separated from each other, so that the number of their bases is not enough to contact each other in a manner that hybridizes to each other. Hybridization conditions will typically include a salt concentration of less than about 1 M, more typically less than about 500 mM and may be less than about 200 mM. Hybridization buffers include buffered saline solutions, such as 5% SSPE, or other such buffers known in the art. The hybridization temperature may be as low as 5° C., but is typically greater than 22° C., and more typically greater than about 30° C., and typically exceeds 37° C. Hybridization is typically performed under stringent conditions, i.e., conditions under which the probe will hybridize to its target subsequence but will not hybridize to other non-complementary sequences. Stringent conditions are sequence-dependent and are different in different situations, and can be routinely determined by those skilled in the art.

[0222] As used herein, the term "plurality" is intended to represent a population of two or more members, where the members may all be the same or two or more members may be different. Multiple numbers may be in the range of small, medium, large to extremely large sizes. The size of a small multiple number may be in the range of, for example, several members to tens of members. A medium-sized multiple number may be in the range of, for example, tens of members to about 100 members or hundreds of members. A large multiple number may be in the range of, for example, about hundreds of members to about 1000 members, to thousands of members, and up to tens of thousands of members. An extremely large multiple number may be in the range of, for example, tens of thousands of members to about hundreds of thousands, one million, several million, tens of millions, and up to or exceeding hundreds of millions of members. Therefore, a plurality of numbers may be in the range of two to far exceeding 100 million members and all sizes as measured by the number of members, between the above exemplary ranges, and exceeding the above exemplary ranges. Therefore, the definition of the term is intended to include all integer values ​​greater than two. The features of the exemplary number within the microarray include 1.28 cm 2 A plurality of about 500,000 or more discrete features within a nucleic acid. Exemplary nucleic acid plurality numbers include, for example, about 1×105 pcs, 5×10 5 and 1×10 6 The term "polynucleotide" refers to a population of one or more different nucleic acid species. Thus, the definition of the term is intended to include all integer values ​​greater than two. The upper limit of the plurality of numbers can be set, for example, by the theoretical diversity of the oligonucleotide sequences in the nucleic acid sample.

[0223] As used herein, the term "attachment" refers to the state in which two things are joined, fastened, adhered, connected or combined with each other. For example, an oligonucleotide can be attached to a material, such as a bead, by a covalent bond or a non-covalent bond. A covalent bond is characterized by sharing electron pairs between atoms. A non-covalent bond is a chemical bond that does not involve sharing electron pairs, and can include, for example, hydrogen bonds, ionic bonds, van der Waals forces, hydrophilic interactions, and hydrophobic interactions.

[0224] In some embodiments, nucleic acids in tissue samples are transferred and captured onto an array. For example, tissue sections are placed in contact with the array, and nucleic acids are captured onto the array and tagged with spatial addresses. For example, spatially tagged DNA molecules are released from the array and analyzed by high-throughput next-generation sequencing (NGS), such as synthetic sequencing (SBS). In some embodiments, nucleic acids in tissue sections (e.g., formalin-fixed paraffin-embedded (FFPE) tissue sections) are transferred to the array and captured onto the array by hybridization with capture probes or capture oligonucleotides. In some embodiments, the capture oligonucleotide can be a universal capture probe that hybridizes with, for example, an adapter region and / or a poly-A tail of an mRNA in a nucleic acid sequencing library. In some embodiments, the capture probe can be a gene-specific capture probe that hybridizes with, for example, a specifically targeted mRNA or cDNA in a sample, such as TruSeq TM Custom Amplicon (TSCA) Oligonucleotide Probes (Illumina, Inc.) The capture oligonucleotide can be a plurality of capture oligonucleotides, for example, a plurality of the same or different capture oligonucleotides.

[0225] In some embodiments, a combined indexing (addressing) system is used to provide spatial information for analyzing nucleic acids in a tissue sample. The combined indexing system may involve the use of two or more spatial address sequences (e.g., two, three, four, five or more spatial address sequences).

[0226] In some embodiments, two spatial address sequences are incorporated into the nucleic acid during the preparation of the sequencing library. The first spatial address can be used to define a certain position in the X dimension on the capture array (i.e., capture site), and the second spatial address sequence can be used to define a position in the Y dimension on the capture array (i.e., capture site). During library sequencing, the X and Y spatial address sequences can be determined, and the sequence information can be analyzed to define a specific position on the capture array.

[0227] In some embodiments, three spatial address sequences are incorporated into the nucleic acid during the preparation of the sequencing library. The first spatial address can be used to define a certain position in the X dimension on the capture array (i.e., a capture site), the second spatial address sequence can be used to define a position in the Y dimension on the capture array (i.e., a capture site), and the third spatial address sequence can be used to define the position of a two-dimensional sample slice in a sample (e.g., a tissue biopsy) (e.g., the position of a slice of a tissue sample) to provide positional spatial information in three dimensions (Z dimension) of the sample. During library sequencing, the X, Y, and Z spatial address sequences can be determined, and the sequence information can be analyzed to define a specific position on the capture array.

[0228] In some embodiments, the time address sequence (T) is optionally incorporated into the nucleic acid during the preparation of the sequencing library. In some embodiments, the time address sequence can be combined with two or three spatial address sequences. The time address sequence can be used to determine the time-dependent changes in gene expression in a tissue sample, for example, in the context of a time course experiment. The time-dependent changes in gene expression can occur in a tissue sample, for example, in response to chemical, biological or physical stimulation (e.g., toxins, drugs or heat). The nucleic acid samples obtained from comparable tissue samples (e.g., the proximal section of a tissue sample) at different time points can be merged and sequenced in large quantities. The optional first spatial address can be used to define a certain position (i.e., capture site) in the X dimension on the capture array, the second optional spatial address sequence can be used to define the position (i.e., capture site) in the Y dimension on the capture array, and the third optional spatial address sequence can be used to define the position of the two-dimensional sample slice in the sample (e.g., tissue biopsy) (e.g., the position of the slice of the tissue sample), to provide the positional spatial information in the three-dimensional (Z dimension) of the sample. During library sequencing, the T, X, Y, and Z address sequences are determined and the sequence information is analyzed to determine the specific X, Y (and optionally Z) position on the capture array for each time point (T).

[0229] The address sequences X, Y, and optionally Z and / or T can be contiguous nucleic acid sequences, or the address sequences can be separated by one or more nucleic acids (e.g., 2 or more, 3 or more, 10 or more, 30 or more, 100 or more, 300 or more, or 1,000 or more). In some embodiments, the X, Y, and optionally Z and / or T address sequences can each individually and independently be a combined nucleic acid sequence.

[0230] In some embodiments, the length of the address sequence (e.g., X, Y, Z, or T) can each individually and independently be 100 nucleic acids or less, 90 nucleic acids or less, 80 nucleic acids or less, 70 nucleic acids or less, 60 nucleic acids or less, 50 nucleic acids or less, 40 nucleic acids or less, 30 nucleic acids or less, 20 nucleic acids or less, 15 nucleic acids or less, 10 nucleic acids or less, 8 nucleic acids or less, 6 nucleic acids or less, or 4 nucleic acids or less. The lengths of two or more address sequences in a nucleic acid can be the same or different. For example, if the length of address sequence X is 10 nucleic acids, the length of address sequence Y can be, for example, 8 nucleic acids, 10 nucleic acids, or 12 nucleic acids.

[0231] The address sequence (eg, a spatial address sequence such as X or Y) may be a partially or fully degenerate sequence.

[0232] In some embodiments, the spatially addressed capture probes on the array can be released from the array onto a tissue section for generating a spatially addressed sequencing library. In some embodiments, the capture probes comprise random primer sequences for in situ synthesis of spatially tagged cDNA from RNA in the tissue section. In some embodiments, the capture probes are TruSeq for capturing and spatially tagging genomic DNA in tissue sections. TM Custom Amplicon (TSCA) Oligonucleotide Probes (Illumina, Inc.) Spatially tagged nucleic acid molecules (eg, cDNA or genomic DNA) are recovered from tissue sections and processed in a single tube reaction to generate a spatially tagged amplicon library.

[0233] In some embodiments, magnetic nanoparticles can be used to capture nucleic acids (eg, cDNA synthesized in situ) in tissue samples to generate spatially addressed libraries.

[0234] In some embodiments, spatial detection and analysis of nucleic acids in tissue samples can be performed on a droplet actuator.

[0235] Improved methods and compositions for spatial omics applications are described herein, which retain spatial information related to the source of RNA or DNA in tissues. Examples of spatial omics applications include, but are not limited to: spatial genomics applications, spatial proteomics applications; spatial transcriptomics applications; spatial agricultural genomics applications; spatial epigenomics applications; spatial phenotypic omics applications; spatial ligandomics applications; and spatial multi-omics applications (e.g., transcriptomics and genomics applications).

[0236] Oligonucleotides

[0237] Oligonucleotide is a polymer composed of nucleotides. Oligonucleotides of the present disclosure can be any length, and in various embodiments include DNA oligonucleotides, RNA oligonucleotides, their analogs or their combinations. In any aspect or embodiment described herein, oligonucleotides are single-stranded, double-stranded or partially double-stranded.

[0238] Nucleotides may include naturally occurring nucleotides and functional analogs thereof. Examples of functional analogs are those that can hybridize with nucleic acids in a sequence-specific manner or can be used as templates for replicating specific nucleotide sequences. Naturally occurring nucleotides typically have a backbone containing a phosphodiester bond. Similar structures may have alternative backbone bonds, including any of a variety of backbone bonds known in the art. Naturally occurring nucleotides typically have deoxyribose (e.g., present in DNA) or ribose (e.g., present in RNA). Similar structures may have alternative sugar moieties, including any of a variety of sugar moieties known in the art. Nucleotides may include natural or non-natural bases. Natural DNA may include one or more of adenine, thymine, cytosine and / or guanine, and natural RNA may include one or more of adenine, uracil, cytosine and / or guanine. Any non-natural bases may be used, such as locked nucleic acids (LNA) and bridge nucleic acids (BNA). Exemplary modified nucleotides include inosine, xathanine, hypoxanthine, isocytosine, isoguanine, 2-aminopurine, 5-methylcytosine, 5-hydroxymethylcytosine, 2-aminoadenine, 6-methyladenine, 6-methylguanine, 2-propylguanine, 2-propyladenine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 15-halouracil, 15-halocytosine, 5-propynyluracil, 5-propynylcytosine, 6-azouracil, In some embodiments, the nucleotides of the present invention are substituted 5'- ...

[0239] Oligonucleotides contemplated by the present disclosure also include those oligonucleotides having at least one modified internucleotide connection. In some embodiments, the oligonucleotide is all or part of a peptide nucleic acid. Other modified internucleotide connections include at least one phosphorothioate connection. Other modified oligonucleotides include those oligonucleotides comprising one or more universal bases. "Universal base" refers to a molecule that can replace any one of A, C, G, T and U in a binding nucleic acid by forming a hydrogen bond without significant structural destabilization. Examples of universal bases include but are not limited to 5'-nitroindole-2'-deoxynucleoside, 3-nitropyrrole, inosine and hypoxanthine.

[0240] In various aspects, the oligonucleotides of the present disclosure or modified forms thereof are generally from about 5 nucleotides to about 150 nucleotides in length. In other embodiments, the oligonucleotides of the present disclosure are from about 5 to about 125 nucleotides in length, from about 5 to about 100 nucleotides in length, from about 5 to about 90 nucleotides in length, from about 5 to about 50 nucleotides in length, from about 5 to about 45 nucleotides in length, from about 5 to about 40 nucleotides in length, from about 5 to about 35 nucleotides in length, from about 5 to about 30 nucleotides in length, from about 5 to about 25 nucleotides in length, from about 5 to about 20 nucleotides in length, from about 5 to about 15 nucleotides in length, from about 5 to about 10 nucleotides in length, from about 10 to about 150 nucleotides in length. , about 10 to about 125 nucleotides in length, about 10 to about 100 nucleotides in length, about 10 to about 90, about 10 to 50 nucleotides in length, about 10 to about 45 nucleotides in length, about 10 to about 40 nucleotides in length, about 10 to about 35 nucleotides in length, about 10 to about 30 nucleotides in length, about 10 to about 25 nucleotides in length, about 10 to about 20 nucleotides in length, about 10 to about 15 nucleotides in length, and all oligonucleotides are intermediate in length to the specifically disclosed sizes, to the extent that the oligonucleotide is able to achieve the desired result.Thus, in various embodiments, the oligonucleotides of the present disclosure are or are at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 , 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82 2, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198In other embodiments, the oligonucleotides of the present disclosure are less than 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 2, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83 3, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195 In various embodiments, the length of the oligonucleotides (such as primers) of the present disclosure is about 5 base pairs (bp) to 40bp, or about 5bp to 35bp, or about 5bp to 30bp, or about 10bp to 35bp, or about 10bp to 30bp, or about 20bp to 40bp, or about 20bp to 35bp, or about 20bp to 30bp, or about 9bp to 20bp, or about 5bp to 15bp, or about 9bp to 15bp. In some embodiments, the length of the oligonucleotides (such as primers) of the present disclosure is about 10bp, 13bp, 15bp, 20bp, 25bp, 30bp, 35bp or 40bp. As described herein, in various embodiments, the oligonucleotides can be P5 primers, P5' primers, P7 primers or P7' primers.

[0241] Preparation of polynucleotides

[0242] The present disclosure is based in part on the recognition that there is a need to improve the amount of RNA or DNA information that can be isolated from fresh or frozen tissue samples and FFPE tissue samples to provide information related to the genetic profile of the tissue sample. The present disclosure provides methods for improving genetic information capture by increasing the amount and quality of RNA isolated from tissue samples, which RNA can be used for spatial transcriptomic analysis.

[0243] Total RNA may include ribosomal RNA (rRNA), messenger RNA (mRNA), transfer RNA (tRNA), microRNA, small nucleolar RNA (snoRNA), small nuclear RNA (snRNA). In various embodiments, the RNA is rRNA and / or mRNA.

[0244] In various embodiments, the RNA capture oligonucleotide is selected from a poly-T sequence, a random oligonucleotide, a semi-random oligonucleotide or a target-specific probe. In various embodiments, the target-specific probe comprises a plurality of different target-specific RNA capture probe sequences. In various embodiments, the RNA capture probe or surface capture probe is 8 to 80 nucleotides. In certain embodiments, the RNA capture probe or surface probe is 10 to 80 nucleotides, 10 to 70 nucleotides, 10 to 60 nucleotides, 10 to 50 nucleotides, 10 to 40 nucleotides, 10 to 30 nucleotides, 10 to 20 nucleotides, 20 to 80 nucleotides, 20 to 70 nucleotides, 20 to 60 nucleotides, 20 to 50 nucleotides, 20 to 40 nucleotides, or 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, or 80 nucleotides.

[0245] As described herein, the capture oligonucleotide may include a capture sequence, a spatial barcode sequence (SBC) and an adapter sequence. The capture sequence includes a poly-T sequence, a poly-A sequence, a gene-specific capture sequence or a universal capture sequence. The universal capture sequence is a random nucleotide sequence or a non-self-complementary semi-random sequence. In various embodiments, the capture oligonucleotide includes a 5' clustering sequence, a random spatial barcode (SBC), a full-length read 2 adapter sequence (Rd2 FL), a molecular identifier (MI), a fixed sequence (FS) and / or a poly T capture sequence (polyTVN) with a 3' VN terminus.

[0246] The oligonucleotide comprising the surface oligonucleotide (e.g., poly T sequence) may also comprise a spatial index sequence, including but not limited to one or more of a P7 sequence, an index sequence and / or a read 2 adapter sequence (Rd2 FL). In various embodiments, the surface oligonucleotide comprises a P7 anchor sequence, a spatial barcode, and a sequence that hybridizes to a splint oligonucleotide.

[0247] In some embodiments, total RNA is released from a tissue sample. Release includes lysis of the tissue or permeabilization of the tissue. In various embodiments, one or more samples that have been contacted with a solid support may be lysed to release the target nucleic acid. Cleavage can be performed using known techniques, such as those using one or more of chemical treatment, enzyme treatment, electroporation, heating, hypotonic treatment, ultrasonic treatment, etc. In the method, it is considered that before contacting the tissue sample with multiple capture oligonucleotides, the tissue sample is permeabilized. In various embodiments, in the method, before contacting the tissue sample with multiple capture oligonucleotides, the tissue sample is treated with one or more blocking agents. In various embodiments, in the method, before the step of contacting the tissue sample with multiple capture oligonucleotides, the tissue sample is permeabilized and treated with one or more blocking agents.

[0248] In some embodiments, the tissue sample will be processed to remove the embedding material (e.g., paraffin or formalin) from the sample before releasing, capturing or modifying the nucleic acid. This can be achieved by contacting the sample with a suitable solvent (e.g., xylene and ethanol washing solution). The treatment can be performed before the tissue sample contacts the solid support described herein, or the treatment can be performed when the tissue sample is on the solid support. It is also contemplated to remove the tissue from the sample by enzymatic degradation. In various embodiments, tissue removal is performed before RNA is removed from the tissue. In various embodiments, tissue is removed by degradation with proteinase K (e.g., 40 minutes at 37° C.). An exemplary method for operating a tissue used with a solid support attached to a nucleic acid is described in U.S. Patent Application Publication No. 2014 / 0066318, which is incorporated herein by reference.

[0249] Formalin-fixed tissue samples can also be decrosslinked using known techniques. In various embodiments, decrosslinking is performed using, for example, Tris-EDTA (TE) buffer at pH 8, pH 9, or another suitable buffer at a suitable pH. Decrosslinking can also be performed at high heat (e.g., 70° C.).

[0250] The above methods can also be used to improve the capture efficiency of RNA transcripts prepared from in situ RNA transcript libraries, and / or to increase the nucleotide length of polynucleotides used to generate in situ transcriptome libraries (e.g., increasing the polynucleotide size of cDNA transcribed from mRNA isolated from a sample and used to generate an in situ transcriptome library).

[0251] Spatial detection and analysis of nucleic acids in tissue samples

[0252] According to the methods described herein, spatial detection and analysis of nucleic acids in tissue samples can be performed using a group of two or more capture probes (e.g., 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more capture probes). Typically, at least the first capture probe in a group of capture probes is fixed to a capture array or nanostructure. In some embodiments, the second capture probe may be fixed to the same capture array as the first capture probe, for example, near the first capture probe, for example, in the same capture site. In some embodiments, the second capture probe may be fixed to a nanostructure or particle (such as a magnetic particle or a magnetic nanoparticle). In some embodiments, the second capture probe can be in a solution, for example, for in situ reaction with nucleic acids in a tissue sample. The capture probes in the capture probe group can individually and independently have a variety of different regions, for example, a capture region (e.g., a first universal or gene-specific capture region or a first cluster region), a primer binding region (e.g., an SBS primer region, such as an SBS3 or SBS12 region) or a second universal region / cluster sequence, such as a P5 or P7 region, a spatial address region (e.g., a partial or combined spatial address region) or a cleavable region.

[0253] Exemplary sequences include the following Rd1 and Rd2 adaptor sequences. Second universal adaptor - Rd1SBS3 (long): ACACTCTTTCCCTACACGAC GCTCTTCCGATCT (SEQ ID NO: 13); Second universal adapter - Rd1 SBS3 (short): ACACTCTTTCCCTACACGAC (SEQ ID NO: 14); First universal adapter - Rd2SBS12 (long): GTGACTGGAGTTCAGACGTGT GCTCTTCCGATCT (SEQ ID NO: 15); First universal adaptor - Rd2 SBS12 (short): GTGACTGGAGTTCAGACGTGT (SEQ ID NO: 16).

[0254] In some embodiments, only one capture probe in a set of capture probes comprises a capture region. In some embodiments, two or more capture probes in a set of capture probes comprise a capture region.

[0255] In some embodiments, only one probe in a set of capture probes comprises a spatial address region, for example, a complete spatial address region such as describing the location of a capture site on a capture array. In some embodiments, two or more probes in a set of capture probes may comprise a spatial address region, for example, two or more probes may each comprise a partial spatial address region (i.e., a combined address region), wherein each partial address region describes the location of a capture site on a capture array, for example, along the x-axis or y-axis.

[0256] In some embodiments, a set of capture probes (e.g., RNA and surface capture probes) may include at least one capture probe comprising a capture region and a spatial address region (e.g., a complete or partial spatial address region). In some embodiments, no capture probe in a set of capture probes comprises both a capture region and a spatial address region.

[0257] In some embodiments, the capture site on the substrate is a plurality of capture sites. In some embodiments, the plurality of capture sites is 2 or more, 10 or more, 30 or more, 100 or more, 300 or more, 1,000 or more, 3,000 or more, 10,000 or more, 30,000 or more, 100,000 or more, 300,000 or more, 1,000,000 or more, 3,000,000 or more, or 10,000,000, or 1,000,000,000 or more capture sites.

[0258] In various embodiments, the capture array or substrate comprises 2 )A capture site density of 1 or more, 2 or more, 10 or more, 30 or more, 100 or more, 300 or more, 1,000 or more, 3,000 or more, 10,000 or more, 100,000 or more, 1,000,000 or more capture sites.

[0259] In various embodiments, the capture probe pairs in the capture site are multiple pairs of capture probes. In some embodiments, the multiple capture probes are 2 or more, 10 or more, 30 or more, 100 or more, 300 or more, 1,000 or more, 3,000 or more, 10,000 or more, 30,000 or more, 100,000 or more, 300,000 or more, 1,000,000 or more, 3,000,000 or more, or 10,000,000 or more, 100,000,000 or more, or 1,000,000,000 or more capture probes.

[0260] In some embodiments, the capture probe pairs in the capture sites of the substrate are multiple pairs of capture probes. In some embodiments, each RNA capture probe in multiple pairs of capture probes in the same capture site comprises the same spatial address sequence. In some embodiments, each RNA capture probe in multiple pairs of capture probes in different capture sites comprises different spatial address sequences.

[0261] In some embodiments, the surface of the capture array is a flat surface, e.g., a glass surface. In some embodiments, the surface of the capture array includes one or more holes. In some embodiments, the one or more holes correspond to one or more capture sites. In some embodiments, the surface of the capture array is a bead surface.

[0262] In some embodiments, the capture region in the surface capture probe is a gene-specific capture region. In some embodiments, the gene-specific capture region in the surface capture probe comprises a TruSeq TM Sequences of Custom Amplicon (TSCA) Oligonucleotide Probes (Illumina, Inc.) For example, the gene-specific capture regions in the plurality of second capture probes in a capture site can comprise a plurality of TSCA oligonucleotide probe sequences.

[0263] In another embodiment, the present disclosure provides a substrate comprising a probe that can be spatially addressed as disclosed herein, such as a flow cell, a nanoparticle or a bead. In a specific embodiment, the bead comprises a probe that can be spatially addressed as disclosed herein. In another embodiment, the bead comprises streptavidin on the surface of the bead. In yet another embodiment, the bead comprises a plurality of oligonucleotides bound to the bead via a bond or a reversible bond. Examples of reversible bonds include biotin molecules, such as ddBio molecules. The oligonucleotides bound to the substrate generally comprise an adapter sequence, such as a P5 sequence or a P7 sequence. As used herein, the P5 sequence comprises a sequence defined by AAT GAT ACG GCG ACC ACC GA (SEQ ID NO: 1) or AAT GAT ACG GCGACC ACC GAG ATC TAC AC (SEQ ID NO: 2), and the P7 sequence comprises a sequence defined by CAA GCA GAA GACGGC ATA CG (SEQ ID NO: 3) or CAA GCA GAA GAC GGC ATA CGA GAT (SEQ ID NO: 4). In some embodiments, P5 or P7 sequence may also include spacer polynucleotides, and its length may be 1 to 20 nucleotides, such as 1 to 15 or 1 to 10 nucleotides, such as 2, 3, 4, 5, 6, 7, 8, 9 or 10 nucleotides. In some embodiments, the spacer includes 10 nucleotides. In some embodiments, the spacer includes 10 nucleotides. In some embodiments, the spacer is a polyT spacer, such as a 10T spacer. Spacer nucleotides may be included in the 5' end of the polynucleotide, which may be attached to a suitable carrier by a key with the 5' end of the oligonucleotide. Attachment may be achieved by sulfur-containing nucleophiles (such as thiophosphates) present at the 5' end of the polynucleotide. In some embodiments, the oligonucleotide will include a polyT spacer and a 5' thiophosphate group. Thus, in some embodiments, the P5 sequence comprises 5' phosphorothioate-TTTTTTTTTTAATGATACGGCGACCACCGA-3' (SEQ ID NO: 17), and in some embodiments, the P7 sequence comprises 5' phosphorothioate-TTTTTTTTTTCAAGCAGAAGACGGCATACGA-3' (SEQ ID NO: 18). In certain embodiments, the oligonucleotide attached to the bead comprises an address sequence that allows the x, y position of the oligonucleotide / bead to be determined when decoded.In other embodiments, the address sequence is 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nucleotides in length, or a range including or between any two of the above nucleotides. In another embodiment, the oligonucleotide attached to the beads comprises a transposome hybridization region (Tsm hyb). In yet other embodiments, the oligonucleotide comprises a sequencing primer site sequence. Examples of sequencing primer site sequences include and from Illumina. TM The oligonucleotide may further comprise one or more linker sequences. In yet another embodiment, the oligonucleotide may further comprise one or more index sequences. In certain embodiments, the oligonucleotide may comprise one or more unique molecular identifier (UMI) sequences. A unique molecular identifier (UMI) is a class of molecular barcodes that provide error correction and increased accuracy during sequencing. These molecular barcodes are short sequences used to uniquely mark each molecule in a sample library. UMI is used in a wide range of sequencing applications, many of which are PCR replications around DNA and cDNA. UMI deduplication can also be used for RNA-seq gene expression analysis and other quantitative sequencing methods. As previously noted, the oligonucleotide comprises a portion or sequence that can specifically bind to a polynucleotide from a biological sample (e.g., a tissue sample). Therefore, the oligonucleotide attached to the bead is a spatially addressable probe for a polynucleotide from a biological sample. A portion or sequence that can specifically bind to a polynucleotide from a biological sample can be selected for use in a specific omics application. For example, the oligonucleotide may comprise a oligo d (T) sequence for transcriptomics or for determination (e.g., RNA-seq determination). Alternatively, the oligonucleotide may comprise a sequence that binds to genomic DNA from a biological sample for genomic applications or for determination (e.g., ATAC-seq determination). As provided in the embodiments presented herein, the nanostructure may comprise various types of oligonucleotides having different parts or sequences, so that a spatially addressable probe may specifically bind to two or more different types of polynucleotides from a biological sample. The use of various types of oligonucleotides is ideally suitable for multi-omics or multi-determination applications.

[0264] The generation of the second complementary chain can be carried out "on the surface" or "outside the surface". In some embodiments, in order to generate the second complementary chain on the surface, the first complementary chain remains fixed on the surface, and the second complementary chain is extended using the first complementary chain as a template. In some embodiments, the second complementary chain is removed (eluted) from the surface, and then the second complementary chain is subjected to index PCR for amplification. In some embodiments, in order to generate the second complementary chain on the surface, an exclusion amplification (ExAmp) mixture comprising an adapter-index oligonucleotide is contacted with the first complementary chain on the surface, thereby generating the second complementary chain by chain invasion and isothermal amplification. In various embodiments, the ExAmp mixture also includes a recombinase, a single-stranded DNA binding protein (e.g., a gp32 ssDNA binding protein) and a polymerase. As with any method for generating the second complementary chain described herein, the generation of the second complementary chain can be followed by amplification of the second complementary chain (e.g., by index PCR), during which a second clustering primer sequence (e.g., P5) can be added to one or more of the second complementary chains. In some embodiments, amplification includes index PCR, during which the first primer is hybridized with the first cluster primer sequence, and the second primer is hybridized with the adapter nucleotide sequence, wherein the second primer comprises the second cluster primer sequence. In various embodiments, during amplification, an index sequence (e.g., i5) is also added to one or more of the second complementary strands. In some embodiments, the second primer also comprises an index sequence. In various embodiments, the second cluster primer sequence and an optional index sequence are added to one or more of the second complementary strands and occur outside the surface (e.g., in solution). The amplification of the second complementary strand can be subsequently sequenced. Sequencing information can then be associated with the spatial position of the target nucleic acid in the biological sample.

[0265] In some embodiments, one or more of the multiple capture oligonucleotides are fixed on the surface by a cleavage site. In other embodiments, the cleavage site is an enzyme cleavage site. In various embodiments, the enzyme cleavage site includes a restriction enzyme site, uracil, 8-oxoguanine or a combination thereof. In some embodiments, the cleavage site is a chemical cleavage site. In other embodiments, one or more of the multiple capture oligonucleotides are fixed on the surface by a cleavage site. In some embodiments, the cleavage site is an enzyme cleavage site. In other embodiments, the enzyme cleavage site includes a restriction enzyme site, uracil, 8-oxoguanine or a combination thereof.

[0266] In some embodiments, for the second complementary chain to be produced outside the surface, the formation of the first complementary chain is followed by the cutting of the first complementary chain from the surface, and the synthesis of the second complementary chain is carried out outside the surface (for example, in solution). In some embodiments, the second complementary chain is then amplified (for example, by index PCR), during which time the second clustering primer sequence (for example, P5) can be added to one or more of the second complementary chain. In various embodiments, during amplification, an index sequence (for example, i5) is also added to one or more of the second complementary chain. In various embodiments, the second clustering primer sequence and optional index sequence are added to one or more of the second complementary chain and occur outside the surface (for example, in solution). The amplification of the second complementary chain can be subsequently sequenced. Sequencing information can then be associated with the spatial position of the target nucleic acid in the biological sample.

[0267] In various embodiments, the disclosure also provides a method for digesting a biological sample / tissue sample. In various embodiments, the digestion of the biological sample may occur after the first complementary strand is produced. In some embodiments, the digestion of the biological sample occurs after the first complementary strand is produced but before the second complementary strand is produced. The disclosure also provides a method for removing a target nucleic acid (e.g., RNA) from a surface. In various embodiments, removing a target nucleic acid from a surface may occur after the first complementary strand is produced. In some embodiments, the removal of a target nucleic acid occurs after the first complementary strand is produced but before the second complementary strand is produced. In various embodiments, removing a target nucleic acid from a surface is achieved by changing conditions. In other embodiments, the condition is temperature, pH, formamide concentration, or a combination thereof.

[0268] Aspects of the present disclosure include those in which a plurality of capture oligonucleotides are fixed on a surface. In various embodiments, the capture oligonucleotides are hybridized with a target nucleic acid of a biological sample. In some embodiments, each of the plurality of capture oligonucleotides comprises the same capture nucleotide sequence. In other embodiments, the plurality of capture oligonucleotides comprises a plurality of different capture nucleotide sequences. In further embodiments, a plurality of different capture nucleotide sequences comprises one or more gene-specific capture sequences, one or more universal capture sequences, or a combination thereof. In various embodiments, the capture nucleotide sequence is a poly-T sequence, a poly-A sequence, a gene-specific capture sequence, or a universal capture sequence. In other embodiments, the universal capture sequence is a random nucleotide sequence or a non-self-complementary semi-random sequence. Aspects of the present disclosure also include those in which the capture nucleotide sequence is extended after the capture oligonucleotide is hybridized with the target nucleic acid. In some embodiments, the extension of the capture nucleotide sequence is performed using a reverse transcriptase. In some specific implementations of the method of the present disclosure, the target nucleic acid is polyadenylated before hybridization with the capture nucleotide sequence. In some embodiments, the target nucleic acid is polyadenylated using a poly(A) polymerase. In additional embodiments, the target nucleic acid is polyadenylated using chemical or enzymatic ligation.

[0269] Methods for normalizing library size

[0270] In one aspect, the present disclosure relates to methods for normalizing library size for library preparation applications on a surface. In various aspects, the present disclosure also provides methods for spatially capturing target nucleic acids of tissue samples. The use of the methods of the present disclosure provides the ability to spatially maintain the position of target nucleic acids in biological samples (e.g., tissue samples). The technology disclosed herein provides several advantages, including but not limited to: (1) The technology of the present disclosure provides the ability to capture target analytes (e.g., mRNA or other analytes for multi-omics methods) on a surface (e.g., an Illumina flow cell (Illumina Inc., San Diego CA)), followed by sequencing readout using a suitable (e.g., Illumina Inc., San Diego CA) sequencing infrastructure. This technology allows non-targeted spatial detection of mRNA / analytes to allow de novo mapping of signals in a tissue context; (2) The technology of the present disclosure provides the ability to generate spatial transcriptome libraries, the size of which is optimal for sequencing. For example, but not limited to, in some embodiments, the methods of the present disclosure allow the generation of transcriptome libraries containing fragments of target analytes (e.g., target nucleic acids) having a length of about 100 to 1000 nucleotides. In other embodiments, the methods of the present disclosure allow the generation of transcriptome libraries comprising fragments of target analytes (e.g., target nucleic acids) having a length of about 100 to 800 nucleotides. In some embodiments, the methods of the present disclosure allow the generation of transcriptome libraries comprising fragments of target analytes (e.g., target nucleic acids) having a length of about 800 nucleotides. In some embodiments, the methods of the present disclosure allow the generation of transcriptome libraries comprising fragments of target analytes (e.g., target nucleic acids) having a length of about 700 nucleotides.

[0271] In many aspects, the present disclosure provides a method for preparing a fixed library of target nucleic acids of a biological sample, including providing a surface comprising a capture oligonucleotide hybridized or otherwise associated with a target nucleic acid of a biological sample, extending (e.g., by reverse transcription) the capture oligonucleotide to form a first complementary strand of the target nucleic acid, thereby preparing a fixed library of the target nucleic acid. In some embodiments, after forming the first complementary strand, a plurality of oligonucleotide primers are hybridized with the first complementary strand, and a plurality of oligonucleotide primers are extended to produce one or more second complementary strands. As described above, the technology disclosed herein provides the ability to generate a spatial transcriptome library, the size of which is optimal for sequencing. In order to normalize the size of the library fragments, the method disclosed herein includes using an extension termination portion during the extension of the capture oligonucleotide to form a first complementary strand. The extension termination portion is used to terminate the synthesis of the growing nucleic acid chain. Extension termination moieties contemplated by the present disclosure include, but are not limited to, allyl-T or deoxyuridine triphosphate (dUTP), dideoxynucleoside triphosphate (ddNTP), deoxynucleoside triphosphate (dNTP) comprising a 3' phosphate group, deoxynucleoside triphosphate (dNTP) comprising a 3' phosphate group, dideoxynucleoside triphosphate (ddNTP) comprising a first click chemistry handle, or combinations thereof.

[0272] The generation of the second complementary strand can be performed "on the surface" or "off the surface". In some embodiments, in order to generate the second complementary strand on the surface, the first complementary strand is kept fixed on the surface while the second complementary strand is extended using the first complementary strand as a template. See, e.g. Fig.16 , Fig.19 and Fig. 20. In some embodiments, the second complementary chain is removed (eluted) from the surface, and then the second complementary chain is subjected to index PCR for amplification. In some embodiments, in order to produce the second complementary chain on the surface, the exclusion amplification (ExAmp) mixture containing the adapter-index oligonucleotide is contacted with the first complementary chain on the surface, thereby producing the second complementary chain by chain invasion and isothermal amplification. In various embodiments, the Examp mixture also includes a recombinase, a single-stranded DNA binding protein (e.g., a gp32 ssDNA binding protein) and a polymerase. As with any method for producing the second complementary chain described herein, the generation of the second complementary chain can be followed by amplification of the second complementary chain (e.g., by index PCR), during which a second clustering primer sequence (e.g., P5) can be added to one or more of the second complementary chain. In some embodiments, amplification includes index PCR, during which the first primer hybridizes with the first clustering primer sequence, and the second primer hybridizes with the adapter nucleotide sequence, wherein the second primer comprises a second clustering primer sequence. In various embodiments, an index sequence (e.g., i5) is also added to one or more of the second complementary strands during amplification. In some embodiments, the second primer also comprises an index sequence. In various embodiments, the second clustering primer sequence and the optional index sequence are added to one or more of the second complementary strands outside the surface (e.g., in solution). The amplification of the second complementary strand can be subsequently sequenced. The sequencing information can then be associated with the spatial position of the target nucleic acid in the biological sample.

[0273] In some embodiments, for the second complementary strand to be generated outside the surface, the formation of the first complementary strand is followed by cleavage of the first complementary strand from the surface, and the synthesis of the second complementary strand is performed outside the surface (e.g., in solution). See, e.g. Fig.18 In some embodiments, the second complementary strand is then amplified (e.g., by index PCR), during which a second clustering primer sequence (e.g., P5) may be added to one or more of the second complementary strands. In various embodiments, an index sequence (e.g., i5) is also added to one or more of the second complementary strands during amplification. In various embodiments, the addition of the second clustering primer sequence and the optional index sequence to one or more of the second complementary strands occurs outside the surface (e.g., in solution). The amplification of the second complementary strand may then be sequenced. The sequencing information may then be associated with the spatial position of the target nucleic acid in the biological sample.

[0274] In some aspects, a method for preparing a fixed library of target nucleic acids of a biological sample, comprising providing a surface comprising a capture oligonucleotide hybridized or otherwise associated with a target nucleic acid of a biological sample, extending (e.g., by reverse transcription) the capture oligonucleotide to form a first complementary strand of the target nucleic acid, wherein the extension is performed in the presence of an extension termination portion, and wherein the extension termination portion is allyl-T or deoxyuridine triphosphate (dUTP), thereby preparing a fixed library of target nucleic acids. In various embodiments, one or more of the capture oligonucleotides comprises from 5' to 3': (i) a first clustering primer sequence; (ii) a spatial barcode (SBC) sequence; (iii) a first sequencing primer sequence; and (iv) a capture nucleotide sequence. In some embodiments, a second complementary strand is generated on the surface, and the second complementary strand is removed (e.g., eluted) from the surface. In some embodiments, a second complementary strand is generated on the surface, and the second complementary strand is removed (e.g., eluted) from the surface by an ExAmp mixture. In some embodiments, after the first complementary strand is generated, the surface is contacted with an exonuclease (e.g., to remove unbound surface capture oligonucleotides from the surface), and a plurality of oligonucleotide primers are hybridized to the first complementary strand, wherein each of the plurality of oligonucleotide primers comprises from 5' to 3': (i) an adapter nucleotide sequence (e.g., B15); and (ii) a random nucleotide sequence (comprising, for example, about 5 to 10 nucleotides, 7 to 10 nucleotides, or 9 nucleotides). In some embodiments, the plurality of oligonucleotide primers are then extended to generate one or more second complementary strands comprising an adapter nucleotide sequence at the end. In some embodiments, one or more second complementary strands are removed from the surface and amplified. In other embodiments, amplification is performed in the presence of an exclusion amplification (ExAmp) mixture, wherein the ExAmp mixture comprises a primer containing a clustering primer sequence. In various embodiments, the ExAmp mixture further comprises a recombinase, a single-stranded DNA binding protein (e.g., a gp32 ssDNA binding protein), and a polymerase. In some embodiments, one or more of the plurality of capture oligonucleotides are fixed on the surface by a cleavage site. In some embodiments, the cleavage site is an enzyme cleavage site. In various embodiments, the enzyme cleavage site includes a restriction enzyme site, uracil, 8-oxoguanine or a combination thereof. In some embodiments, the cleavage site is a chemical cleavage site. In various embodiments, the cleavage site is cut after the capture nucleotide sequence has been extended and the first complementary strand has been formed. In some embodiments, the extension termination portion is deoxyuridine triphosphate (dUTP), and the method also includes contacting the surface with uracil-DNA glycosylase (UDG). In some embodiments, after the first complementary strand is produced and before the second complementary strand is produced, the surface is contacted with UDG.In some embodiments, the extension termination portion is an allyl-T, and the method further comprises contacting the surface with a universal cleavage mixture (UCM) (see, e.g., International Application Publication No. WO 2019 / 222264, for a discussion of cleavage mixtures, which is incorporated herein by reference in its entirety). In some embodiments, contacting the surface with a universal cleavage mixture (UCM) occurs before a plurality of oligonucleotide primers are hybridized to the first complementary strand. In some embodiments, the second complementary strand is generated outside the surface (e.g., in solution).

[0275] In some aspects, a method for preparing a fixed library of target nucleic acids of a biological sample, comprising providing a surface comprising a capture oligonucleotide hybridized or otherwise associated with a target nucleic acid of a biological sample, extending (e.g., by reverse transcription) the capture oligonucleotide to form a first complementary strand of the target nucleic acid, wherein the extension is performed in the presence of an extension termination portion, and wherein the extension termination portion is a dideoxynucleoside triphosphate (ddNTP), thereby preparing a fixed library of target nucleic acids. In some embodiments, one or more of a plurality of capture oligonucleotides comprises from 5' to 3': (i) a first clustering primer sequence; (ii) a spatial barcode (SBC) sequence; (iii) a first sequencing primer sequence; and (iv) a capture nucleotide sequence. In some embodiments, a second complementary strand is generated on the surface, and the second complementary strand is removed (e.g., eluted) from the surface. In some embodiments, a second complementary strand is generated on the surface, and the second complementary strand is removed (e.g., eluted) from the surface by an Examp mixture. In some embodiments, the second complementary strand is generated outside the surface (e.g., in a solution). More specifically, in some embodiments, the surface is contacted with an exonuclease, and multiple oligonucleotide primers are hybridized with the first complementary strand, wherein each of the multiple oligonucleotide primers comprises from 5' to 3': (i) an adapter nucleotide sequence (e.g., B15); and (ii) a random nucleotide sequence (comprising, for example, about 5 to 10 nucleotides, 7 to 10 nucleotides, or 9 nucleotides). Then, multiple oligonucleotide primers are extended to generate one or more second complementary strands comprising an adapter nucleotide sequence at the end. In various embodiments, after removing one or more second complementary strands from the surface, one or more second complementary strands are amplified by, for example, index PCR. The amplification of one or more second complementary strands causes a second clustering primer sequence (e.g., P5) to be added to one or more of the second complementary strands. In various embodiments, an index sequence (e.g., i5) is also added to one or more second complementary strands during amplification. Therefore, in some embodiments, the amplification of one or more second complementary strands causes a second clustering primer sequence (e.g., P5) and an index sequence (e.g., i5) to be added to one or more second complementary strands. In various embodiments, one or more second complementary chains are removed from the surface in the presence of an exclusion amplification (ExAmp) mixture, wherein the ExAmp mixture comprises a primer containing a first clustering primer sequence. In some embodiments, one or more of a plurality of capture oligonucleotides are fixed on the surface by a cleavage site. In some embodiments, the cleavage site is an enzyme cleavage site. In various embodiments, the enzyme cleavage site includes a restriction enzyme site, uracil, 8-oxoguanine or a combination thereof. In some embodiments, the cleavage site is a chemical cleavage site. In various embodiments, the cleavage site is cleaved after the capture nucleotide sequence of the capture oligonucleotide of the extended hybridization.In some embodiments, the cleavage site is cleaved after producing one or more second complementary strands. In some embodiments, the ddNTP includes a first click chemistry handle. In other embodiments, after extending the capture nucleotide sequence of the hybridized capture oligonucleotide, the surface is contacted with an adapter oligonucleotide, which includes a second click chemistry handle that can be cross-linked to the first click chemistry handle, thereby connecting the adapter oligonucleotide to the first complementary strand. Any click chemistry portion is contemplated for use in the methods of the present disclosure. In some embodiments, the adapter oligonucleotide also includes a second sequencing primer sequence. In some embodiments, the first click chemistry handle is an azide, a tetrazine, a strained olefin, or an alkyne. In some embodiments, the second click chemistry handle is an azide, a tetrazine, a strained olefin, or an alkyne.

[0276] In some aspects, a method of preparing an immobilized library of target nucleic acids from a biological sample comprises providing a surface comprising a capture oligonucleotide hybridized or otherwise associated with a target nucleic acid from the biological sample, extending (e.g., by reverse transcription) the capture oligonucleotide to form a first complementary strand of the target nucleic acid, wherein the extension is performed in the presence of an extension termination moiety, and wherein the extension termination moiety is a deoxynucleoside triphosphate (dNTP) comprising a 3' phosphate group, thereby preparing an immobilized library of target nucleic acids. See, e.g. Figure 6. In various embodiments, one or more of the plurality of capture oligonucleotides comprises from 5' to 3': (i) a first clustering primer sequence; (ii) a spatial barcode (SBC) sequence; (iii) a first sequencing primer sequence; and (iv) a capture nucleotide sequence. Then, the surface is contacted with an exonuclease, followed by connection to connect the adapter oligonucleotide to the first complementary strand. The adapter oligonucleotide comprises (i) an adapter nucleotide sequence (e.g., B15); and (ii) a random nucleotide sequence (comprising, for example, about 5 to 10 nucleotides, 7 to 10 nucleotides, or 9 nucleotides). In some embodiments, the adapter oligonucleotide further comprises a second oligonucleotide hybridized to the adapter nucleotide sequence. In some embodiments, the adapter nucleotide sequence comprises a second sequencing primer sequence. In various embodiments, the connection occurs by connecting the adapter oligonucleotide to the splint of the first complementary strand. In various embodiments, the connection is made using T4 DNA ligase. In some embodiments, the connection occurs by connecting the single-stranded DNA of the adapter oligonucleotide to the first complementary strand. In related embodiments, the ligase is a DNA / RNA ligase. More generally, about connection, in some embodiments, the adapter oligonucleotide also includes a second oligonucleotide hybridized to the adapter nucleotide sequence; The adapter oligonucleotide including the second oligonucleotide hybridized to the adapter nucleotide sequence can be used to promote splint connection, for example. In various embodiments, the connection is enzymatic connection. In other embodiments, the enzymatic connection is a splint connection. In some embodiments, the enzymatic connection is a single-stranded DNA connection. In some embodiments, the connection is a chemical connection. In some embodiments, the chemical connection is a splint connection. In some embodiments where a splint connection is utilized, the second complementary chain is generated on the surface using the adapter nucleotide sequence as a primer sequence. In some embodiments where a single-stranded DNA connection is utilized, the second complementary chain is generated on the surface using a primer complementary to the adapter nucleotide sequence. In some embodiments, the second complementary chain is then removed (e.g., eluted) from the surface. In some embodiments, the second complementary chain is generated on the surface, and the second complementary chain is removed (e.g., eluted) from the surface by an ExAmp mixture. In some embodiments where a splint connection is utilized, the second complementary chain is generated outside the surface (e.g., in solution) using the adapter nucleotide sequence as a primer sequence. In some embodiments where single-stranded DNA is used for connection, a second complementary strand is produced outside the surface (e.g., in solution) using a primer complementary to the adapter nucleotide sequence. After the adapter oligonucleotide is connected to the first complementary strand, the adapter oligonucleotide is extended to produce one or more second complementary strands. Then one or more second complementary strands are removed from the surface and amplified. In various embodiments, amplification is performed in the presence of an exclusion amplification (ExAmp) mixture. In some embodiments, one or more of a plurality of capture oligonucleotides are fixed on the surface by a cleavage site.In some embodiments, the cleavage site is an enzyme cleavage site. In other embodiments, the enzyme cleavage site includes a restriction enzyme site, uracil, 8-oxoguanine or a combination thereof. In some embodiments, the cleavage site is a chemical cleavage site. In various embodiments, the cleavage site is cut after the capture nucleotide sequence of the capture oligonucleotide extending the hybridization. In some embodiments, the cleavage site is cut after the surface is contacted with a ligase, so that the adapter oligonucleotide is connected to the first complementary strand.

[0277] In some aspects, a method of preparing an immobilized library of target nucleic acids from a biological sample comprises providing a surface comprising a capture oligonucleotide hybridized or otherwise associated with a target nucleic acid from the biological sample, extending (e.g., by reverse transcription) the capture oligonucleotide to form a first complementary strand of the target nucleic acid, wherein the extension is performed in the presence of an extension termination moiety, and wherein the extension termination moiety is a deoxynucleoside triphosphate (dNTP) comprising a 3' phosphate group or a dideoxynucleoside triphosphate (ddNTP) comprising a first click chemistry handle, thereby preparing an immobilized library of target nucleic acids. See, e.g. Figure 6. In various embodiments, one or more of the multiple capture oligonucleotides comprises from 5' to 3': (i) a first clustering primer sequence; (ii) a spatial barcode (SBC) sequence; (iii) a first sequencing primer sequence; and (iv) a capture nucleotide sequence. In some embodiments, the extension termination portion is a deoxynucleoside triphosphate (dNTP) comprising a 3' phosphate group. In these embodiments, the adapter oligonucleotide is then chemically connected to the first complementary strand by a cross-linking group, wherein the adapter oligonucleotide comprises from 5' to 3': (i) an adapter nucleotide sequence (e.g., B15); and (ii) a random nucleotide sequence (comprising, for example, about 5 to 10 nucleotides, 7 to 10 nucleotides, or 9 nucleotides). In some embodiments, the adapter oligonucleotide also comprises a second oligonucleotide that hybridizes to the adapter nucleotide sequence. In some embodiments, the adapter nucleotide sequence comprises a second sequencing primer sequence. In various embodiments, the cross-linking group is a carboxyl-amine reactive group, a BCN-azide reactive group, a DBCO-azide reactive group, a tetrazine-TCO reactive group, or a combination thereof. In some embodiments, the extension termination portion is a dideoxynucleoside triphosphate (ddNTP) comprising a first click chemistry handle. In these embodiments, the adapter oligonucleotide is then connected to the first complementary strand by click chemistry, wherein the adapter oligonucleotide comprises from 5' to 3': (i) an adapter nucleotide sequence; and (ii) a random nucleotide sequence, and wherein the adapter oligonucleotide also comprises a second oligonucleotide hybridized to the sequencing primer sequence, wherein the second oligonucleotide comprises a second click chemistry handle. In some embodiments, the adapter nucleotide sequence comprises a second sequencing primer sequence. In various embodiments, the first click chemistry handle is an azide, a tetrazine, a strained olefin, or an alkyne. In additional embodiments, the second click chemistry handle is an azide, a tetrazine, a strained olefin, or an alkyne.

[0278] In various embodiments, the disclosure also provides a method for digesting a biological sample. In various embodiments, the digestion of the biological sample may occur after the first complementary strand is produced. In some embodiments, the digestion of the biological sample occurs after the first complementary strand is produced but before the second complementary strand is produced. The disclosure also provides a method for removing a target nucleic acid (e.g., RNA) from a surface. In various embodiments, removing the target nucleic acid from the surface may occur after the first complementary strand is produced. In some embodiments, the removal of the target nucleic acid occurs after the first complementary strand is produced but before the second complementary strand is produced. In various embodiments, removing the target nucleic acid from the surface is achieved by changing conditions. In other embodiments, the condition is temperature, pH, formamide concentration, or a combination thereof.

[0279] Aspects of the present disclosure include those in which a plurality of capture oligonucleotides are fixed on a surface. In various embodiments, the capture oligonucleotides are hybridized with a target nucleic acid of a biological sample. In some embodiments, each of the plurality of capture oligonucleotides comprises the same capture nucleotide sequence. In other embodiments, the plurality of capture oligonucleotides comprises a plurality of different capture nucleotide sequences. In further embodiments, a plurality of different capture nucleotide sequences comprises one or more gene-specific capture sequences, one or more universal capture sequences, or a combination thereof. In various embodiments, the capture nucleotide sequence is a poly-T sequence, a poly-A sequence, a gene-specific capture sequence, or a universal capture sequence. In other embodiments, the universal capture sequence is a random nucleotide sequence or a non-self-complementary semi-random sequence. Aspects of the present disclosure also include those in which the capture nucleotide sequence is extended after the capture oligonucleotide is hybridized with the target nucleic acid. In some embodiments, the extension of the capture nucleotide sequence is performed using a reverse transcriptase. In some specific implementations of the method of the present disclosure, the target nucleic acid is polyadenylated before hybridization with the capture nucleotide sequence. In some embodiments, the target nucleic acid is polyadenylated using a poly(A) polymerase. In additional embodiments, the target nucleic acid is polyadenylated using chemical or enzymatic ligation.

[0280] In various embodiments, the primers used in the methods of the present disclosure (e.g., oligonucleotide primers that hybridize to the first complementary strand and then extend) are used at a concentration in the range of 0.1 μM to 100 μM, 1 μM to 100 μM, or 3 μM to 75 μM, or 5 μM to 50 μM. In some embodiments, the primers are used at a concentration of 0.25 μM, 0.5 μM, or 1.1 μM or 2.2 μM. In further embodiments, the primers are used at a concentration of 1 μM, 5 μM, 10 μM, 25 μM, or 50 μM. In various embodiments, such primers are P5 primers, P5' primers, P7 primers, or P7' primers.

[0281] Reagent test kit

[0282] Kits and articles are also encompassed herein. Such kits may include carriers, packages or containers, such as vials, tubes, etc., separated to receive one or more containers, each container including one of the independent elements to be used in the methods described herein. Suitable containers include, for example, bottles, vials, syringes and test tubes. The container may be formed of a variety of materials, such as glass or plastic. For example, a container may include one or more spatially addressable probes disclosed herein, optionally in a composition or in combination with another reagent disclosed herein (e.g., arrays, bead chips). Optionally, the container has a sterile inlet (e.g., the container may be an intravenous bag or a vial with a stopper that can be pierced by a hypodermic needle). Optionally, such kits include an identification description or label or instructions for use thereof in the methods described herein.

[0283] The kit will typically include one or more additional containers, each with one or more of the various materials (such as reagents and / or devices, optionally in concentrated form) that are desirable from a commercial and user standpoint for use with the spatially addressable probes described herein. Non-limiting examples of such materials include, but are not limited to: buffers, diluents, filters, needles, syringes; carriers, packaging, containers, vials, and / or tube labels listing the contents and / or instructions for use, and package inserts with instructions for use. A set of instructions will also typically be included.

[0284] The mark may be on or associated with the container. In the case where the letters, numbers or other characters forming the mark are attached, molded or etched to the container itself, the mark may be on the container, and when it is present in a receptacle or carrier that also supports the container, such as in a package insert, the mark may be associated with the container. The mark may be used to indicate that the contents will be used for a specific spatial omics application. Such as in the method described herein, the mark may also indicate the direction in which the contents are used.

[0285] The following examples are intended to illustrate but not to limit the present disclosure. Although they are typical of methods that can be used, other methods known to those skilled in the art may alternatively be used.

[0286] Example

[0287] Example 1

[0288] Fresh frozen tissue was sectioned and mounted on a barcoded polyT capture flow cell. The tissue was fixed in methanol at -20°C for 30 minutes, then stained with hematoxylin and eosin, air-dried, and imaged with a light microscope. The substrate was then placed in a proprietary device with sealable wells that allowed for heat incubation on a thermal cycler. Each well had a surface area of ​​approximately 28 mm^2 covering each tissue section.

[0289] The samples were incubated in a first strand cDNA synthesis mix with a template switch oligonucleotide containing Rd1 at 53°C for 1 hour. The wells were then washed 3 times with water. NaOH was added to the wells and incubated at room temperature for 5 minutes three times.

[0290] The flow cell is assembled into a pad that creates a separate sample well on the tissue section. The wells are coated with 0.1×SSC / RNase inhibitor and the solution is removed. 25 μL of preheated permeabilization mixture (0.1% pepsin, 0.1N HCl) is added to the wells and the flow cell is incubated at 37°C for 7 minutes, followed by washing three times at room temperature in space wash buffer. The permeabilization mixture is then removed and 25 μL of 1×RT buffer containing RNase inhibitor is added to the wells. The buffer is then removed and 25 μL of cDNA synthesis mixture (reverse transcriptase (RT) enzyme, reducing agent, TSO primer, RT reagent, water) is added to the wells. The flow cell is incubated at 53°C for 1 hour in a first-strand cDNA synthesis mixture with a template switching oligonucleotide containing Rd1. The solution is then discarded from the wells and washed three times with water. 25 μL of 100% formamide is added to the wells and the flow cell is incubated at 80°C for 10 minutes.

[0291] The mRNA eluate was stored at -80 ° C for RT-qPCR QC. The wells were then washed three times with water. 25 μL 0.08M KOH was added to the wells and the flow cell was incubated at room temperature for 5 minutes. The solution was discarded and the wells were washed once with 50 μL buffer EB (Qiagen). The second strand synthesis was then performed by adding 25 μL of second strand synthesis mixture (second strand reagent, TSO primer, second strand enzyme) to the wells, and the flow cell was incubated at 65 ° C for 15 minutes. The solution was then discarded and the wells were washed with 50 μL buffer EB. The buffer was then discarded, 25 μL 0.08M KOH was added to the wells, and the flow cell was incubated at room temperature for 10 minutes.

[0292] The cDNA eluted in KOH was transferred to a strip tube and neutralized with 3.6 μL Tris (1 M, pH 7.0). Poly-TVN extension mix (Illumina ASM chain displacement extension mix) was then added to the neutralized cDNA, and the mixture was subjected to the following parameters on a thermal cycler: 37°C for 10 minutes, 60°C for 10 minutes, and kept at 4°C. The extension product was 0.7×SPRI purified and eluted in 12 μL water. Tagmentation was then performed using the Illumina Surecell protocol (with diluted transposomes). The tagmentation reaction mixture (tagmentation enzyme, tagmentation buffer) was added to the purified sample and incubated at 55°C for 5 minutes. Tagmentation was terminated with 10 μL tagmentation termination buffer and incubated at room temperature for 5 minutes. The index PCR mix (tag PCR mix, P7 primer, N5XX primer) was then added to the sample and the following parameters were used: 95°C for 30 seconds, followed by 15 cycles of 95°C for 10 seconds, 60°C for 45 seconds, and 72°C for 60 seconds, followed by a final extension at 72°C for 5 minutes and hold at 4°C. The samples were then purified with 1× SPRI and quantified for sequencing. Each NovaSeq 6000S4 flow cell sequenced the library with a read structure of 100 bases Read 1 (custom primer), 28 bases Index Read 1, 8 bases Read 2 ( Figure 2 ).

[0293] Referring to Figure 4, data generated from the TSO-TAG treatment described above are shown. An amplicon was generated from the TSO-TAG second strand cDNA using P7 and TSO primers and purified with 0.7× SPRI to simulate an optimized PolyTVN extension product. This amplicon was used for in-solution tagmentation evaluation, as Figure 4A Reference Figure 4B, high input P7 / TSO amplicon (2.5ng) used as control (optimal input for tagmentation with Illumina Surecell library preparation kit) was tagmented starting at 100 femtomoles to 0 femtomoles with 2-fold dilution of Surecell transposome (B15 transposome diluted in Illumina standard storage buffer) relative to low input amplicon (100pg). Tagmentation was performed according to the Illumina standard Surecell tagmentation protocol. Fragment size titration was observed. The library was then purified with 0.7×SPRI. 15 cycles of PCR were performed with B15-index-P5 and P7, and the product was then purified with 0.7×SPRI. The library was then run on a D5000 DNA screening tape on an Agilent Tapestation. When transposed with 12.5 moles of B15 transposome, a sequencing library with a peak at 477bp could be observed with low input tagmentation (60nM yield). This demonstrates that low input indexing can generate the desired sequencing libraries (desired size range 200 bp-800 bp with high yield), as shown by readout on the D5000 DNA screener on the Tapestation, and does not require the addition of carrier gDNA to prevent over-indexing.

[0294] refer to Figure 6 , different conditions were tested to evaluate how process parameters affect final library preparation. 12.5 femtomoles B15 Tn5 transposase and 1.25 femtomoles B15 Tn5 transposase in the tagging mixture were tested, as well as 0.7×SPRI and no SPRI to purify the post-tagmentation pre-index PCR. The gene map numbers for these different conditions are shown in the table below, as well as a comparison with the commercial library preparation method-Visium (10x genome). Compared to the commercial product, the method according to the present disclosure has improved mapped genes as measured in transcripts per million (TPM).

[0295] hole TSM (Femtomolar) SPRI Pre-PCR TPM(>1) 3 12.5 + 13372 4 12.5 + 13400 5 12.5 - 13190 6 12.5 - 13138 7 1.25 + not applicable 8 1.25 + 12805 9 1.25 - 12529 10 1.25 - 13103 Commercial Products 10477

[0296] Coding alignment data for all TSO-TAG libraries were generated using the Illumina RNA-seq Alignment Software (v2.0.2) on BaseSpace. Figure 7 , the alignment profile of the disclosed method is also similar to the commercially available Visium process. Transcript coverage sequencing data for all TSO-TAG libraries were generated using the Illumina RNA-seq alignment software (v2.0.2) on BaseSpace. Figure 8 Transcript coverage for the TSO-TAG method is shown. Using the transposition-based library preparation method of the present disclosure, a slight shift in the 3' coverage bias was observed.

[0297] Example 2

[0298] The library preparation method described in Example 1 was performed, except that transposition was performed on beads. A14 transposome beads were formed and stored in 15% glycerol storage buffer. 500 pg, 100 pg, and 10 pg of P7 / TSO amplicons were transposed using A14 beads. The reaction was terminated with buffer and amplified with short P7 / A14 for 15 cycles using the same thermal cycling parameters as described in Example 1. The library was purified with 0.9×-SPRI and run on the HD500 Tapestation. Figure 5A is a schematic diagram of this method, Figure 5B is a graph of library fragment sizes, where 500pg, 100pg, and 10pg are consistent.

[0299] The TSO-TAG workflow can also be performed in a "one-pot" reaction when using a biotinylated TSO second strand oligonucleotide in the second strand cDNA synthesis. TSO-TAG is performed in the same manner as outlined in Figure 1. After elution and neutralization of the second strand cDNA, the second strand cDNA can be hybridized to streptavidin beads and the subsequent steps (Poly-TVN extension, tagmentation, washing and PCR) can be performed on the beads with a simple washing step on a magnet ( Fig.9A ).

[0300] TSO-TAG can be carried out on the surface ( Fig. 9B ). After RNA removal, 3'-blocked SBS12'-PolyA is hybridized to cDNA. TSO complementary sequence oligonucleotides are then gap filled into the 5'polyA region (using a non-strand displacement polymerase). The SBS12'-PolyA region is then heated to melt. On-surface tagmentation (A14 transposome) is then performed to introduce UMIs and add adapters. A proprietary extension mix is ​​then added to the surface to add P7 and A14 adapters to the cDNA. The second strand product is then eluted from the surface and index PCR is performed.

[0301] In addition to TSO-TAG (SBC-TAG and UMI-TAG), various library preparation methods including transposition were considered ( Fig.10 In one approach, SBC-TAG and UMI-TAG used random primers (no template switching) and a second strand mix with N9-SBS3 random oligonucleotides for second strand cDNA synthesis. The second strand cDNA was then eluted in a proprietary buffer and redundancy was built using global preamplification prior to transposition using the same cycling parameters as described in Figure 1. The amplified library was purified with SPRI and followed Figure 4BThe library was also amplified using the P7 and D5XX primers to generate UMI information. This method leaves double-stranded barcode information, which allows transposition on the capture sequence region.

[0302] Example 3

[0303] The following experiment was performed to show the feasibility of transposition of an amplified TSO library. 0.6×SPRI purified second strand cDNA (generated as described in FIG. 1 ) was transposed using Nextera XT transposome (input 1 ng library), Surecell transposome (input 3 ng library), or custom A14ME transposome (input 3 ng library). Tagging was performed according to the Illumina standard tagmentation protocol. Nextera libraries were amplified with UD index primers using the following cycle parameters: 72°C for 3 minutes, 95°C for 30 seconds, followed by 12 cycles of 95°C for 10 seconds, 55°C for 30 seconds, and 72°C for 30 seconds, and finally extended at 72°C for 5 minutes and held at 10°C. Surecell libraries were amplified with P7 / N5XX primers using the following cycle parameters: 95°C for 30 seconds, followed by 12 cycles of 95°C for 10 seconds, 60°C for 45 seconds, and 72°C for 60 seconds, and finally extended at 72°C for 5 minutes and held at 10°C. The custom A14ME library was amplified with P7 / A14-index-P5 primers using the following cycling parameters: 95°C for 30 sec, followed by 12 cycles of 95°C for 10 sec, 60°C for 45 sec, and 72°C for 60 sec, and a final extension at 72°C for 5 min and hold at 10°C. The library was purified with 0.6× SPRI and used with Figure 2 The same parameters as described in sequencing.

[0304] Using the sequencing analysis pipeline, determine the base composition map of Read 1 ( Fig. 11B ). The A14ME custom library showed little to no amplification in the adapter region of the amplified library. There was no transposition in the adapter region of the Nextera library due to the A14 / B15 transposome.

[0305] The 0.6× SPRI purified library was run on the HSD5000 DNA Screentape on the Agilent Tapestation to determine the library concentration for sequencing ( Fig. 11C ). The A14ME library showed similar library conversion to the Nextera library, where Surecell tagmentation was insufficient.

[0306] Using the sequencing analysis pipeline, determine the number of UMIs per 5M input raw reads ( Fig.11D). The highest UMI count was determined for the A14ME transposon library. A low number of UMIs were determined for Nextera XT due to the A14 / B15 transposome.

[0307] Example 4

[0308] Spatial transcriptomics enables highly multiplexed in situ gene expression profiling within complex tissues. A key challenge in achieving single-cell resolution is assay sensitivity, where tissue RNA is converted into sequence-ready libraries. This paper describes a method that combines on-surface template switching, single-stranded enzymatic ligation (TSO-LIG), and isothermal amplification to efficiently convert captured tissue RNA (e.g., mRNA) into spatially barcoded libraries.

[0309] An exemplary workflow is shown in Fig.12 .

[0310] In steps 1 to 2 of the workflow, a tissue section is permeabilized to release RNA, e.g., mRNA, from the sample. The released mRNA is then captured by an anchored polyTVN strand immobilized on a solid substrate. The anchored strand is then converted to first-strand cDNA by a template-switching reverse transcriptase. During cDNA synthesis, a template-switching oligonucleotide (TSO), e.g., encoding a portion of a read 1 sequencing adapter (Rd1'), is attached (e.g., by hybridization) to the 3' end of the first-strand cDNA. In this example, the capture oligonucleotide design consists of six components as follows: a) a 5'P7 sequence (for clustering), b) a random spatial barcode (SBC, which encodes unique positional information of the transcript), c) a full-length read 2 adapter sequence (Rd2 FL) for decoding the SBC and surface UMI, d) a unique molecular identifier (UMI) that provides a discrete barcode for each captured mRNA transcript, e) a fixed sequence (FS) for quality control, and f) a poly T capture sequence with a 3'VN terminus to anchor the captured mRNA at the 3'UTR.

[0311] After exonuclease I treatment (to remove all single-stranded capture oligonucleotides) and RNA removal (to remove bound RNA and TSO), an oligonucleotide ligation blocker is hybridized (step 3) to prevent template switching molecules from ligating to the Rd1 adaptor (X) during the subsequent enzymatic ligation step. The ligation blocker is an oligonucleotide complementary to the Rd1' sequence. An alternative strategy to neutralize surface capture oligonucleotides is to hybridize a complementary oligonucleotide blocker to create a double-stranded end at the 3' end of the capture oligonucleotide to prevent ligation.

[0312] During the single-stranded ligation step (step 4), the splint Rd1 adapter is attached to all cDNA molecules without template switching. The splint adapter consists of two parts: a single-stranded splint composed of random bases (NX) with a blocking group (*) at the 3' end, and a double-stranded portion Rd1 adapter sequence containing a blocking group (*) at the ends of the two chains farthest from the splint. The adapter blocking group prevents the adapter from self-ligating. cDNA UMI can also be incorporated into TSO and adapter design to aid in downstream analysis of RNA sequences. The 5' end of the Rd1' sequence contains a phosphate group to enable enzymatic ligation to the 3'OH end of the captured non-template-switched cDNA. After alkaline treatment (e.g., 0.08M KOH or 0.1N NaOH at room temperature for 5 minutes) to remove the splint chain of the ligation blocker and adapter (step 5), all cDNAs containing Rd1' are amplified on the surface isothermally (step 6). Exponential amplification (ExAmp) is performed by priming a single full-length Rd1 primer (Rd1 FL) and a surface P7 lawn primer, resulting in elution of the amplified second-strand cDNA product (step 7). These eluted products are then converted into sequence-ready libraries by index PCR, during which the i5 index and clusterable P5 ends are appended (step 8). Strategies for normalizing the fragment lengths of single-stranded or double-stranded cDNA products (including tagging) are contemplated as described in co-owned U.S. Provisional Application No. 63 / 586,872 (Agent Docket No. IP-2576-P) and U.S. Provisional Application No. 63 / 477,103 (Agent Docket No. IP-2528-P).

[0313] The relative sensitivity of generating second-strand cDNA using template switching (TSO), single-strand splint ligation (LIG), and a combination of the two methods (TSO+LIG) was determined. Fresh frozen sections (10 μm) from mouse kidney were fixed on a substrate containing spatially barcoded capture oligonucleotides. The tissue was fixed in methanol for 30 minutes at -20°C, then stained with hematoxylin and eosin, air-dried, and imaged with an optical microscope. The substrate was then placed in a device with sealable holes that allowed heated incubation on a thermal cycler. Each well had a surface area of ​​approximately 28 mm^2 covering each tissue section, resulting in a surface reaction volume of 80 μL. The tissue sections were then permeabilized with a proprietary permeabilization reagent at 37°C for 7 minutes, followed by three washes at room temperature.

[0314] For TSO only, samples were incubated overnight at 42°C in a first-strand cDNA synthesis mix with a template-switching oligonucleotide containing Rd1; for single-strand ligation only (LIG), samples were incubated overnight at 42°C in a first-strand cDNA synthesis mix without a template-switching oligonucleotide containing Rd1; for TSO+LIG, samples were incubated overnight at 42°C in a first-strand cDNA synthesis mix with a template-switching oligonucleotide containing Rd1, followed by ligation.

[0315] After first-strand cDNA synthesis, samples were treated as follows: incubation in oligonucleotide digestion mix at 37°C for 45 minutes, a tissue removal step in tissue removal mix at 37°C for 40 minutes, an RNA removal step including three 5-minute incubations at room temperature in RNA removal solution, and finally one wash in space wash buffer at room temperature. For samples undergoing ligation, a proprietary ligation blocking mix was added and incubated at 40°C for 10 minutes, followed by one wash in space wash buffer at room temperature. The ligation mix (with a splint adapter containing Rd1) was then added and incubated at 37°C for 75 minutes, followed by one wash in space wash buffer at room temperature. Blocker removal solution was added, incubated at room temperature for 5 minutes, followed by one wash in space wash buffer at room temperature.

[0316] For all three preparations, a proprietary second-strand mix was added and incubated at 65°C for 15 minutes. After washing once at room temperature in space wash buffer, the second-strand cDNA was eluted into a PCR tube by two 5-minute room temperature incubations, using 22 μL of elution solution each time. Neutralization solution (6 μL) was added, followed by 0.6× SPRI purification. In a 50 μL PCR reaction using 2× KapaHiFi PCR mixture (98°C for 45 seconds, 95°C for 30 seconds, 60°C for 1 minute, 72°C for 1 minute for 11 cycles, and finally incubated at 72°C for 2 minutes), the index primer was attached to 10% of the eluted second-strand cDNA. A 0.7× SPRI purification step was used to clean up the PCR reaction. Each NovaSeq 6000S4 flow cell sequenced 16 libraries with a read structure of 100 bases Read 1, 28 bases index Read 1, and 8 bases Read 2. Each sample received approximately 1,200,000,000 reads, after which the median UMI count per 100 μm × 100 μm area was extracted using proprietary spatial software and then normalized relative to TSO conditions ( Fig.14 ).

[0317] After the captured tissue mRNA is converted into first-strand cDNA on a spatially barcoded substrate (similar to Fig.12), the Rd1 adaptor was attached by TSO, LIG, or both (TSO+LIG). Fig.12 Samples were further processed and sequenced as described in . Sensitivity was calculated as the median UMI detected per 100 μm × 100 μm and then normalized to TSO conditions. Fig.14 Increased sensitivity was shown in samples using both TSO+ ligation methods.

[0318] Relative Rd1 adapter addition efficiency to first-strand cDNA was determined using template switching (TSO), single-strand splint ligation (LIG), and a combination of both methods (TSO+LIG). After elution of the second-strand cDNA material from the spacer substrate, the cleavage mix was added and the samples were incubated at 60°C for 30 minutes to cleave the first-strand cDNA from the spacer substrate. The first-strand cDNA was then cleaved from the substrate and subjected to internal (5' gene-specific) and external (5' gene-specific + Rd1) qPCR assays to determine Rd1 adapter addition efficiency ( Fig.15A ). qPCR reactions used a probe-based assay and 2× KapaqPCR mix in a final volume of 10 μL and were cycled as follows: 95°C for 3 min, followed by 40 cycles of 95°C for 15 s and 60°C for 90 s. The adapter addition efficiency was calculated as 2 -(Cq内部-Cq外部) , and then normalized relative to the TSO condition. Fig. 15B The efficiency of Rd1 adaptor addition was shown to increase in samples using both TSO+ ligation methods.

[0319] The key step in converting synthetic cDNA containing Rd2 into a sequencing library is the addition of the Rd1 sequence by single-stranded ligation. An exemplary method for achieving this is described in Fig.13 middle.

[0320] Ligation options for appending the Rd1 adaptor sequence to the 3' end of the first strand cDNA include enzymatic and chemical methods. Examples of enzymatic methods include: T4 DNA ligase-mediated ligation with splint adaptors (see Fig.12) and thermostable 5'App DNA / RNA ligase-mediated ligation to synthetic pre-adenylated single-stranded oligonucleotide adapters. Chemical ligation methods include: click chemistry-mediated ligation, in which the 3'azido terminus is joined to a synthetic 5'alkyne single-stranded oligonucleotide, or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)-mediated ligation, in which a cDNA with a 3'phosphate group is connected to a splint adapter with a 5'hydroxyl terminus. Incorporation of 3'azido-ddNTP or 3'Phos-dATP can occur during first-strand cDNA synthesis, during which truncated cDNA molecules are produced. Both enzymatic and chemical methods are compatible with adapters incorporating molecular identifiers (e.g., NX) to aid downstream analysis and capping groups (*) to minimize adapter self-ligation.

[0321] Example 5

[0322] Provided herein are methods for preparing an immobilized library of target nucleic acids from a biological sample (eg, a tissue sample). The disclosed methods advantageously normalize library size for library preparation applications on a surface.

[0323] A schematic workflow of the method disclosed herein is shown in Fig.16 middle. Fig.16 A spatial workflow is shown, wherein a tissue section is placed on a flow cell (FC) surface, wherein the FC surface comprises a plurality of capture oligonucleotides comprising a first clustering primer sequence (e.g., Fig. 20 P7 primer sequence shown in ). Fig.16 How to control the library fragment size by adding an optimal concentration of dUTP / allyl-T in a reverse transcription (RT) reaction is shown. The method is performed by first capturing transcripts on a barcoded surface comprising a capture oligonucleotide, which comprises a polyT capture nucleotide sequence. The reverse transcriptase is initiated with dUTP / allyl-T incorporated into the reaction. After RT, a substrate for UDG / UCM cutting is prepared by performing exonuclease digestion, tissue digestion, and RNA removal steps. As described herein, the tissue digestion step is optional. UDG / UCM cutting is used to generate fragments, wherein the first dUTP / allyl-T site incorporated will be the 3' termination site of the cDNA chain. The substrate is then washed and then a second chain synthesis is performed with a random oligonucleotide primer comprising an adapter. The random oligonucleotide sequence will serve as the UMI of the transcript. After the second chain is synthesized, the second cDNA chain is eluted and subjected to index PCR and purification, and then loaded onto a sequencer. Fig.17The sequencing read structure of the amplified second complementary strand is depicted. Read 1 reads in the cDNA; Read 2 reads in the spatial barcode; and Read 3 reads in the sample index. In this example, the total insert size is 155 bp + the short cDNA insert size.

[0324] Another schematic workflow of the method disclosed herein is shown in Fig.18 middle. Fig.18 A spatial workflow is shown, wherein a tissue section is placed on a flow cell (FC) surface, wherein the FC surface comprises a plurality of capture oligonucleotides comprising a first clustering primer sequence (e.g., Fig. 20 ), wherein one or more of the plurality of capture oligonucleotides are immobilized on the surface via a cleavage site. Fig.18 A schematic diagram of using dUTP / allyl-T to normalize the library fragment size with in-tube second strand synthesis is shown. Fig.18 Adding alternative cutting chemistry upstream of P7 (shown in Figure 1) allows library preparation in solution after RT. Two different cutting chemistries allow washing steps on the surface to remove unbound cDNA fragments. In this workflow, transcripts are captured on a barcoded surface containing capture oligonucleotides, which contain polyT capture nucleotide sequences. Reverse transcriptase is initiated with dUTP / allyl-T incorporated into the reaction. After RT, a substrate for UDG / UCM cutting is prepared by performing exonuclease digestion, tissue digestion, and RNA removal steps. Cutting with UDG / UCM will produce fragments in which the first dUTP / allyl-T site incorporated will be the 3' termination site of the cDNA chain. The substrate is then washed and an additional cutting step upstream of P7 will elute the cDNA from the surface. Second chain synthesis is performed with random oligonucleotide primers containing adapters. The random oligonucleotide sequence will serve as the UMI of the transcript. After the second chain is synthesized, the second cDNA chain (i.e., the second complementary chain) is eluted and subjected to index PCR and purification before being loaded onto the sequencer.

[0325] Another schematic workflow of the method disclosed herein is shown in Fig.19 middle. Fig.19 A spatial workflow is shown, wherein a tissue section is placed on a flow cell (FC) surface, wherein the FC surface comprises a plurality of capture oligonucleotides comprising a first clustering primer sequence (e.g., Fig. 20 P7 primer sequence shown in ). Fig.19A schematic diagram of library size normalization with ddNTPs in a reverse transcription reaction is shown. Shorter library fragments can be achieved by adding ddNTPs to the RT reaction. In this workflow, transcripts are captured on a barcoded surface comprising a capture oligonucleotide, which comprises a polyT capture nucleotide sequence. Reverse transcriptase is initiated with ddNTPs incorporated into the reaction. After RT, a substrate for second complementary chain synthesis is prepared by performing exonuclease digestion, tissue digestion, and RNA removal steps. The second complementary chain is synthesized with a random oligonucleotide primer containing an adapter. The random oligonucleotide sequence will serve as the UMI of the transcript. After the second complementary chain is synthesized, the second cDNA chain (i.e., the second complementary chain) is eluted and subjected to index PCR and purification, and then loaded onto a sequencer.

[0326] Another schematic workflow of the method disclosed herein is shown in Fig. 20 In. Similar to Fig.16 , Fig.18 and Fig.19 , Fig. 20 A spatial workflow is shown, wherein a tissue section is placed on a flow cell (FC) surface, wherein the FC surface comprises a plurality of capture oligonucleotides comprising a first clustering primer sequence (e.g., Fig. 20 P7 primer sequence shown in ). Fig. 20 A schematic diagram is shown in which ExAMP is used as a cDNA elution reagent and redundant pre-sequencing is established. In some embodiments, when an exonuclease step is added to the post-RT workflow (e.g., to remove unbound surface capture oligonucleotides from the surface), this allows the opportunity to use the ExAMP reaction on the surface to elute the barcoded surface-bound library and establish library yield. After the second complementary chain is synthesized, an ExAMP mixture (which includes P7 and sample index primers) can be added to the substrate. Isothermal amplification of primer chain invasion is then used to generate an index P5 / P7 library. The eluate is then transferred to a tube, where it is purified and loaded onto a sequencer. The effective exonuclease digestion of unbound surface oligonucleotides improves the workflow.

[0327] Another schematic workflow of the method disclosed herein is shown in Fig.21 middle. Fig.21 A spatial workflow is shown, wherein the FC surface comprises a plurality of capture oligonucleotides comprising a first clustering primer sequence (e.g., Fig.21 P7 primer sequence shown in ). Fig.21It is described how to shorten cDNA fragments with 3' phosphate dNTPs or azido-ddNTPs. First, 3' Phos dNTPs are added to the RT reaction. The substrate can then be treated with an exonuclease to convert the 3' phosphate group to OH, allowing enzymatic ligation of UMI and adapter sequences with PNK (splint ligation with ssDNA ligation). Additionally, chemical ligation with water-soluble carbodiimide (EDC) can be performed. In additional embodiments, azido-ddNTPs are added to the RT reaction, followed by azide / alkyne splint ligation to add UMI and adapter sequences.

[0328] The foregoing description has been given only for clear understanding of the invention, and no unnecessary limitations should be understood therefrom, since modifications within the scope of the disclosure may be apparent to those skilled in the art.

[0329] All patents, patent applications, government publications, government regulations, and references cited in this specification are incorporated herein by reference in their entirety. In the event of a conflict, the present detailed description and the definitions included therein will control.

[0330] Throughout the specification, when compounds, compositions, methods and / or processes are described as including components, steps or materials, unless otherwise described, it is contemplated that compounds, compositions, methods and / or processes may also include, consist essentially of, or consist of any combination of the components or materials. Unless otherwise specifically stated, component concentrations may be expressed as weight concentrations. Combinations of components are contemplated to include homogeneous and / or heterogeneous mixtures, as will be understood by one of ordinary skill in the art in view of the foregoing disclosure.

Claims

1. A method for preparing an RNA sequence library, the method comprising: mounting the tissue sample on a substrate comprising a plurality of capture oligonucleotides, wherein the capture oligonucleotides comprise a polyT sequence and library barcode information comprising a spatial barcode sequence (SBC); capturing polyadenylated mRNA transcripts on the substrate with the capture oligonucleotide; contacting the substrate with a first strand synthesis mixture comprising a reverse transcriptase and a template switching oligonucleotide (TSO) under conditions that produce a first strand comprising a first cDNA complementary to the polyadenylated mRNA transcript and a TSO-complementary sequence hybridized to a 5' end of the first cDNA, wherein the reverse transcriptase incorporates a non-templated cytosine nucleotide at the 5' end of the first cDNA and the TSO comprises a sequence that hybridizes to the non-templated cytosine nucleotide, and the reverse transcriptase extends to produce the TSO-complementary sequence as a complement of the TSO at the 5' end of the first cDNA; eluting the polyadenylated mRNA transcripts from the substrate; contacting the first strand with a second strand synthesis mixture comprising a TSO primer, and extending the TSO primer using the first strand as a template to generate a second strand complementary to the first strand, the second strand comprising the TSO, a second cDNA complementary to the first cDNA, and second strand barcode information comprising a spatial barcode sequence complementary sequence (SBC') complementary to the spatial barcode sequence (SBC); eluting the second strand; contacting the second strand with a Poly-TVN extension mixture comprising a Poly-TVN primer, and extending the Poly-TVN primer using the second strand as a template to generate a double-stranded product while maintaining a single-stranded 3' region containing the library barcode information; contacting the double-stranded product with a transposome under conditions that tag the double-stranded product to form a tagmentation product comprising a unique molecular identifier (UMI) and a PCR adapter; as well as The tagmentation products were amplified using indexed PCR to generate the library. 2 . The method of claim 1 , wherein the TSO primer in the second strand synthesis mixture is a biotinylated TSO primer, such that the second strand comprises biotinylated TSO. 3 . The method of claim 2 , further comprising contacting the eluted second strand comprising the biotinylated TSO with functionalized beads. The method of claim 3 , wherein the functionalized beads are streptavidin beads.

5. The method according to any one of the preceding claims, wherein the second strand is neutralized after elution and before contacting with the Poly-TVN extension mixture.

6. The method of any one of the preceding claims, wherein contacting the first strand with the second strand synthesis mixture comprises incubating the first strand with the second strand synthesis mixture for an incubation time of less than 2 hours.

7. The method of claim 6, wherein the incubation time is from about 10 minutes to about 60 minutes.

8. The method of claim 7, wherein the incubation time is from about 15 minutes to about 30 minutes.

9. The method according to any one of the preceding claims, wherein the transposome is an A14 transposome or a B15 transposome.

10. The method according to any one of the preceding claims, wherein the transposome is a transposome-modified bead.

11. The method according to any one of the preceding claims, comprising purifying the double-stranded product prior to tagmentation.

12. The method according to any one of the preceding claims, comprising purifying the double-stranded product after index PCR.

13. The method of any of the preceding claims, wherein contacting the second strand with the Poly-TVN extension mixture comprises incubating the second strand with the Poly-TVN extension mixture at a first temperature for a first time, at a second temperature higher than the first temperature for a second time, and holding at a holding temperature.

14. The method of claim 13, wherein the first temperature is about 25°C to about 37°C, and the first time is about 10 minutes to about 30 minutes.

15. The method according to claim 13 or 14, wherein the second temperature is about 60°C to about 65°C, and the second time is about 10 minutes to about 30 minutes.

16. The method according to claims 13 to 15, wherein the holding temperature is 4°C.

17. The method according to any one of the preceding claims, wherein indexed PCR is performed using about 10 to 24 cycles, each cycle comprising 15 to 50 minutes.

18. The method of claim 17, wherein the indexed PCR comprises a final extension comprising a hold of about 5 minutes to 10 minutes.

19. The method according to any one of the preceding claims, wherein the tagmentation product is amplified with P7 and a primer comprising transposome-index-P5.

20. The method of any one of the preceding claims, wherein tagmentation comprises contacting the double-stranded product with the transposome and vector gDNA.

21. The method of any one of the preceding claims, wherein the sequence to which the untemplated cytosine nucleotide hybridizes comprises 2 to 5 guanosines.

22. The method of claim 21, wherein the guanosine is riboguanosine.

23. The method of claim 22, wherein the sequence is rGrGrG.

24. A method for preparing an RNA sequence library, the method comprising: mounting the tissue sample on a substrate comprising a plurality of capture oligonucleotides, wherein the capture oligonucleotides comprise a polyT sequence and library barcode information comprising a spatial barcode sequence (SBC); capturing polyadenylated mRNA transcripts on the substrate with the capture oligonucleotide; contacting the substrate with a first strand synthesis mixture comprising a reverse transcriptase and a template switching oligonucleotide (TSO) under conditions that produce a first strand comprising a first cDNA complementary to the polyadenylated mRNA transcript and a TSO complementary sequence hybridized to the 5' end of the first cDNA; eluting the polyadenylated mRNA transcripts from the substrate; contacting the first strand with a blocker oligonucleotide and a TSO such that the blocker oligonucleotide and the TSO hybridize to the first strand, wherein the blocker oligonucleotide hybridizes to the TSO such that a gap exists between the blocker oligonucleotide and the TSO; contacting the hybridized first strand with a non-strand-displacing polymerase to fill the gap and produce a second cDNA; removing the blocker oligonucleotide to form a blocker-free first strand; contacting the blocker-free first strand with a transposome under conditions that tagment the blocker-free first strand to form a tagmentation product comprising a unique molecular identifier (UMI) and a PCR adapter; contacting the tagmentation product with an extension mixture to generate a second strand complementary to the first strand, the second strand comprising second strand barcode information having a spatial barcode sequence complementary sequence (SBC') complementary to the spatial barcode sequence, the second cDNA, the unique molecular identifier, and the PCR adapter; eluting the second strand; and The second strand is amplified using indexed PCR to generate the library.

25. The method of claim 24, wherein the blocker oligonucleotide is a 3'-blocked SBS12'-PolyA oligonucleotide.

26. A method for preparing an RNA sequence library, the method comprising: mounting the tissue sample on a substrate comprising a plurality of capture oligonucleotides, wherein the capture oligonucleotides comprise a polyT sequence and a barcode comprising a spatial barcode sequence (SBC); capturing polyadenylated mRNA transcripts on the substrate with the capture oligonucleotide; contacting the substrate with a first strand synthesis mixture comprising a reverse transcriptase under conditions to produce a first strand comprising a first cDNA complementary to the polyadenylated mRNA transcript; eluting the polyadenylated mRNA transcripts from the substrate; contacting the first strand with a second strand synthesis mixture comprising random primers to produce a second strand comprising a second cDNA and a unique molecular identifier (UMI); eluting the second strand; amplifying the second strand to generate a double-stranded product; contacting the double-stranded product with a transposome under conditions where a tagmentation product is formed; as well as The library is generated by amplifying the tagmentation products in a first indexed PCR to determine the SBC and amplifying the tagmentation products in a second indexed PCR to determine the UMI.

27. A method for preparing an RNA sequence library, the method comprising: mounting the tissue sample on a substrate comprising a plurality of capture oligonucleotides, wherein the capture oligonucleotides comprise one or more gene-specific capture sequences and library barcode information comprising a spatial barcode sequence (SBC); capturing the mRNA transcripts on the substrate with the capture oligonucleotide; contacting the substrate with a first strand synthesis mixture comprising a reverse transcriptase and a template switching oligonucleotide (TSO) under conditions that produce a first strand, the first strand comprising a first cDNA complementary to the mRNA transcript and a TSO-complementary sequence hybridized to a 5' end of the first cDNA, wherein the reverse transcriptase incorporates a non-templated cytosine nucleotide at the 5' end of the first cDNA, and the TSO comprises a sequence that hybridizes to the non-templated cytosine nucleotide, and the reverse transcriptase extends to produce the TSO-complementary sequence as a complement of the TSO at the 5' end of the first cDNA; eluting the mRNA transcripts from the substrate; contacting the first strand with a second strand synthesis mixture comprising a TSO primer, and extending the TSO primer using the first strand as a template to generate a second strand complementary to the first strand, the second strand comprising the TSO, a second cDNA complementary to the first cDNA, and second strand barcode information comprising a spatial barcode sequence complementary sequence (SBC') complementary to the spatial barcode sequence (SBC); eluting the second strand; contacting the second strand with an extension mixture comprising an extension primer, and extending the extension primer using the second strand as a template to generate a double-stranded product while maintaining a single-stranded 3' region comprising the library barcode information, wherein the extension primer hybridizes to a region of the second strand that does not comprise the second strand barcode information; contacting the double-stranded product with a transposome under conditions that tag the double-stranded product to form a tagmentation product comprising a unique molecular identifier (UMI) and a PCR adapter; as well as The tagmentation products were amplified using indexed PCR to generate the library.

28. The method of claim 27, wherein the second strand is neutralized after elution and before contacting with the extension mixture.

29. The method of claim 27 or 28, wherein contacting the first strand with the second strand synthesis mixture comprises incubating the first strand with the second strand synthesis mixture for an incubation time of less than 2 hours.

30. The method of claim 29, wherein the incubation time is from about 10 minutes to about 60 minutes.

31. The method of claim 30, wherein the incubation time is from about 15 minutes to about 30 minutes.

32. The method according to any one of claims 27 to 31, wherein the transposome is an A14 transposome or a B15 transposome.

33. The method of any one of claims 27 to 32, wherein the transposome is a transposome-modified bead.

34. The method according to any one of claims 27 to 33, comprising purifying the double-stranded product prior to tagmentation.

35. The method of any one of claims 27 to 34, comprising purifying the double-stranded product after indexed PCR.

36. The method of any one of claims 27 to 35, wherein contacting the second strand with the extension mixture comprises incubating the second strand with the extension mixture at a first temperature for a first time, at a second temperature higher than the first temperature for a second time, and holding at a holding temperature.

37. The method of claim 36, wherein the first temperature is from about 25°C to about 37°C and the first time is from about 10 minutes to about 30 minutes.

38. The method of claim 36 or 37, wherein the second temperature is about 60°C to about 65°C and the second time is about 10 minutes to about 30 minutes.

39. The method of claims 36 to 38, wherein the holding temperature is 4°C.

40. The method according to any one of claims 36 to 39, wherein indexed PCR is performed using about 10 to 24 cycles, each cycle comprising 15 to 50 minutes.

41. The method of claim 40, wherein the indexed PCR comprises a final extension comprising a hold of about 5 minutes to 10 minutes.

42. The method of any one of claims 36 to 41, wherein the tagmentation product is amplified with P7 and a primer comprising transposome-index-P5.

43. The method of any one of claims 36 to 42, wherein tagmentation comprises contacting the double-stranded product with the transposome and vector gDNA.

44. The method of any one of claims 36 to 43, wherein the sequence to which the untemplated cytosine nucleotide hybridizes comprises 2 to 5 guanosines.

45. The method of claim 44, wherein the guanosine is riboguanosine.

46. ​​The method of claim 45, wherein the sequence is rGrGrG.

47. A method for preparing an RNA sequence library, the method comprising: mounting the tissue sample on a substrate comprising a plurality of capture oligonucleotides, wherein the capture oligonucleotides comprise one or more gene-specific capture sequences and library barcode information comprising a spatial barcode sequence (SBC); capturing the mRNA transcripts on the substrate with the capture oligonucleotide; contacting the substrate with a first strand synthesis mixture comprising a reverse transcriptase and a template switching oligonucleotide (TSO) under conditions that produce a first strand comprising a first cDNA complementary to the mRNA transcript and a TSO complementary sequence hybridized to the 5' end of the first cDNA; eluting the mRNA transcripts from the substrate; contacting the first strand with a blocker oligonucleotide and a TSO such that the blocker oligonucleotide and the TSO hybridize to the first strand, wherein the blocker oligonucleotide hybridizes to the TSO such that a gap exists between the blocker oligonucleotide and the TSO; contacting the hybridized first strand with a non-strand-displacing polymerase to fill the gap and produce a second cDNA; removing the blocker oligonucleotide to form a blocker-free first strand; contacting the blocker-free first strand with a transposome under conditions that tagment the blocker-free first strand to form a tagmentation product comprising a unique molecular identifier (UMI) and a PCR adapter; contacting the tagmentation product with an extension mixture to generate a second strand complementary to the first strand, the second strand comprising second strand barcode information having a spatial barcode sequence complementary sequence (SBC') complementary to the spatial barcode sequence, the second cDNA, the unique molecular identifier, and the PCR adapter; eluting the second strand; and The second strand is amplified using indexed PCR to generate the library.

48. A method for preparing an RNA sequence library, the method comprising: mounting the tissue sample on a substrate comprising a plurality of capture oligonucleotides, wherein the capture oligonucleotides comprise one or more gene-specific capture sequences and a barcode comprising a spatial barcode sequence (SBC); capturing the mRNA transcripts on the substrate with the capture oligonucleotide; contacting the substrate with a first strand synthesis mixture comprising a reverse transcriptase under conditions to produce a first strand comprising a first cDNA complementary to the mRNA transcript; eluting the mRNA transcripts from the substrate; contacting the first strand with a second strand synthesis mixture comprising random primers, and extending the random primers to produce a second strand comprising a second cDNA and a unique molecular identifier (UMI); eluting the second strand; amplifying the second strand to generate a double-stranded product; contacting the double-stranded product with a transposome under conditions where a tagmentation product is formed; as well as The library is generated by amplifying the tagmentation products in a first indexed PCR to determine the SBC and amplifying the tagmentation products in a second indexed PCR to determine the UMI.

49. A method for preparing a spatially barcoded RNA library from a tissue sample, the method comprising: a) contacting the tissue sample with a plurality of capture oligonucleotides immobilized on a solid substrate and capable of hybridizing with RNA in the tissue sample, wherein the capture oligonucleotides comprise a capture nucleotide sequence, a spatial barcode sequence (SBC), and an adapter sequence, wherein RNA transcripts are captured by the capture nucleotide sequence of the plurality of capture oligonucleotides; b) contacting the RNA transcript with a first strand synthesis mixture comprising a reverse transcriptase (RT) and a template switching oligonucleotide (TSO) encoding a first adaptor sequence under conditions that produce a first strand cDNA comprising a first strand cDNA complementary to said RNA transcript and a TSO appended to the 3' end of said first cDNA, wherein said reverse transcriptase incorporates a non-templated cytosine nucleotide at said 3' end of said first strand cDNA, and said TSO comprising a first adaptor sequence hybridizes to said 3' end of said first cDNA, and said reverse transcriptase extends to produce a TSO complementary sequence; wherein said contacting produces a mixture of template-switched molecules and non-template-switched molecules, wherein said non-template-switched molecules lack a complementary sequence to said first adaptor sequence; c) contacting the mixture with a plurality of oligonucleotide ligation blockers, the plurality of oligonucleotide ligation blockers comprising the first adaptor sequence and capable of hybridizing to the 3' end of the template switching molecule, the 3' end of the template switching molecule comprising the complementary sequence of the first adaptor sequence; d) performing a single-stranded ligation step comprising hybridizing a splint adaptor to the non-template switching molecule, wherein the splint adaptor comprises i) a single-stranded splint sequence comprising a random base sequence (NX) and ii) a double-stranded first adaptor sequence comprising a hybridized first adaptor and a complementary sequence to the first adaptor sequence, wherein the complementary sequence at the 5' end of the first adaptor sequence contains a phosphate group for ligating to the 3'OH end of the captured non-template switching molecule, and ligating the 5' end of the splint adaptor complementary sequence to the 3'OH end of the non-template switching molecule; and e) removing said ligation blocker and said splint sequence and first adaptor from said ligated molecules.

50. The method of claim 49, comprising contacting the mixture of template-switching molecules and non-template-switching molecules with an exonuclease.

51. The method of claim 50, wherein the exonuclease is DNA exonuclease I or RNase H.

52. The method of any one of claims 49 to 51, wherein the NX sequence has a capping group at the 5' end of the NX sequence.

53. The method of any one of claims 49 to 52, wherein the hybridized first adaptor and the complement of the first adaptor sequence both comprise a capping group at the ends of the first adaptor and the complement of the first adaptor sequence that are farthest from the splint sequence.

54. The method of any one of claims 50 to 53, further comprising contacting the mixture with an alkaline solution after the exonuclease.

55. The method according to any one of claims 49 to 54, further comprising, after the removal step, amplifying the template-switching molecule and the non-template-switching molecule by contacting the mixture with a second-chain synthesis mixture comprising a single first adapter primer and using the first-chain cDNA or its complementary sequence as a template to extend the first adapter primer to produce a second-chain cDNA complementary to the first chain or its complementary sequence, wherein the second-chain cDNA comprises a second cDNA complementary to the first-chain cDNA, and a second-chain barcode information containing a spatial barcode sequence complementary sequence (SBC') complementary to the spatial barcode sequence (SBC) in the capture oligonucleotide.

56. The method of claim 55, wherein the first adapter primer is a full-length primer or a partial primer.

57. The method according to any one of claims 49 to 56, further comprising eluting the amplified first-strand and / or second-strand cDNA molecules from the substrate, and generating a spatially barcoded RNA library from the eluted molecules using a library preparation kit.

58. The method of any one of claims 49 to 57, wherein the ligated molecule of step (d) further comprises a cleavage sequence.

59. The method of claim 58, wherein removing the ligation blocker, the splint sequence and the first adaptor from the ligated molecules is performed outside of the substrate.

60. The method of claim 57 or 58, wherein amplifying the template-switching molecule and the non-template-switching molecule, eluting the second strand cDNA, and generating a spatially barcoded library are performed in solution.

61. The method of any one of claims 49 to 60, wherein the amplification step is performed on the substrate.

62. The method of claim 61, wherein the amplified first strand and / or second strand further comprises a cleavage sequence.

63. The method of claim 61 or 62, wherein eluting the second strand cDNA and generating the spatially barcoded library are performed in solution.

64. A method for preparing a spatially barcoded RNA library from a tissue sample, the method comprising: a) contacting the tissue sample with a plurality of capture oligonucleotides immobilized on a solid substrate and capable of hybridizing with RNA in the tissue sample, wherein the capture oligonucleotides comprise a capture nucleotide sequence, a spatial barcode sequence (SBC), and an adapter sequence, wherein RNA transcripts are captured by the capture nucleotide sequence of the plurality of capture oligonucleotides; b) contacting the RNA transcript with a first strand synthesis mixture comprising a reverse transcriptase (RT) and a template switching oligonucleotide (TSO) encoding a first adaptor sequence under conditions that produce a first strand cDNA comprising a first strand cDNA complementary to said RNA transcript and a TSO hybridized to a 3' end of said first strand cDNA, wherein said reverse transcriptase incorporates a non-templated cytosine nucleotide at said 3' end of said first strand cDNA, and said TSO comprising a first adaptor sequence is appended to said 3' end of said first strand cDNA, and said reverse transcriptase extends to produce a TSO complementary sequence; and wherein said contacting produces a mixture of template-switched molecules and non-template-switched molecules, wherein said non-template-switched molecules lack a complementary sequence to said first adaptor sequence; c) contacting the mixture with a plurality of oligonucleotide ligation blockers and a plurality of complementary oligonucleotide blockers to generate a double-stranded 3' end of the capture oligonucleotide, wherein the plurality of oligonucleotide ligation blockers comprise the first adaptor sequence and are capable of hybridizing with the 3' end of the template switching molecule, wherein the 3' end of the template switching molecule comprises the complementary sequence of the first adaptor sequence, and the plurality of complementary oligonucleotide blockers comprise a nucleotide sequence complementary to all or part of the capture nucleotide sequence and a fixed sequence in the capture oligonucleotide; d) performing a single-stranded ligation step comprising hybridizing a splint adaptor to the non-template switching molecule, wherein the splint adaptor comprises i) a single-stranded splint sequence comprising a random base sequence (NX) and ii) a double-stranded portion of a first adaptor sequence comprising a hybridized first adaptor and a complementary sequence to the first adaptor sequence, wherein the complementary sequence at the 5' end of the first adaptor sequence contains a phosphate group for ligating to the 3' OH end of the captured non-template switching molecule, and ligating the 5' end of the splint adaptor complementary sequence to the 3' OH end of the non-template switching molecule; and e) removing the ligation blocker and splint strands of the adaptor.

65. The method of claim 64, comprising contacting the mixture of template-switching molecules and non-template-switching molecules with an exonuclease.

66. The method of claim 65, wherein the exonuclease is DNA exonuclease I or RNase H.

67. The method of any one of claims 64 to 66, wherein the NX sequence has a capping group at the 5' end of the NX sequence.

68. The method of any one of claims 64 to 67, wherein the hybridized first adaptor and the complement of the first adaptor sequence both comprise a capping group at the ends of the first adaptor and the complement of the first adaptor sequence that are farthest from the splint sequence.

69. The method of any one of claims 65 to 68, further comprising contacting the mixture with an alkaline solution after the exonuclease.

70. The method according to any one of claims 64 to 69, further comprising, after the removal step, amplifying the template-switching molecule and the non-template-switching molecule by contacting the mixture with a second-chain synthesis mixture comprising a single first adapter primer and using the first-chain cDNA as a template to extend the first adapter primer to produce a second-chain cDNA complementary to the first chain, wherein the second-chain cDNA comprises a second cDNA complementary to the first-chain cDNA, and a second-chain barcode information containing a spatial barcode sequence complementary sequence (SBC') complementary to the spatial barcode sequence (SBC) in the capture oligonucleotide.

71. The method of claim 70, wherein the first adaptor primer is a full-length primer or a partial primer.

72. The method of any one of claims 49 to 71, further comprising eluting the amplified first-strand and / or second-strand cDNA molecules from the substrate, and generating a spatially barcoded RNA library from the eluted molecules using a library preparation kit.

73. The method of any one of claims 65 to 72, wherein the ligated molecule of step (d) further comprises a cleavage sequence.

74. The method of claim 73, wherein removing the ligation blocker, the splint sequence and the first adaptor from the ligated molecules is performed outside of the substrate.

75. The method of claim 73 or 74, wherein amplifying the template-switching molecule and the non-template-switching molecule, eluting the second strand cDNA, and generating a spatially barcoded library are performed in solution.

76. A method according to any one of claims 49 to 75, wherein the amplification step is performed on the substrate.

77. The method of claim 76, wherein the amplified first strand and / or second strand further comprises a cleavage sequence.

78. The method of claim 76 or 77, wherein eluting the second strand cDNA and generating the spatially barcoded library are performed in solution.

79. The method of any one of claims 49 to 78, optionally comprising fixing the tissue sample on a substrate comprising the plurality of capture oligonucleotides prior to contacting the tissue with the plurality of capture oligonucleotides.

80. The method of any one of claims 49 to 79, wherein the capture nucleotide sequence is a poly-T sequence, a poly-A sequence, a gene-specific capture sequence, or a universal capture sequence.

81. The method of claim 80, wherein the universal capture sequence is a random nucleotide sequence or a non-self-complementary semi-random sequence.

82. The method of any one of claims 49 to 81, wherein the capture oligonucleotide comprises: a 5' clustering sequence, a random spatial barcode (SBC), a full-length second adapter sequence (2FL), a molecular identifier (MI), a fixed sequence (FS), and a poly T capture sequence (polyTVN) with a 3' VN terminus.

83. The method of claim 82, wherein the first adapter sequence is a read 1 (Rd1) sequence and the second adapter sequence is a read 2 (Rd2) sequence.

84. The method of any one of claims 49 to 83, wherein the first adaptor is a partial adaptor sequence.

85. The method of claim 84, wherein the molecular identifier is a unique molecular identifier, an endogenous molecular identifier, an exogenous molecular identifier, or a virtual molecular identifier.

86. The method of any one of claims 49 to 85, wherein the ligating step comprises enzymatically ligating the splint adaptor to the non-template switching molecule.

87. The method of claim 86, wherein the enzymatic ligation is performed by ligation with synthetic pre-adenylated single-stranded oligonucleotide adaptors mediated by T4 ligase, other DNA ligases, or thermostable 5'App DNA / RNA ligase.

88. The method of any one of claims 49 to 87, wherein the ligating step comprises chemically ligating the splint adaptor to the non-template switching molecule.

89. The method of claim 88, wherein the chemical ligation is performed using click chemistry-mediated ligation in which the 3' azido terminus is joined to a synthetic 5' alkyne single-stranded oligonucleotide or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)-mediated ligation in which a cDNA having a 3' phosphate group is ligated to a splint adaptor having a 5' hydroxyl terminus.

90. The method of claim 89, wherein during first strand cDNA synthesis, 3' Azido-ddNTP or 3' Phos-dATP is incorporated onto the Rd1 adaptor.

91. The method of any one of claims 49 to 90, wherein the splint adaptor random sequence comprises 6 to 10 nucleotides.

92. The method of any one of claims 49 to 91, wherein the splint adaptor random sequence comprises 7 nucleotides.

93. The method of any one of claims 49 to 92, wherein the splint adaptor comprises capping groups at both 3' ends and the 5' end of the splint sequence, and comprises a linking capping group complementary to the splint strand at the 5' end of the adaptor strand.

94. The method of claim 93, wherein the linkage blocker group is a phosphate group.

95. The method of any one of claims 49 to 94, wherein the ligation blocker and the splint adaptor are removed by alkaline treatment.

96. The method of claim 95, wherein the alkaline treatment comprises treatment with 0.08 M KOH or 0.1 N NaON at room temperature for 5 minutes.

97. The method of any one of claims 49 to 96, wherein the 5' clustering sequence comprises a P7 sequence.

98. The method of any one of claims 49 to 97, wherein the capture oligonucleotide further comprises a random oligonucleotide, a semi-random sequence, or a target-specific probe.

99. The method of any one of claims 49 to 98, wherein the sequence to which the untemplated cytosine nucleotide hybridizes comprises 2 to 5 guanosines.

100. The method of claim 99, wherein the guanosine is riboguanosine, a modified nucleic acid, or a locked nucleic acid (LNA).

101. The method of claim 100, wherein the sequence is rGrGrG.

102. The method of any one of claims 49 to 101, wherein the polyT sequence is 20 to 30 nucleotides.

103. The method of any one of claims 49 to 102, wherein the SBC is a random oligonucleotide.

104. The method of any one of claims 49 to 103, wherein the SBC is 20 to 30 nucleotides.

105. The method of any one of claims 49 to 104, wherein the capture oligonucleotide comprises at least 10 deoxythymidine residues.

106. The method of claim 105, wherein the capture oligonucleotide comprises a plurality of different target-specific RNA capture probe sequences.

107. The method of claim 78, wherein the target-specific probe comprises at least 10 nucleotides that are complementary to a nucleotide sequence of a target RNA.

108. The method of any one of claims 49 to 107, wherein the capture oligonucleotide is 8 to 80 nucleotides.

109. The method according to any one of claims 49 to 108, further comprising a step of performing end repair of the RNA using a polynucleotide kinase prior to the step of capturing the RNA from the tissue sample.

110. The method according to any one of claims 49 to 108, further comprising a step of in situ polyadenylation using a poly(A) polymerase prior to the step of capturing RNA from the tissue sample.

111. The method according to any one of claims 49 to 108, further comprising the step of end repair of said RNA with a polynucleotide kinase followed by in situ polyadenylation with a poly(A) polymerase prior to said step of capturing RNA from said tissue sample.

112. The method of any one of claims 49 to 111, wherein the RNA comprises ribosomal RNA (rRNA), messenger RNA (mRNA), non-coding RNA (ncRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA) and / or micro RNA (miRNA).

113. The method of any one of claims 49 to 112, wherein the tissue sample is formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen (FF) tissue.

114. The method of any one of claims 49 to 113, wherein removing the RNA is performed by melting the RNA or digesting with RNase.

115. The method of any one of claims 49 to 114, wherein the tissue sample is permeabilized prior to contacting the tissue sample with a plurality of capture oligonucleotides.

116. The method of any one of claims 49 to 115, wherein the tissue sample is treated with one or more blocking reagents prior to contacting the tissue sample with a plurality of capture oligonucleotides.

117. The method of any one of claims 49 to 116, wherein the tissue sample is permeabilized and treated with one or more blocking reagents prior to contacting the tissue sample with a plurality of capture oligonucleotides.

118. The method of any one of claims 49 to 117, wherein the method comprises polyadenylation of RNA in the sample.

119. The method of claim 118, wherein the RNA is polyadenylated using a poly(A) polymerase.

120. The method of claim 118, wherein the RNA is polyadenylated using chemical ligation or enzymatic ligation.

121. The method of any one of claims 49 to 120, wherein the substrate is a bead, a bead array, a spotted array, a substrate comprising a plurality of wells, a flow cell, aggregated particles arranged on the surface of a chip, a membrane or a plate.

122. The method of claim 121, wherein the substrate comprises a plurality of nanopores or micropores.

123. The method of any one of claims 49 to 122, wherein the RNA library is an mRNA library.

124. The method of any one of claims 49 to 123, further comprising indexing and sequencing the second strand cDNA, comprising: performing PCR on the second strand cDNA to generate a PCR template representing one or more RNA transcripts in the tissue sample; eluting the PCR template; as well as Index PCR is performed to generate a double-stranded PCR product comprising the first-strand PCR product and a second strand complementary to the first-strand PCR product.

125. The method of claim 124, further comprising sequencing the PCR products and determining the location of the RNA transcripts in the tissue based on the spatial barcode.

126. The method of claim 124 or 125, wherein the double-stranded PCR product comprises a second clustering sequence on the second strand that is complementary to the first-strand PCR product, and optionally comprises an index sequence.

127. The method of claim 124 or 125, wherein the double-stranded PCR product is further processed by tagmentation to generate a spatial transcriptomics library.

128. The method of claim 127, wherein the labeling comprises labeling on a substrate.

129. The method of claim 127 or 128, wherein tagmentation comprises contacting the double-stranded product with the transposome and vector gDNA.

130. The method of any one of claims 49 to 129, further comprising determining the spatial positions of the spatial barcodes of the plurality of capture oligonucleotide molecules prior to the step of contacting the tissue with the substrate.

131. The method of claim 130, further comprising sequencing at least a portion of the spatially barcoded first-strand cDNA or a copy thereof to determine the spatial barcode sequence of each molecule.

132. The method of claim 131, wherein the spatially barcoded first-strand cDNA is sequenced in situ.

133. According to the method according to claim 131 or 132, the method also includes determining the spatial position of one or more of the spatially barcoded first-chain cDNA or its copies by associating the spatial barcode sequence of the spatially barcoded first-chain cDNA or its copies with the spatial position of the capture oligonucleotide molecule on the substrate containing the corresponding spatial barcode sequence.

134. The method of claim 132, further comprising recovering the spatially barcoded first-strand cDNA, and amplifying the first-strand cDNA to generate a cDNA library.

135. A method according to claim 134, wherein the spatially barcoded first-strand cDNA on the substrate is recovered by contacting the spatially barcoded first-strand cDNA with a DNA polymerase and one or more primers to produce a spatially barcoded second-strand cDNA complementary to the spatially barcoded first-strand cDNA and removing the spatially barcoded second-strand cDNA from the substrate.

136. The method of claim 135, wherein the one or more primers each comprise a random priming sequence.

137. The method of claim 136, wherein the random priming sequence comprises nine random nucleotides.

138. The method of claim 136 or 137, wherein the spatially barcoded second-strand cDNAs each comprise a unique molecular identifier (UMI), wherein the UMI comprises an intrinsic sequence and an extrinsic sequence, wherein the extrinsic sequence is a sequence complementary to the random priming sequence used to generate the second-strand cDNA, and wherein the intrinsic sequence is a sequence complementary to the first-strand cDNA template sequence used to generate the second-strand cDNA.

139. The method of claim 135, wherein each of the one or more primers comprises a molecular identifier barcode.

140. The method of claim 135, wherein the one or more primers each comprise a UMI barcode.

141. The method of any one of claims 135 to 140, wherein the spatially barcoded second strand cDNA is removed from the substrate by chemical or physical dehybridization.

142. A method according to claim 135, wherein the capture oligonucleotide comprises an anchor sequence, the anchor sequence comprises a cutting site for anchoring the capture oligonucleotide to the substrate, and the hybrid of the spatially barcoded first-strand cDNA and the second-strand cDNA is removed from the substrate by enzymatic cleavage at the cutting site.

143. The method of claim 142, wherein the cleavage site is a binding site for a restriction endonuclease.

144. The method of any one of claims 134 to 143, further comprising sequencing at least a portion of the cDNA library to determine the spatial barcode sequence of each molecule.

145. The method according to claim 144 further comprises determining the spatial position of the one or more cDNA molecules by associating the spatial barcode sequence of the one or more cDNA molecules with the spatial position of the surface oligonucleotide molecules on the substrate containing the corresponding spatial barcode sequence.

146. The method of any one of claims 49 to 145, wherein RNA expression is determined in single cells within the tissue.

147. The method of any one of claims 49 to 146, wherein RNA expression is determined in subcellular fractions within a single cell.

148. The method of claim 147, wherein the subcellular component is nucleus, mitochondria, ribosomes, or cytoplasm.

149. The method of any one of claims 49 to 148, wherein the substrate or the surface of the substrate comprises a material selected from glass, silicon, poly-L-lysine coated material, nitrocellulose, polystyrene, cyclic olefin copolymer (COC), cyclic olefin polymer (COP), polyacrylamide, polypropylene, polyethylene or polycarbonate.

150. A kit comprising a) a solid substrate comprising a capture oligonucleotide immobilized on the solid substrate, wherein the capture oligonucleotide comprises a capture nucleotide sequence, a spatial barcode sequence (SBC), and an adapter sequence; b) a reverse transcriptase (RT) and a template switching oligonucleotide (TSO) encoding a first adaptor sequence; and c) a splint adaptor, wherein the splint adaptor comprises i) a single-stranded splint sequence comprising a random base sequence (NX) having a blocking group at the 5' end of the NX sequence; and ii) a double-stranded first adapter sequence comprising the hybridized first adapter sequence and a sequence complementary to the first adapter sequence, optionally, wherein the hybridized first adaptor sequence and the sequence complementary to the first adaptor sequence comprise a capping group at the 5' end of the first adaptor and at the 3' end of the complementary sequence to the first adaptor sequence.

151. A method for preparing an immobilized library of target nucleic acids from a biological sample, the method comprising: (a) providing a surface comprising a plurality of capture oligonucleotides immobilized thereon, wherein one or more of the plurality of capture oligonucleotides comprises, from 5' to 3': (i) a first cluster primer sequence; (ii) spatial barcode (SBC) sequence; (iii) a first sequencing primer sequence; and (iv) capturing nucleotide sequences; (b) contacting the biological sample with the surface, the contacting causing the target nucleic acid of the biological sample to hybridize with the capture nucleotide sequences of the plurality of capture oligonucleotides to form hybridized capture oligonucleotides; (c) extending the capture nucleotide sequence of the hybridized capture oligonucleotide to form a first complementary strand of the target nucleic acid, wherein the extension is performed in the presence of an extension terminating moiety, and wherein the extension terminating moiety is allyl-T or deoxyuridine triphosphate (dUTP), Thereby, an immobilized library of the target nucleic acid is prepared.

152. The method of claim 151, further comprising: (d) contacting the surface with an exonuclease; (e) hybridizing a plurality of oligonucleotide primers to the first complementary strand, wherein each of the plurality of oligonucleotide primers comprises, from 5′ to 3′: (i) an adaptor nucleotide sequence; and (ii) random nucleotide sequences; (f) extending the plurality of oligonucleotide primers, thereby generating one or more second complementary strands comprising the adaptor nucleotide sequence at the terminus.

153. The method of claim 152, further comprising: (g) removing the one or more second complementary strands from the surface and amplifying the one or more second complementary strands.

154. The method of claim 153, wherein step (g) is performed in the presence of an exclusion amplification (ExAmp) mixture, wherein the ExAmp mixture comprises primers comprising the clustering primer sequences.

155. The method of claim 151, wherein one or more of the plurality of capture oligonucleotides is immobilized on the surface via a cleavage site.

156. The method of claim 155, wherein the cleavage site is an enzyme cleavage site.

157. The method of claim 156, wherein the enzyme cleavage site comprises a restriction enzyme site, uracil, 8-oxoguanine, or a combination thereof.

158. The method of claim 155, wherein the cleavage site is a chemical cleavage site.

159. The method of any one of claims 155 to 158, wherein the cleavage site is cleaved after step (c).

160. The method of claim 152, wherein one or more of the plurality of capture oligonucleotides is immobilized on the surface via a cleavage site.

161. The method of claim 160, wherein the cleavage site is an enzyme cleavage site.

162. The method of claim 161, wherein the enzyme cleavage site comprises a restriction enzyme site, uracil, 8-oxoguanine, or a combination thereof.

163. The method of claim 160, wherein the cleavage site is a chemical cleavage site.

164. The method of any one of claims 160 to 163, wherein the cleavage site is cleaved after step (f).

165. The method of any one of claims 151 to 164, wherein the extension terminating moiety is deoxyuridine triphosphate (dUTP), and the method further comprises contacting the surface with uracil-DNA glycosylase (UDG).

166. The method of any one of claims 151 to 164, wherein the extension terminating moiety is allyl-T, and wherein the method further comprises contacting the surface with a universal cleavage mixture (UCM).

167. The method of any one of claims 152 to 164, wherein the extension terminating moiety is deoxyuridine triphosphate (dUTP), and the method further comprises contacting the surface with uracil-DNA glycosylase (UDG).

168. The method of any one of claims 152 to 164, wherein the extension terminating moiety is allyl-T, and wherein the method further comprises, prior to step (e), contacting the surface with a universal cleavage mixture (UCM).

169. A method for preparing an immobilized library of target nucleic acids from a biological sample, the method comprising: (a) providing a surface comprising a plurality of capture oligonucleotides immobilized thereon, wherein one or more of the plurality of capture oligonucleotides comprises, from 5' to 3': (i) a first cluster primer sequence; (ii) spatial barcode (SBC) sequence; (iii) a first sequencing primer sequence; and (iv) capturing nucleotide sequences; (b) contacting the biological sample with the surface, the contacting causing the target nucleic acid of the biological sample to hybridize with the capture nucleotide sequences of the plurality of capture oligonucleotides to form hybridized capture oligonucleotides; (c) extending the capture nucleotide sequence of the hybridized capture oligonucleotide to form a first complementary strand of the target nucleic acid, wherein the extension is performed in the presence of an extension terminating moiety, and wherein the extension terminating moiety is a dideoxynucleoside triphosphate (ddNTP), Thereby, an immobilized library of the target nucleic acid is prepared.

170. The method of claim 169, further comprising: (d) contacting the surface with an exonuclease; (e) hybridizing a plurality of oligonucleotide primers to the first complementary strand, wherein each of the plurality of oligonucleotide primers comprises, from 5′ to 3′: (i) an adaptor nucleotide sequence; and (ii) random nucleotide sequences; (f) extending the plurality of oligonucleotide primers, thereby generating one or more second complementary strands comprising the adaptor nucleotide sequence at the terminus.

171. The method of claim 170, further comprising: (g) removing the one or more second complementary strands from the surface and amplifying the one or more second complementary strands.

172. The method of claim 171, wherein step (g) is performed in the presence of an exclusion amplification (ExAmp) mixture, wherein the ExAmp mixture comprises primers comprising the first clustering primer sequence.

173. The method of claim 169, wherein one or more of the plurality of capture oligonucleotides is immobilized on the surface via a cleavage site.

174. The method of claim 173, wherein the cleavage site is an enzyme cleavage site.

175. The method of claim 174, wherein the enzyme cleavage site comprises a restriction enzyme site, uracil, 8-oxoguanine, or a combination thereof.

176. The method of claim 173, wherein the cleavage site is a chemical cleavage site.

177. The method of any one of claims 173 to 176, wherein the cleavage site is cleaved after step (c).

178. The method of claim 170, wherein one or more of the plurality of capture oligonucleotides is immobilized on the surface via a cleavage site.

179. The method of claim 178, wherein the cleavage site is an enzyme cleavage site.

180. The method of claim 179, wherein the enzyme cleavage site comprises a restriction enzyme site, uracil, 8-oxoguanine, or a combination thereof.

181. The method of claim 178, wherein the cleavage site is a chemical cleavage site.

182. The method of any one of claims 178 to 181, wherein the cleavage site is cleaved after step (f).

183. The method of any one of claims 169 to 182, wherein the ddNTP comprises a first click chemistry handle.

184. A method according to claim 183, wherein the method further comprises, after step (c), contacting the surface with an adapter oligonucleotide, wherein the adapter oligonucleotide comprises a second click chemistry handle capable of cross-linking to the first click chemistry handle, thereby connecting the adapter oligonucleotide to the first complementary strand.

185. The method of claim 184, wherein the adaptor oligonucleotide further comprises a second sequencing primer sequence.

186. The method of claim 184 or claim 185, wherein the first click chemistry handle is an azide, a tetrazine, a strained olefin, or an alkyne.

187. The method of any one of claims 184 to 186, wherein the second click chemistry handle is an azide, a tetrazine, a strained olefin, or an alkyne.

188. A method for preparing an immobilized library of target nucleic acids from a biological sample, the method comprising: (a) providing a surface comprising a plurality of capture oligonucleotides immobilized thereon, wherein one or more of the plurality of capture oligonucleotides comprises, from 5' to 3': (i) a first cluster primer sequence; (ii) spatial barcode (SBC) sequence; (iii) a first sequencing primer sequence; and (iv) capturing nucleotide sequences; (b) contacting the biological sample with the surface, the contacting causing the target nucleic acid of the biological sample to hybridize with the capture nucleotide sequences of the plurality of capture oligonucleotides to form hybridized capture oligonucleotides; (c) extending the capture nucleotide sequence of the hybridized capture oligonucleotide to form a first complementary strand of the target nucleic acid, wherein the extension is performed in the presence of an extension termination moiety, and wherein the extension termination moiety is a deoxynucleoside triphosphate (dNTP) comprising a 3' phosphate group, Thereby, an immobilized library of the target nucleic acid is prepared.

189. The method of claim 188, further comprising: (d) contacting the surface with an exonuclease; as well as (e) contacting the surface with a ligase, thereby ligating an adaptor oligonucleotide to the first complementary strand, wherein the adaptor oligonucleotide comprises, from 5′ to 3′: (i) an adaptor nucleotide sequence; and (ii) random nucleotide sequences, And wherein the adaptor oligonucleotide further comprises a second oligonucleotide that hybridizes to the adaptor nucleotide sequence.

190. The method of claim 189, wherein the adaptor nucleotide sequence comprises a second sequencing primer sequence.

191. The method of claim 189, wherein the ligation occurs by splinting of the adaptor oligonucleotide to the first complementary strand.

192. The method of any one of claims 189 to 191, wherein the ligase is T4 DNA ligase.

193. The method of any one of claims 189 to 192, further comprising: (f) extending the adaptor oligonucleotide to generate one or more second complementary strands.

194. The method of claim 188, further comprising: (d) contacting the surface with an exonuclease; as well as (e) contacting the surface with a ligase, thereby ligating an adaptor oligonucleotide to the first complementary strand, wherein the adaptor oligonucleotide comprises, from 5′ to 3′: (i) random nucleotide sequences; and (ii) Adaptor nucleotide sequence.

195. The method of claim 194, wherein the adaptor nucleotide sequence comprises a second sequencing primer sequence.

196. The method of claim 194 or claim 195, wherein the ligation occurs via single-stranded DNA ligation of the adaptor oligonucleotide to the first complementary strand.

197. The method of any one of claims 194 to 196, wherein the ligase is a DNA / RNA ligase.

198. The method of any one of claims 194 to 197, further comprising: (f) extending the adaptor oligonucleotide to generate one or more second complementary strands.

199. The method of claim 193 or claim 198, further comprising: (g) removing the one or more second complementary strands from the surface and amplifying the one or more second complementary strands.

200. The method of claim 199, wherein step (g) is performed in the presence of an exclusion amplification (ExAmp) mixture.

201. The method of claim 188, wherein one or more of the plurality of capture oligonucleotides are immobilized on the surface via a cleavage site.

202. The method of claim 201, wherein the cleavage site is an enzyme cleavage site.

203. The method of claim 202, wherein the enzyme cleavage site comprises a restriction enzyme site, uracil, 8-oxoguanine, or a combination thereof.

204. The method of claim 201, wherein the cleavage site is a chemical cleavage site.

205. The method of any one of claims 201 to 204, wherein the cleavage site is cleaved after step (c).

206. The method of claim 189 or claim 194, wherein one or more of the plurality of capture oligonucleotides are immobilized on the surface via a cleavage site.

207. The method of claim 206, wherein the cleavage site is an enzyme cleavage site.

208. The method of claim 207, wherein the enzyme cleavage site comprises a restriction enzyme site, uracil, 8-oxoguanine, or a combination thereof.

209. The method of claim 206, wherein the cleavage site is a chemical cleavage site.

210. The method of any one of claims 206 to 209, wherein the cleavage site is cleaved after step (e).

211. A method for preparing a fixed library of target nucleic acids from a biological sample, the method comprising: (a) providing a surface comprising a plurality of capture oligonucleotides immobilized thereon, wherein one or more of the plurality of capture oligonucleotides comprises, from 5' to 3': (i) a first cluster primer sequence; (ii) spatial barcode (SBC) sequence; (iii) a first sequencing primer sequence; and (iv) capturing nucleotide sequences; (b) contacting the biological sample with the surface, the contacting causing the target nucleic acid of the biological sample to hybridize with the capture nucleotide sequences of the plurality of capture oligonucleotides to form hybridized capture oligonucleotides; (c) extending the capture nucleotide sequence of the hybridized capture oligonucleotide to form a first complementary strand of the target nucleic acid, wherein the extension is performed in the presence of an extension termination moiety, and wherein the extension termination moiety is a deoxynucleoside triphosphate (dNTP) comprising a 3' phosphate group or a dideoxynucleoside triphosphate (ddNTP) comprising a first click chemistry handle, Thereby, an immobilized library of the target nucleic acid is prepared.

212. The method of claim 211, wherein the extension termination moiety is a deoxynucleoside triphosphate (dNTP) comprising a 3' phosphate group.

213. The method of claim 211 or claim 212, further comprising: (d) chemically linking an adaptor oligonucleotide to the first complementary strand via a cross-linking group, wherein the adaptor oligonucleotide comprises from 5′ to 3′: (i) an adaptor nucleotide sequence; and (ii) random nucleotide sequences, And wherein the adaptor oligonucleotide further comprises a second oligonucleotide that hybridizes to the adaptor nucleotide sequence.

214. The method of claim 213, wherein the adaptor nucleotide sequence comprises a second sequencing primer sequence.

215. The method of claim 213, wherein the cross-linking group is a carboxyl-amine reactive group, a BCN-azide reactive group, a DBCO-azide reactive group, a tetrazine-TCO reactive group, or a combination thereof.

216. The method of claim 211, wherein the extension termination moiety is a dideoxynucleoside triphosphate (ddNTP) comprising a first click chemistry handle.

217. The method of claim 211 or claim 216, further comprising: (d) attaching an adaptor oligonucleotide to the first complementary strand by click chemistry, wherein the adaptor oligonucleotide comprises from 5′ to 3′: (i) an adaptor nucleotide sequence; and (ii) random nucleotide sequences, And wherein the adaptor oligonucleotide further comprises a second oligonucleotide that hybridizes to the sequencing primer sequence, wherein the second oligonucleotide comprises a second click chemistry handle.

218. The method of claim 217, wherein the adaptor nucleotide sequence comprises a second sequencing primer sequence.

219. The method of any one of claims 211, 215, or 217, wherein the first click chemistry handle is an azide, a tetrazine, a strained olefin, or an alkyne.

220. The method of any one of claims 217 to 219, wherein the second click chemistry handle is an azide, a tetrazine, a strained olefin, or an alkyne.

221. The method of any one of claims 213 to 220, further comprising: (e) extending the adaptor oligonucleotide to generate one or more second complementary strands.

222. The method of claim 221, further comprising: (f) removing the one or more second complementary strands from the surface and amplifying the one or more second complementary strands.

223. The method of claim 222, wherein step (f) is performed in the presence of an exclusion amplification (ExAmp) mixture.

224. The method of claim 211, wherein one or more of the plurality of capture oligonucleotides is immobilized on the surface via a cleavage site.

225. The method of claim 224, wherein the cleavage site is an enzyme cleavage site.

226. The method of claim 225, wherein the enzyme cleavage site comprises a restriction enzyme site, uracil, 8-oxoguanine, or a combination thereof.

227. The method of claim 224, wherein the cleavage site is a chemical cleavage site.

228. The method of any one of claims 224 to 227, wherein the cleavage site is cleaved after step (c).

229. The method of claim 213 or claim 217, wherein one or more of the plurality of capture oligonucleotides are immobilized on the surface via a cleavage site.

230. The method of claim 229, wherein the cleavage site is an enzyme cleavage site.

231. The method of claim 230, wherein the enzyme cleavage site comprises a restriction enzyme site, uracil, 8-oxoguanine, or a combination thereof.

232. The method of claim 229, wherein the cleavage site is a chemical cleavage site.

233. The method of any one of claims 229 to 232, wherein the cleavage site is cleaved after step (d).

234. The method of any one of claims 151 to 233, further comprising removing the target nucleic acid from the surface after step (c).

235. The method of any one of claims 151 to 234, further comprising, after step (d), removing the biological sample from the surface.

236. The method of any one of claims 151 to 235, wherein each of the plurality of capture oligonucleotides comprises the same capture nucleotide sequence.

237. The method of any one of claims 151 to 235, wherein the plurality of capture oligonucleotides comprises a plurality of different capture nucleotide sequences.

238. The method of claim 237, wherein the plurality of different capture nucleotide sequences comprises one or more gene-specific capture sequences, one or more universal capture sequences, or a combination thereof.

239. The method of any one of claims 151 to 237, wherein the capture nucleotide sequence is a poly-T sequence, a poly-A sequence, a gene-specific capture sequence, or a universal capture sequence.

240. The method of claim 238 or claim 239, wherein the universal capture sequence is a random nucleotide sequence or a non-self-complementary semi-random sequence.

241. The method of any one of claims 151 to 240, wherein the target nucleic acid is mRNA, gDNA, rRNA, tRNA, or a combination thereof.

242. The method of any one of claims 151 to 240, wherein the target nucleic acid is RNA, mRNA, or a combination thereof.

243. The method of any one of claims 151 to 242, wherein the extension of the capture nucleotide sequence in step (c) is performed using a reverse transcriptase.

244. The method of any one of claims 151 to 243, wherein the target nucleic acid is polyadenylated prior to hybridization of the target nucleic acid to the capture nucleotide sequence.

245. The method of claim 94, wherein the target nucleic acid is polyadenylated using a poly(A) polymerase.

246. The method of claim 94, wherein the target nucleic acid is polyadenylated using chemical ligation or enzymatic ligation.

247. The method of any one of claims 153, 171, 199 or 222, wherein the amplifying comprises adding a second clustering primer sequence to the one or more second complementary strands.

248. The method of claim 247, wherein the amplifying further comprises adding an index sequence.

249. A method according to claim 247 or claim 248, wherein the amplification includes indexed PCR, during which a first primer hybridizes to the first cluster primer sequence and a second primer hybridizes to the linker nucleotide sequence, wherein the second primer comprises the second cluster primer sequence.

250. The method of claim 249, wherein the second primer further comprises the index sequence.

251. The method of any one of claims 49 to 149, wherein the first adaptor primer comprises a molecular identifier (SMI) sequence.

252. A method according to claim 251, wherein the molecular identifier of the first adapter primer is incorporated during the synthesis of the second strand cDNA.

253. The method of claim 251 or 252, wherein the SMI is a UMI.